Saatja: <
[email protected]>
Saadetud: 02.12.2020 14:38
Teema: WHO: C.L.54.2020 (recommended INN list 84)
Dear Member States of the World Health Organization,Please find attached,
in the six official languages, C.L54.2020 regarding the list of
recommended international nonproprietary names for pharmaceutical
substances which has been published by the World Health Organization in
WHO Drug Information, Vol. 34, N°3, 2020.The annex is the same in all
languages and is attached to the English version.Best regards,Department
of Governing BodiesWorld Health Organization
20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
Ref.: C.L.54.2020
The World Health Organization presents its compliments and has the honour to forward
herewith, in accordance with Articles 3.A and 7 of the “Procedure for the Selection of
Recommended International Nonproprietary Names for Pharmaceutical Substances” adopted by
the Executive Board in its resolution EB15.R71, a list of names which has been published as
International Nonproprietary Names recommended by the World Health Organization
(abbreviation Rec. INN).
In accordance with Article 8 of the above-mentioned Procedure, the World Health
... Organization requests that the enclosed list of names* be recognized as the nonproprietary names
for the substances in question, and that the necessary steps be taken to prevent the acquisition of
proprietary rights in the names, including prohibition of registration of the names as trade-marks
or trade-names.
GENEVA, 1 December 2020
1
Annex to resolution EB15.R7, Off. Rec. Wld Hlth Org., No. 60, pp. 3 and 55. This text was amended by
resolution EB43.R9, Off. Rec. Wld Hlth Org., No. 173, p. 10 and resolution EB115.R4, Executive Board,
115th Session, Resolutions and Decisions (EB115/2005/REC/1), p. 2.
... ENCL.: (1)* Rec. INN: List 84 published in WHO Drug Information, Vol. 34, No.3, 2020.
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names: List 84
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection
of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off.
Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9);
Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as
Recommended International Nonproprietary Names. The inclusion of a name in the lists of
Recommended International Nonproprietary Names does not imply any recommendation of
the use of the substance in medicine or pharmacy.
Lists of Proposed (1–1117) and Recommended (1–78) International Nonproprietary Names
can be found in Cumulative List No. 17, 2017 (available in CD-ROM only).
Dénominations communes internationales des Substances pharmaceutiques
(DCI)
Dénominations communes internationales RECOMMANDÉES: Liste 84
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en
vue du choix de Dénominations communes internationales recommandées pour les
Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7);
1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les
dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que
dénominations communes internationales recommandées. L’inclusion d’une dénomination
dans les listes de DCI recommandées n’implique aucune recommandation en vue de
l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–117)
et recommandées (1–78) dans la Liste récapitulative No. 17, 2017 (disponible sur CD-ROM
seulement).
Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas
(DCI)
Denominaciones Comunes Internacionales RECOMENDADAS: Lista 84
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de
Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas
[Act. Of. Mund. Salud, 1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9);
Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el
presente anuncio que las denominaciones que a continuación se expresan han sido
seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión
de una denominación en las listas de las Denominaciones Comunes Recomendadas no
supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o
en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–117) y Recomendadas
(1–78) se encuentran reunidas en Cumulative List No. 17, 2017 (disponible sólo en CD-ROM).
687
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
Latin, English, French, Spanish: Chemical name or description; Molecular formula;
Recommended INN Graphic formula
DCI Recommandée Nom chimique ou description; Formule brute;
Formule développée
DCI Recomendada Nombre químico o descripción; Fórmula molecular;
Fórmula desarrollada
acidum aligomanuxicum
aligomanuxic acid O-[oligo-(1→4)-β-D-mannopyranuronan-β-osyl]-(1→3)-
D-mannaric, -(1→2)-D-arabinaric, -(1→3)-D-arabinaric,
(1→2)-D-erythraric, -(1→2)-D-threaric, and -(1→2)-
glyceraric acids, produced from alginates of brown
seaweeds by acid-catalysed partial hydrolysis,
isolation of oligomannuronans and oxidation of the
reducing end group
acide aligomanuxique acides O-[oligo-(1→4)-β-D-mannopyranuronan-β-osyl]-
(1→3)-D-mannarique, -(1→2)-D-arabinarique, -(1→3)-
D-arabinarique, (1→2)-D-érythrarique, -(1→2)-D-
thréarique, et -(1→2)-glycérarique, produits à partir
d'algues brunes par hydrolyse partielle par catalyse
acide, isolation des oligomannuronanes et oxydation
du groupe réducteur terminal
ácido aligomanúxico ácidos O-[oligo-(1→4)-β-D-manopiranuronan-β-osil]-
(1→3)-D-manárico, -(1→2)-D-arabinárico, -(1→3)-D-
arabinárico, (1→2)-D-eritrárico, -(1→2)-D-treárico, y
-(1→2)-glicerárico, producido a partir de algas pardas
por hidrólisis parcialmente por catálisis ácida,
aislamiento de los oligomanuronanos y oxidación del
grupo reductor terminal
(C6H8O6)n (CH2O)m+m' C3H4O5
acidum norucholicum
norucholic acid 3α,7β-dihydroxy-24-nor-5β-cholan-23-oic acid
acide norucholique acide 3α,7β-dihydroxy-24-nor-5β-cholan-23-oïque
ácido norucólico ácido 3α,7β-dihidroxi-24-nor-5β-colan-23-oico
688
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
C23H38O4
acoramidisum
acoramidis 3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-4-
fluorobenzoic acid
acoramidis acide 3-[3-(3,5-diméthyl-1H-pyrazol-4-yl)propoxy]-4-
fluorobenzoïque
acoramidis ácido 3-[3-(3,5-dimetil-1H-pirazol-4-il)propoxi]-4-
fluorobenzoico
C15H17FN2O3
adebrelimabum #
adebrelimab immunoglobulin G4-kappa, anti-[Homo sapiens CD274
(programmed death ligand 1, PDL1, PD-L1, B7
homolog 1, B7H1)], monoclonal antibody;
gamma4 heavy chain (1-446) [VH (Homo sapiens
IGHV1-46*01 (89.8%) -(IGHD) -IGHJ4*01 (93.3%))
CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1-119) -
Homo sapiens IGHG4*01, G4v5 h P10, G4v4 CH2
A1.3, A1.2 (CH1 (120-217), hinge 1-12 S10>P (227)
(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339),
CH3 (340-444), CHS (445-446)) (120-446)], (133-
218')-disulfide with kappa light chain (1'-218') [V-
KAPPA (Mus musculus IGKV3-5*01 (84.8%) -
IGKJ2*03 (90.9%)/Homo sapiens IGKV4-1*01 (68.3%)
-IGKJ2*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-
56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%)
Km3 A45.1 (157), V101 (195) (112'-218')];
dimer (225-225":228-228")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
adébrélimab immunoglobuline G4-kappa, anti-[Homo sapiens
CD274 (ligand 1 de mort programmée, PDL1, PD-L1,
homologue 1 de B7, B7H1)], anticorps monoclonal;
689
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
chaîne lourde gamma4 (1-446) [VH (Homo sapiens IGHV1-
46*01 (89.8%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.12]
(26-33.51-58.97-108) (1-119) -Homo sapiens IGHG4*01, G4v5 h
P10, G4v4 CH2 A1.3, A1.2 (CH1 (120-217), charnière 1-12
S10>P (227) (218-229), CH2 F1.3>A (233), L1.2>A (234) (230-
339), CH3 (340-444), CHS (445-446)) (120-446)], (133-218')-
disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA (Mus
musculus IGKV3-5*01 (84.8%) -IGKJ2*03 (90.9%)/Homo
sapiens IGKV4-1*01 (68.3%) -IGKJ2*01 (100%)) CDR-IMGT
[10.3.9] (27-36.54-56.93-101) (1'-111') -Homo sapiens IGKC*01
(100%) Km3 A45.1 (157), V101 (195) (112'-218')];
dimère (225-225":228-228")-bisdisulfure, produit dans des
cellules ovariennes de hamster chinois (CHO), glycoforme alfa
adebrelimab inmunoglobulina G4-kappa, anti-[Homo sapiens CD274 (ligando
1 de muerte programada, PDL1, PD-L1, homólogo 1 de B7,
B7H1)], anticuerpo monoclonal;
cadena pesada gamma4 (1-446) [VH (Homo sapiens IGHV1-
46*01 (89.8%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.12]
(26-33.51-58.97-108) (1-119) -Homo sapiens IGHG4*01, G4v5 h
P10, G4v4 CH2 A1.3, A1.2 (CH1 (120-217), bisagra 1-12 S10>P
(227) (218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339),
CH3 (340-444), CHS (445-446)) (120-446)], (133-218')-disulfuro
con la cadena ligera kappa (1'-218') [V-KAPPA (Mus musculus
IGKV3-5*01 (84.8%) -IGKJ2*03 (90.9%)/Homo sapiens IGKV4-
1*01 (68.3%) -IGKJ2*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-
56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1
(157), V101 (195) (112'-218')];
dímero (225-225":228-228")-bisdisulfuro, producido por células
ováricas de hamster chino (CHO), forma glicosilada alfa
Heavy chain / Chaîne lourde / Cadena pesada
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWMHWVRQA PGQGLEWMGR 50
IGPNSGFTSY NEKFKNRVTM TRDTSTSTVY MELSSLRSED TAVYYCARGG 100
SSYDYFDYWG QGTTVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY 200
TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEAAGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLGK 446
Light chain / Chaîne légère / Cadena ligera
DIVLTQSPAS LAVSPGQRAT ITCRASESVS IHGTHLMHWY QQKPGQPPKL 50
LIYAASNLES GVPARFSGSG SGTDFTLTIN PVEAEDTANY YCQQSFEDPL 100
TFGQGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC 218
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 146-202 260-320 366-424
22''-96'' 146''-202'' 260''-320'' 366''-424''
Intra-L (C23-C104) 23'-92' 138'-198'
23'''-92''' 138'''-198'''
Inter-H-L (CH1 10-CL 126) 133-218' 133''-218'''
Inter-H-H (h 8, h 11) 225-225'' 228-228''
N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1:
1, 1''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
690
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
afamitresgenum autoleucelum #
afamitresgene autoleucel Autologous CD4+ and CD8+ T cells obtained by
leukapheresis, transduced with an HIV-derived self-
inactivating (SIN) lentiviral vector, encoding an
enhanced-affinity T cell receptor (TCR) specific for the
human melanoma antigen A4 (MAGE family member
A4, antigen MAGE A4) HLA-A*02 peptide driven by
the elongation factor 1 alpha (EF1α) promoter. Cells
express lymphonode-homing markers CCR7 and
CD62L, CD45 isoforms CD45RA and CD45R0, co-
stimulatory markers CD27 and CD28, IL-7 receptor
CD127, and chemokine receptor CXCR3. Cells
secrete interleukin 2 (IL-2), tumor necrosis factor α
(TNF-alpha, TNFα), interferon gamma (interferon γ,
IFN-gamma), granzyme, interleukin 4 (IL-4), interleukin
13 (IL-13) and interleukin 17 (IL-17) upon activation.
afamitresgène autoleucel Lymphocytes T CD4+ et CD8+ autologues obtenus par
leucophérèse, transduits par un vecteur lentiviral auto-
inactivant (SIN), dérivé du virus de l'immunodéficience
humaine (VIH), codant pour un récepteur de
lymphocytes T (TCR) à affinité augmentée spécifique
du peptide HLA-A*02 de l'antigène du mélanome
humain A4 (membre A4 de la famille MAGE, antigène
MAGE-4), sous le contrôle d'un promoteur du facteur
d'élongation alpha 1 (EF1α). Les cellules expriment les
marqueurs de migration des ganglions lymphatiques
CCR7 et CD62L, les isoformes CD45RA and CD45R0
du CD45, les marqueurs co-stimulateurs CD27 et
CD28, le récepteur CD127 de l'interleukine 7 (IL-7) et
les récepteurs de chimiokines CXCR3. Les cellules
secrètent de l'interleukine 2 (IL-2), facteur de nécrose
tumorale α (TNF-alpha, TNFα), interféron gamma
(interféron γ, IFN-gamma), granzyme, interleukine 4
(IL-4), interleukine 13 (IL-13) et l'interleukine 17 (IL-17)
au moment de leur activation
afamitresgén autoleucel Linfocitos T CD4+ y CD8+ autólogos obtenidos por
leucoaféresis, transducidos con un vector lentiviral
auto inactivante derivado del HIV, que codifica para un
receptor de linfocitos T (TCR) con afinidad aumentada,
específico para el péptido del antígeno de melanoma
humano A4 (MAGE A4) presentado por HLA-A*02,
dirigido por un promotor del factor de elongación 1 alfa
(EF1α). Las células expresan los marcadores de
migración a ganglios linfáticos CCR7 y CD62L, las
isoformas CD45RA y CD45R0 de CD45, los
marcadores coestimuladores CD27 y CD28, el
receptor de IL-7 CD127, y el receptor de quimoquinas
CXCR3. Las células secretan interleukina 2 (IL-2),
factor de necrosis tumoral (TNF-alfa, TNFα), interferón
gamma (interferón γ, IFN-gamma), granzima,
interleukina 4 (IL-4), interleukina 13 (IL-13) e
interleukina 17 (IL-17) tras su activación.
691
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
alsevalimabum #
alsevalimab immunoglobulin G1-kappa, anti-[Homo sapiens
VTCN1 (V-set domain containing T cell activation
inhibitor 1, B7-H4, B7H4)], Homo sapiens monoclonal
antibody;
gamma1 heavy chain Homo sapiens (1-450) [VH
(Homo sapiens IGHV4-39*01 (96.0%) -(IGHD) -
IGHJ5*02 (93.8%)) CDR-IMGT [10.7.12] (26-35.53-
59.98-109) (1-120) -Homo sapiens IGHG1*01 (100%)
G1m17,1 (CH1 K120 (217) (121-218), hinge 1-15
(219-233), CH2 (234-343), CH3 D12 (359), L14 (361)
(344-448), CHS (449-450)) (121-450)], (223-214')-
disulfide with kappa light chain Homo sapiens (1'-214')
[V-KAPPA (Homo sapiens IGKV3-15*01 (96.8%) -
IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-
52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%),
Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (229-229'':232-232'')-bisdisulfide, produced in
Chinese hamster ovary (CHO-FUT8-/-) cells, glycoform
alfa
alsévalimab immunoglobuline G1-kappa, anti-[ Homo sapiens
VTCN1 (inhibiteur 1 de l'activation des cellules T
contenant un V-set domain, B7-H4, B7H4)], anticorps
monoclonal Homo sapiens;
chaîne lourde gamma1 Homo sapiens (1-450) [VH
(Homo sapiens IGHV4-39*01 (96.0%) -(IGHD) -
IGHJ5*02 (93.8%)) CDR-IMGT [10.7.12] (26-35.53-
59.98-109) (1-120) -Homo sapiens IGHG1*01 (100%)
G1m17,1 (CH1 K120 (217) (121-218), charnière 1-15
(219-233), CH2 (234-343), CH3 D12 (359), L14 (361)
(344-448), CHS (449-450)) (121-450)], (223-214')-
disulfure avec la chaîne légère kappa Homo sapiens
(1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01
(96.8%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-
32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01
(100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (229-229'':232-232'')-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO-
FUT8-/-), glycoforme alfa
alsevalimab inmunoglobulina G1-kappa, anti-[ Homo sapiens
VTCN1 (inhibidor 1 de la activación de las células T
que contiene un dominio V-set, B7-H4, B7H4)],
anticuerpo monoclonal Homo sapiens;
cadena pesada gamma1 Homo sapiens (1-450) [VH
(Homo sapiens IGHV4-39*01 (96.0%) -(IGHD) -
IGHJ5*02 (93.8%)) CDR-IMGT [10.7.12] (26-35.53-
59.98-109) (1-120) -Homo sapiens IGHG1*01 (100%)
G1m17,1 (CH1 K120 (217) (121-218), bisagra 1-15
(219-233), CH2 (234-343), CH3 D12 (359), L14 (361)
(344-448), CHS (449-450)) (121-450)], (223-214')-
disulfuro con la cadena ligera kappa Homo sapiens (1'-
214') [V-KAPPA (Homo sapiens IGKV3-15*01 (96.8%)
-IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-
52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%),
Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (229-229'':232-232'')-bisdisulfuro, producido
por células ováricas de hamster chino (CHO-FUT8-/-),
forma glicosilada alfa
692
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
Heavy chain / Chaîne lourde / Cadena pesada
QLQLQESGPG LVKPSETLSL TCTVSGGSIK SGSYYWGWIR QPPGKGLEWI 50
GNIYYSGSTY YNPSLRSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARE 100
GSYPNQFDPW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
Light chain / Chaîne légère / Cadena ligera
EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYG 50
ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YHSFPFTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-97 147-203 264-324 370-428
22''-97'' 147''-203'' 264''-324'' 370''-428''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (h 5-CL 126) 223-214' 223''-214'''
Inter-H-H (h 11, h 14) 229-229'' 232-232''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300''
Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes afucosylés / glicanos de tipo CHO biantenarios complejos afucosilados
C-terminal lysine clipping
H CHS K2:
450, 450''
amcenestrantum
amcenestrant 8-(2,4-dichlorophenyl)-9-(4-{[(3S)-1-(3-
fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H-
benzo[7]annulene-3-carboxylic acid
amcénestrant acide 8-(2,4-dichlorophényl)-9-(4-{[(3S)-1-(3-
fluoropropyl)pyrrolidin-3-yl]oxy}phényl)-6,7-dihydro-5H-
benzo[7]annulène-3-carboxylique
amcenestrant ácido 8-(2,4-diclorofenil)-9-(4-{[(3S)-1-(3-
fluoropropil)pirrolidin-3-il]oxi}fenil)-6,7-dihidro-5H-
benzo[7]anuleno-3-carboxílico
C31H30Cl2FNO3
F N O
H CO2H
Cl
Cl
amdakefalinum #
amdakefalin [6-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-3,6-
diazabicyclo[3.1.1]heptan-3-yl]acetic acid
amdakéfaline acide [6-(D-phénylalanyl-D-phénylalanyl-D-leucyl-D-
lysyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]acétique
amdakefalina ácido [6-(D-fenilalanil-D-fenilalanil-D-leucil-D-lisil)-3,6-
diazabiciclo[3.1.1]heptan-3-il]acético
693
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
C37H53N7O6
aramisulpridum
aramisulpride 4-amino-5-(ethanesulfonyl)-N-{[(2R)-1-ethylpyrrolidin-
2-yl]methyl}-2-methoxybenzamide
aramisulpride 4-amino-5-(éthanesulfonyl)-N-{[(2R)-1-éthylpyrrolidin-
2-yl]méthyl}-2-méthoxybenzamide
aramisulprida 4-amino-5-(etanosulfonil)-N-{[(2R)-1-etilpirrolidin-2-
il]metil}-2-metoxibenzamida
C17H27N3O4S
autogenum cevumeranum #
autogene cevumeran A 5'-capped single-stranded messenger RNA (mRNA)
construct for the expression of patient-specific tumour
neoantigens comprising a 5'-cap, a 5'-untranslated
region derived from human alpha-globin mRNA, an
optimised Kozak sequence, sequences encoding a
secretory signal peptide (sec2.0), transmembrane and
cytoplasmic domains of a major histocompatibility
complex (MHC) Class I molecule (MITD), a 3'-
untranslated region (FI) and a poly(A)-tail; sequences
encoding patient specific antigens are inserted
between the secretory signal peptide and the
transmembrane/cytoplasmic encoding domains.
autogène cévuméran ARN messager (ARNm) de simple brin coiffé en 5'
construit pour l'expression de néoantigènes tumoraux
spécifiques du patient comprenant une coiffe en 5',
une région en 5' non-traduite dérivée de l'ARNm de la
globine alpha humaine, une séquence optimisée
Kozak, et les séquences codant pour un peptide signal
(sec2.0), les domaines transmembranaire et
cytoplasmique du complexe majeur d'histocompatibilité
de groupe I (CMH1) (MITD), une région non traduite
en 3' (FI) et une queue poly(A) ; Les séquences
codant les antigènes spécifiques du patient sont
insérées entre celles codant le peptide signal et les
domaines transmembranaire et cytoplasmique.
694
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
autogén cevumerán Un constructo de RNA mensajero (mRNA) de cadena
sencilla y caperuza en 5', para la expresión de
neoantígenos tumorales específicos de cada paciente,
que contiene una caperuza 5' (5'-cap), una región 5'
no traducida derivada del mRNA de la globina alfa
humana, una secuencia optimizada Kozak, y las
secuencias codificantes para el péptido señal (sec2.0),
los dominios transmembrana y citoplásmico de
complejo mayor de histocompatibilidad de grupo I
(CMHI) (MITD), una región non-traducida en 3' (FI) y
una cola poly(A); las secuencias que codifican los
antígenos específicos del paciente se insertan entre
las del péptido señal y de los dominios
transmembrana y citoplásmico.
azemiglitazonum
azemiglitazone rac-(5R)-5-({4-[2-(3-methoxyphenyl)-2-
oxoethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione
azémiglitazone rac-(5R)-5-({4-[2-(3-méthoxyphényl)-2-
oxoéthoxy]phényl}méthyl)-1,3-thiazolidine-2,4-dione
azemiglitazona rac-(5R)-5-({4-[2-(3-metoxifenil)-2-oxoetoxi]fenil}metil)-
1,3-tiazolidina-2,4-diona
C19H17NO5S
695
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
belzupacapum sarotalocanum #
belzupacap sarotalocan a modified human papillomavirus (HPV) type 16-
derived empty nanoparticle, 55 nm in diameter
conjugated to approximately 200 molecules of a
phthalocyanine-based photosensitizer (sarotalocan
group). Each nanoparticle is comprised of 72
capsomeres, made of 5 molecules of modified viral
capsid protein L1 [P78>R, T176>N, D273>T, N285>T,
S288>N, T353>P, T389>S] and one molecule of viral
capsid protein L2;
human papilloma virus type 16 (HPV16) capsid, a
spherical shell of 72 self-assembling pentagonal
(L1)5(L2)1 capsomere units comprising the
recombinant viral capsid proteins L1 ([P78>R, T176>N,
D273>T, N285>T, S288>N, T353>P, T389>S]-modified) and
L2, conjugated to approximately 200 sarotalocan
groups (near infrared absorbing dye) at N6 of lysine
residues;
produced by human embryonic kidney 293 (HEK293)
cells
belzupacap sarotalocan nanoparticle vide dérivée du virus du papillomavirus
humain 16 (HPV) modifié, 55nm de diamètre,
conjuguée à approximativement 200 molécules d'un
photosensibilisant à base de phthalocyanine (groupe
sarotalocan). Chaque particule est composée de 72
capsomères, faits de 5 molécules de protéine de
capside virale L1 modifiée [P78>R, T176>N, D273>T,
N285>T, S288>N, T353>P, T389>S] et d'une molécule de
protéine de capside virale L2;
capside du virus du papillomavirus humain 16
(HPV16), une coquille sphérique de 72 unités de
capsomère pentagonal (L1)5(L2)1 s'auto-assemblant
comprenant les protéines recombinantes de capside
virale L1 ([P78>R, T176>N, D273>T, N285>T, S288>N,
T353>P, T389>S]-modifiée) et L2, conjuguées à environ
200 groupes sarotalocan (colorant absorbant les
proches infra-rouges) en N6 des résidus lysine ;
produite par des cellules rénales embryonnaires
humaines (HEK293)
belzupacap sarotalocán nanopartícula vacía derivada del virus del
papilomavirus humano 16 (HPV) modificado, 55nm de
diámetro, conjugado con aproximadamente 200
moléculas de un fotosensibilizante a base de
ftalocianina (grupo sarotalocán). Cada partícula se
compone de 72 capsómeros, hechos de 5 moléculas
de proteína de cápside viral L1 modificada [P78>R,
T176>N, D273>T, N285>T, S288>N, T353>P, T389>S] y de
una molécula de proteína de cápside viral L2;
cápside del virus del papilomavirus humano 16
(HPV16), una cavidad esférica de 72 unidades de
capsómero pentagonal (L1)5(L2)1 que se
autoensamblan abarcando las proteínas
recombinantes de cápside viral L1 ([P78>R, T176>N,
D273>T, N285>T, S288>N, T353>P, T389>S]-modificada) y
L2, conjugadas aproximadamente a 200 grupos
sarotalocán (colorante absorbente infrarrojo cercano)
en N6 de los residuos de lisina ;
producido por las células renales embrionarias
humanas (HEK293)
696
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
belzutifanum
belzutifan 3-{[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-
(methanesulfonyl)-2,3-dihydro-1H-inden-4-yl]oxy}-5-
fluorobenzonitrile
belzutifan 3-{[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-
(méthanesulfonyl)-2,3-dihydro-1H-indèn-4-yl]oxy}-5-
fluorobenzonitrile
belzutifán 3-{[(1S,2S,3R)-2,3-difluoro-1-hidroxi-7-
(metanosulfonil)-2,3-dihidro-1H-indén-4-il]oxi}-5-fluoro-
benzonitrilo
C17H12F3NO4S
697
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
bepranemabum #
bepranemab immunoglobulin G4-kappa, anti-[Homo sapiens MAPT
(microtubule-associated protein tau, tau)], humanized
monoclonal antibody;
gamma4 heavy chain humanized (1-445) [VH (Homo
sapiens IGHV4-4*08 (83.5%) -(IGHD) -IGHJ3*01
(93.3%)) CDR-IMGT [8.7.12] (26-33.51-57.96-107) (1-
118)-Homo sapiens IGHG4*01, G4v5 h P10 (CH1
(119-216), hinge 1-12 S10>P (226) (217-228), CH2
(229-338), CH3 (339-443), CHS (444-445)) (119-445)],
(132-219')-disulfide with kappa light chain humanized
(1'-219') [V-KAPPA (Homo sapiens IGKV2-29*02
(90.0%) -IGKJ2*01 (100%)) CDR-IMGT [11.3.9] (27-
37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01
(100%), Km3 A45.1 (158), V101 (196) (113'-219')];
dimer (224-224":227-227")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
bépranémab immunoglobuline G4-kappa, anti-[Homo sapiens
MAPT (protéine tau associée aux microtubules, tau)],
anticorps monoclonal humanisé;
chaîne lourde gamma4 humanisée (1-445) [VH (Homo
sapiens IGHV4-4*08 (83.5%) -(IGHD) -IGHJ3*01
(93.3%)) CDR-IMGT [8.7.12] (26-33.51-57.96-107) (1-
118) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1
(119-216), charnière 1-12 S10>P (226) (217-228),
CH2 (229-338), CH3 (339-443), CHS (444-445)) (119-
445)], (132-219')-disulfure avec la chaîne légère kappa
humanisée (1'-219') [V-KAPPA (Homo sapiens IGKV2-
29*02 (90.0%) -IGKJ2*01 (100%)) CDR-IMGT [11.3.9]
(27-37.55-57.94-102) (1'-112') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-
219')];
dimère (224-224":227-227")-bisdisulfure, produite dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
bepranemab inmunoglobulina G4-kappa, anti-[Homo sapiens MAPT
(proteína tau asociada a los microtúbulos, tau)],
anticuerpo monoclonal humanizado;
cadena pesada gamma4 humanizada (1-445) [VH
(Homo sapiens IGHV4-4*08 (83.5%) -(IGHD) -
IGHJ3*01 (93.3%)) CDR-IMGT [8.7.12] (26-33.51-
57.96-107) (1-118) -Homo sapiens IGHG4*01, G4v5 h
P10 (CH1 (119-216), bisagra 1-12 S10>P (226) (217-
228), CH2 (229-338), CH3 (339-443), CHS (444-445))
(119-445)], (132-219')-disulfuro con la cadena ligera
kappa humanizada (1'-219') [V-KAPPA (Homo sapiens
IGKV2-29*02 (90.0%) -IGKJ2*01 (100%)) CDR-IMGT
[11.3.9] (27-37.55-57.94-102) (1'-112') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-
219')];
dímero (224-224":227-227")-bisdisulfuro, producida
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
698
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
bersacapavirum
bersacapavir N-(3-cyano-4-fluorophenyl)-1-methyl-4-{[(2S)-1,1,1-
trifluoropropan-2-yl]sulfamoyl}-1H-pyrrole-2-carboxamide
bersacapavir N-(3-cyano-4-fluorophényl)-1-méthyl-4-{[(2S)-1,1,1-
trifluoropropan-2-yl]sulfamoyl}-1H-pyrrole-2-carboxamide
bersacapavir N-(3-ciano-4-fluorofenil)-1-metil-4-{[(2S)-1,1,1-
trifluoropropan-2-il]sulfamoil}-1H-pirrolo-2-carboxamida
C16H14F4N4O3S
bexmarilimabum #
bexmarilimab immunoglobulin G4-kappa, anti-[Homo sapiens STAB1
(stabilin 1, STAB-1, CLEVER-1, FEEL-1, FELE-1, FEX1,
SCARH2)], humanized monoclonal antibody;
gamma4 heavy chain humanized (1-449) [VH (Homo sapiens
IGHV2-5*09 (91.8%) -(IGHD) -IGHJ4*01 (100%)) [10.7.14]
(1-122) -Homo sapiens IGHG4*01, G4v5 h P10, G4v3 CH2
E1.2 (CH1 (123-220), hinge 1-12 S10>P (230)(221-232),
CH2 L1.2>E (237) (233-342), CH3 (343-447), CHS (448-
449)) (123-449)], (136-215')-disulfide with kappa light chain
humanized (1'-215') [V-KAPPA (Homo sapiens IGKV3-20*01
(80.2%) -IGKJ2*01 (100%)) [7.3.9] (1'-108') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')];
dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese
hamster ovary (CHO) cells, glycoform alfa
699
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
bexmarilimab immunoglobuline G4-kappa, anti-[Homo sapiens
STAB1 (stabilin 1, STAB-1, CLEVER-1, FEEL-1,
FELE-1, FEX1, SCARH2)], anticorps monoclonal
humanisé;
chaîne lourde gamma4 humanisée (1-449) [VH (Homo
sapiens IGHV2-5*09 (91.8%) -(IGHD) - IGHJ4*01
(100%)) [10.7.14] (1-122) -Homo sapiens IGHG4*01,
G4v5 h P10, G4v3 CH2 E1.2 (CH1 (123-220),
charnière 1-12 S10>P (230) (221-232), CH2 L1.2>E
(237) (233-342), CH3 (343-447), CHS (448-449)) (123-
449)], (136-215')-disulfure avec la chaîne légère kappa
humanisée (1'-215') [V-KAPPA (Homo sapiens IGKV3-
20*01 (80.2%) -IGKJ2*01 (100%)) [7.3.9] (1'-108') -
Homo sapiens IGKC*01 (100%), Km3 A45.1 (154),
V101 (192) (109'-215')];
dimère (228-228'':231-231'')-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
bexmarilimab inmunoglobulina G4-kappa, anti-[Homo sapiens
STAB1 (stabilin 1, STAB-1, CLEVER-1, FEEL-1,
FELE-1, FEX1, SCARH2)], anticuerpo monoclonal
humanizado;
cadena pesada gamma4 humanizada (1-449) [VH
(Homo sapiens IGHV2-5*09 (91.8%) -(IGHD) -
IGHJ4*01 (100%)) [10.7.14] (1-122) -Homo sapiens
IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (123-
220), bisagra 1-12 S10>P (230) (221-232), CH2
L1.2>E (237) (233-342), CH3 (343-447), CHS (448-
449)) (123-449)], (136-215')-disulfuro con la cadena
ligera kappa humanizada (1'-215') [V-KAPPA (Homo
sapiens IGKV3-20*01 (80.2%) -IGKJ2*01 (100%))
[7.3.9] (1'-108') -Homo sapiens IGKC*01 (100%), Km3
A45.1 (154), V101 (192) (109'-215')];
dímero (228-228'':231-231'')-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
700
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
bomedemstatum
bomedemstat N-[(2S)-5-{[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino}-
1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-
triazol-1-yl)benzamide
bomédemstat N-[(2S)-5-{[(1R,2S)-2-(4-fluorophényl)cyclopropyl]amino}-
1-(4-méthylpipérazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-
triazol-1-yl)benzamide
bomedemstat N-[(2S)-5-{[(1R,2S)-2-(4-fluorofenil)ciclopropil]amino}-1-(4-
metilpiperazin-1-il)-1-oxopentan-2-il]-4-(1H-1,2,3-triazol-1-
il)benzamida
C28H34FN7O2
CH3
N
O N F
O
H
N
N
H
N
N N
cevostamabum #
cevostamab immunoglobulin G1-kappa, anti-[Homo sapiens FCRL5 (Fc
receptor like 5, FCRH5, IRTA2, BXMAS1, CD307e)] and
anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)],
monoclonal antibody, bispecific tetravalent;
gamma1 heavy chain anti-FCRL5 (1-450) [VH (Mus
musculus IGHV2-4*01 (77.1%) -(IGHD) -IGHJ3*01
(90.9%)/Homo sapiens IGHV4-4*08 (72.9%) -(IGHD) -
IGHJ5*01 (85.7%)) CDR-IMGT [8.7.14] (26-33.51-57.96-
109) (1-120) -Homo sapiens IGHG1*03v,G1m3>G1m17,
nG1m1, G1v30 CH2 G84.4, G1v32 CH3 W22 (CH1
R120>K (217) (121-218), hinge 1-15 (219-233), CH2
N84.4>G (300) (234-343), CH3 E12 (359), M14 (361),
T22>W (369) (344-448), CHS (449-450)) (121-450)], (223-
214')-disulfide with kappa light chain anti-FCRL5 (1'-214')
[V-KAPPA (Homo sapiens IGKV1-16*01 (83.2%) -
IGKJ1*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97)
(1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1
(153), V101 (191) (108'-214')];
gamma1 heavy chain anti-CD3 (1''-449'') [VH (Homo
sapiens IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%))
CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1''-119'') -Homo
sapiens IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2
G84.4, G1v33 S22, A24, V86 (CH1 R120>K (216) (120-
217), hinge 1-15 (218-232), CH2 N84.4>G (299) (233-
342), CH3 E12 (358), M14 (360), T22>S (368), L24>A
(370), Y86>V (409) (343-447), CHS (448-449)) (120''-
449'')], (222''-219''')-disulfide with kappa light chain anti-
CD3 (1'''-219''') [V-KAPPA (Homo sapiens IGKV4-1*01
(88.8%) -IGKJ1*01 (100%)) CDR-IMGT [12.3.8] (27-38.56-
58.95-102) (1'''-112''') -Homo sapiens IGKC*01 (100%),
Km3 A45.1 (158), V101 (196) (113'''-219''')];
dimer (229-228'':232-231'')-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells
701
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
cévostamab immunoglobuline G1-kappa anti-[Homo sapiens FCRL5 (récepteur Fc
like 5, FCRH5, IRTA2,
BXMAS1, CD307e)] et anti-[Homo sapiens CD3E (CD3 epsilon, Leu-
4)], anticorps monoclonal, bispécifique tétravalent;
chaîne lourde gamma1 anti-FCRL5 (1-450) [VH (Mus musculus
IGHV2-4*01 (77.1%) -(IGHD) -IGHJ3*01 (90.9%)/Homo sapiens
IGHV4-4*08 (72.9%) -(IGHD) -IGHJ5*01 (85.7%)) CDR-IMGT [8.7.14]
(26-33.51-57.96-109) (1-120) -Homo sapiens
IGHG1*03v,G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v32 CH3
W22 (CH1 R120>K (217) (121-218), charnière 1-15 (219-233), CH2
N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369)
(344-448), CHS (449-450)) (121-450)], (223-214')-disulfure avec la
chaîne légère kappa anti-FCRL5 (1'-214') [V-KAPPA (Homo sapiens
IGKV1-16*01 (83.2%) -IGKJ1*01 (91.7%)) CDR-IMGT [6.3.9] (27-
32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3
A45.1 (153), V101 (191) (108'-214')];
chaîne lourde gamma1 anti-CD3 (1''-449'') [VH (Homo sapiens
IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.12]
(26-33.51-58.97-108) (1''-119'') -Homo sapiens IGHG1*03v,
G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v33 S22, A24, V86
(CH1 R120>K (216) (120-217), charnière 1-15 (218-232), CH2
N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368),
L24>A (370), Y86>V (409) (343-447), CHS (448-449)) (120''-449'')],
(222''-219''')-disulfure avec la chaîne légère kappa anti-CD3 (1'''-219''')
[V-KAPPA (Homo sapiens IGKV4-1*01 (88.8%) -IGKJ1*01 (100%))
CDR-IMGT [12.3.8] (27-38.56-58.95-102) (1'''-112''') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'''-219''')];
dimère (229-228'':232-231'')-bisdisulfure, produit dans des cellules
ovariennes de hamster chinois (CHO)
cevostamab inmunoglobulina G1-kappa anti-[Homo sapiens FCRL5 (receptor Fc
like 5, FCRH5, IRTA2,
BXMAS1, CD307e)] y anti-[Homo sapiens CD3E (CD3 épsilon, Leu-
4)], anticuerpo monoclonal, biespecífico tetravalente;
cadena pesada gamma1 anti-FCRL5 (1-450) [VH (Mus musculus
IGHV2-4*01 (77.1%) -(IGHD) -IGHJ3*01 (90.9%)/Homo sapiens
IGHV4-4*08 (72.9%) -(IGHD) -IGHJ5*01 (85.7%)) CDR-IMGT [8.7.14]
(26-33.51-57.96-109) (1-120) -Homo sapiens
IGHG1*03v,G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v32 CH3
W22 (CH1 R120>K (217) (121-218), bisagra 1-15 (219-233), CH2
N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369)
(344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro con la
cadena ligera kappa anti-FCRL5 (1'-214') [V-KAPPA (Homo sapiens
IGKV1-16*01 (83.2%) -IGKJ1*01 (91.7%)) CDR-IMGT [6.3.9] (27-
32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3
A45.1 (153), V101 (191) (108'-214')];
cadena pesada gamma1 anti-CD3 (1''-449'') [VH (Homo sapiens
IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.12]
(26-33.51-58.97-108) (1''-119'') -Homo sapiens IGHG1*03v,
G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v33 S22, A24, V86
(CH1 R120>K (216) (120-217), bisagra 1-15 (218-232), CH2 N84.4>G
(299) (233-342), CH3 E12 (358), M14 (360), T22>S (368), L24>A
(370), Y86>V (409) (343-447), CHS (448-449)) (120''-449'')], (222''-
219''')-disulfuro con la cadena ligera kappa anti-CD3 (1'''-219''') [V-
KAPPA (Homo sapiens IGKV4-1*01 (88.8%) -IGKJ1*01 (100%))
CDR-IMGT [12.3.8] (27-38.56-58.95-102) (1'''-112''') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'''-219''')];
dímero (229-228'':232-231'')-bisdisulfuro, producido por células
ováricas de hamster chino (CHO)
702
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
ciltacabtagenum autoleucelum #
ciltacabtagene autoleucel autologous peripheral blood mononuclear cell (PBMC)-derived
T lymphocytes transduced ex vivo with a non-replicating, self-
inactivating (SIN) lentiviral vector encoding a chimeric antigen
receptor (CAR) targeting two epitopes of the human B cell
maturation antigen (BCMA) under the control of a human
elongation factor 1 alpha (EF1α) promoter
The coding sequence comprises a human CD8 alpha signal
peptide (CD8α SP), a BCMA targeting domain consisting of
two variable heavy chain-only antibodies (VHH1 and VHH2)
targeting two distinct BCMA epitopes, a human CD8 alpha
hinge and transmembrane domain (CD8α hinge + TM), a
human CD137 cytoplasmic domain (4-1BB) and a human CD3
zeta cytoplasmic domain (CD3ζ).
The vector genome contains a chimeric Rous sarcoma virus
(RSV)/truncated 5'LTR and a self-inactivating 3'LTR-SIN (∆-
U3).
703
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
ciltacabtagène autoleucel lymphocytes T autologues dérivés de cellules
mononuclées du sang périphérique (PBMC) transduits
ex vivo avec un vecteur lentiviral non-répliquant, auto-
inactivant (SIN) codant pour un récepteur d'antigène
chimérique (CAR) ciblant deux épitopes de l'antigène
de maturation des lymphocytes B (BCMA) humains
sous le contrôle d'un promoteur du facteur d'élongation
1-alpha humain (EF1α)
La séquence code pour un peptide signal CD8 alpha
humain (CD8α SP), un domaine ciblant le BCMA
consistant en seulement la partie variable des chaînes
lourdes (VHH1 and VHH2) de deux anticorps dirigés
contre deux épitopes du BCMA, une charnière et un
domaine transmembranaire du CD8 alpha humain, un
domaine cytoplasmique du CD 137 humain (4-1BB) et
un domaine cytoplasmique du CD3 zêta humain
(CD3ζ).
Le génome du vecteur contient en 5', une séquence
LTR (terminale longue répétée) tronquée d'un virus du
sarcome de Rous (RSV) chimérique et en 3', une
séquence LTR-SIN (∆-U3) auto-inactivante.
ciltacabtagén autoleucel linfocitos T autólogos derivados de células
mononucleares de sangre periférica (PBMC)
transducidos ex vivo con un vector lentiviral no
replicativo, auto inactivante (SIN), que codifica para un
receptor de antígenos quimérico (CAR) dirigido a dos
epítopos del antígeno de maduración de linfocitos B
(BCMA) humano bajo el control de un promotor del
factor de elongación 1 alfa humano (promotor EF1α)
La secuencia codificante consta de un péptido señal
del CD8 alfa humano, un dominio dirigido a BCMA
consistente en sólo la parte variable de las cadenas
pesadas (VHH1 y VHH2) de dos anticuerpos dirigidos
a dos epítopos de BCMA, una bisagra y un dominio
transmembrana del CD8 alfa humano, un dominio
citoplásmico del CD137 humano (4-1BB) y un dominio
citoplásmico del CD3 zeta humano (CD3ζ).
El genoma del vector contiene un LTR 5'
truncado/RSV (virus del sarcoma de Rous) quimérico
y un LTR 3'-SIN auto inactivante (∆-U3).
conendostatinum
conendostatin L-methionyl-human endostatin [human collagen type
XVIII α-1 (COL18A1) C-terminal (1572-1754)-fragment
(1-183)], canonical D104, R110, S150 form, produced in
Escherichia coli
conendostatine L-méthionyl-endostatine humaine [fragment C-terminal
(1572-1754) du collagène humain de type XVIII α-1
(COL18A1) (1-183)], forme canonique D104, R110, S150,
produit dans Escherichia coli
conendostatina L-metionil-endostatina humana [fragmento C-terminal
(1572-1754) del colágeno humano de tipo XVIII α-1
(COL18A1) (1-183)], forma canónica D104, R110, S150,
producido en Escherichia coli
704
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
cudarolimabum #
cudarolimab immunoglobulin G1-kappa, anti-[Homo sapiens
TNFRSF4 (tumor necrosis factor receptor (TNFR)
superfamily member 4, ACT35, OX40, CD134)], Homo
sapiens monoclonal antibody;
gamma1 heavy chain Homo sapiens (1-453) [VH
(Homo sapiens IGHV3-30*03 (100%) -(IGHD) -
IGHJ3*02 (100%)) CDR-IMGT [8.8.17] (26-33.51-
58.97-113) (1-124) -Homo sapiens IGHG1*01 (100%)
G1m17,1 (CH1 K120 (221) (125-222), hinge 1-15
(223-237), CH2 (238-347), CH3 D12 (363), L14 (365)
(348-452), CHS K>del (453)) (125-453)], (227-213')-
disulfide with kappa light chain Homo sapiens (1'-213')
[V-KAPPA (Homo sapiens IGKV1-33*01 (96.8%) -
IGKJ4*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-
96) (1'-106') -Homo sapiens IGKC*01 (100%), Km3
A45.1 (152), V101 (190) (107'-213')];
dimer (233-233'':236-236'')-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
cudarolimab immunoglobuline G1-kappa, anti-[Homo sapiens
TNFRSF4 (membre 4 de la superfamille des
récepteurs du facteur de nécrose tumorale, ACT35,
OX40, CD134)], anticorps monoclonal Homo sapiens;
chaîne lourde gamma1 Homo sapiens (1-453) [VH
(Homo sapiens IGHV3-30*03 (100%) -(IGHD) -
IGHJ3*02 (100%)) CDR-IMGT [8.8.17] (26-33.51-
58.97-113) (1-124) -Homo sapiens IGHG1*01 (100%)
G1m17,1 (CH1 K120 (221) (125-222), charnière 1-15
(223-237), CH2 (238-347), CH3 D12 (363), L14 (365)
(348-452), CHS K>del (453)) (125-453)], (227-213')-
disulfure avec la chaîne légère kappa Homo sapiens
(1'-213') [V-KAPPA (Homo sapiens IGKV1-33*01
(96.8%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.8] (27-
32.50-52.89-96) (1'-106') -Homo sapiens IGKC*01
(100%), Km3 A45.1 (152), V101 (190) (107'-213')];
dimère (233-233'':236-236'')-bisdisulfure, produite
dans des cellules ovariennes de hamster chinois
(CHO), glycoforme alfa
cudarolimab inmunoglobulina G1-kappa, anti-[Homo sapiens
TNFRSF4 (miembro 4 de la superfamilia de los
receptores del factor de necrosis tumoral, ACT35,
OX40, CD134)], anticuerpo monoclonal Homo
sapiens;
705
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
cadena pesada gamma1 Homo sapiens (1-453) [VH
(Homo sapiens IGHV3-30*03 (100%) -(IGHD) -
IGHJ3*02 (100%)) CDR-IMGT [8.8.17] (26-33.51-
58.97-113) (1-124) -Homo sapiens IGHG1*01 (100%)
G1m17,1 (CH1 K120 (221) (125-222), bisagra 1-15
(223-237), CH2 (238-347), CH3 D12 (363), L14 (365)
(348-452), CHS K>del (453)) (125-453)], (227-213')-
disulfuro con la cadena ligera kappa Homo sapiens (1'-
213') [V-KAPPA (Homo sapiens IGKV1-33*01 (96.8%)
-IGKJ4*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-
52.89-96) (1'-106') -Homo sapiens IGKC*01 (100%),
Km3 A45.1 (152), V101 (190) (107'-213')];
dímero (233-233'':236-236'')-bisdisulfuro, producida
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
Heavy chain / Chaîne lourde / Cadena pesada
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV 50
ISYDGSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARGR 100
PWYSETGTSA FDIWGQGTMV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK KVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPG 453
Light chain / Chaîne légère / Cadena ligera
DIQMTQSPSS LSASVGDRVT ITCQASQDIS NYLNWYQQKP GKAPKLLIYD 50
ASNLETGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ SDHYPTFGGG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC 213
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 151-207 268-328 374-432
22''-96'' 151''-207'' 268''-328'' 374''-432''
Intra-L (C23-C104) 23'-88' 133'-193'
23'''-88''' 133'''-193'''
Inter-H-L (h 5-CL 126) 227-213' 227''-213'''
Inter-H-H (h 11, h 14) 233-233'' 236-236''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 304''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
dapatifagenum navolactibacum #
dapatifagene navolactibac A recombinant live attenuated Lactococcus lactis,
subspecies cremoris (strain MG1363), expressing a
fusion protein comprising lactococcal secretion leader
SSusp45 and human trefoil factor protein 1 (hTFF1),
driven by the promoter from the homologous hllA gene
(PhllA); the transduced gene is located in the
thymidylate synthase A (thyA) locus which has been
deleted (930102-930469).
dapatifagène navolactibac Lactococcus lactis, sous-espèce cremoris,
recombinante (souche MG1363), vivante atténuée
exprimant une protéine de fusion consistant en le
leader de sécrétion lactoccique SSusp45 et le facteur
en trèfle-1 humain (hTFF1), sous le contrôle du
promoteur du gène homologue hIIA (PhllA); le gène
transduit est localisé sur le locus de la thymidylate
synthase A (thyA) qui a été supprimé (930102-
930469).
706
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
dapatifagén navolactibac Lactococcus lactis, subespecie cremoris (cepa MG1363),
recombinante, viva atenuada, que expresa una proteína de
fusión consistente en el leader de secreción lactocócica
SSusp45 y la proteína 1 del factor trébol humano (hTFF1),
dirigida por el promotor del gen homólogo hIIA (PhIIA); el
gen transducido se localiza en el locus de la timidilato
sintasa A (thyA), que ha sido delecionado (930102-
930469).
datopotamabum #
datopotamab immunoglobulin G1-kappa, anti-[Homo sapiens TACSTD2
(tumor-associated calcium signal transducer 2, membrane
component chromosome 1 surface marker 1, M1S1,
gastrointestinal tumor-associated antigen GA7331,
pancreatic carcinoma marker protein GA733-1, epithelial
glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface
glycoprotein Trop-2, TROP2)], humanized monoclonal
antibody;
gamma1 heavy chain humanized (1-451) [VH (Homo
sapiens IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%))
[8.8.14] (1-121) -Homo sapiens IGHG1*03 (100%) G1m3,
nG1m1 (CH1 R120 (218) (122-219), hinge 1-15 (220-234),
CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS
(450-451)) (122-451)], (224-214')-disulfide with kappa light
chain humanized (1'-214') [V-KAPPA (Homo sapiens
IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -
Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101
(191) (108'-214')];
dimer (230-230'':233-233'')-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
datopotamab immunoglobuline G1-kappa, anti-[Homo sapiens TACSTD2
(transducteur 2 de signaux calciques associé aux tumeurs,
composant membranaire du chromosome 1 marqueur de
surface 1, M1S1, antigène GA7331 associé aux tumeurs
gastrointestinales, protéine GA733-1 marqueur de
carcinomes pancréatiques, glycoprotéine épithéliale 1,
EGP-1, antigène 2 du trophoblaste, glycoprotéine Trop-2 à
la surface des cellules, TROP2)], anticorps monoclonal
humanisé;
chaîne lourde gamma1 humanisée (1-451) [VH (Homo
sapiens IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%))
[8.8.14] (1-121) -Homo sapiens IGHG1*03 (100%) G1m3,
nG1m1 (CH1 R120 (218) (122-219), charnière 1-15 (220-
234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449),
CHS (450-451)) (122-451)], (224-214')-disulfure avec la
chaîne légère kappa humanisée (1'-214') [V-KAPPA (Homo
sapiens IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) [6.3.9]
(1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1
(153), V101 (191) (108'-214')];
dimère (230-230'':233-233'')-bisdisulfure, produit dans des
cellules ovariennes de hamster chinois (CHO), glycoforme
alfa
707
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
datopotamab inmunoglobulina G1-kappa, anti-[Homo sapiens TACSTD2
(transductor 2 de señales cálcicas asociado a los tumores,
componente membranario del cromosoma 1 marcador de
superficie 1, M1S1, antígeno GA7331 asociado a los tumores
gastrointestinales, proteína GA733-1 marcador de carcinomas
pancreáticos, glicoproteína epitelial 1, EGP-1, antígeno 2 del
trofoblasto, glicoproteína Trop-2 en la superficie de las
células, TROP2)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 humanizada (1-451) [VH (Homo
sapiens IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%))
[8.8.14] (1-121) -Homo sapiens IGHG1*03 (100%) G1m3,
nG1m1 (CH1 R120 (218) (122-219), bisagra 1-15 (220-234),
CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS
(450-451)) (122-451)], (224-214')-disulfuro con la cadena
ligera kappa humanizada (1'-214') [V-KAPPA (Homo sapiens
IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -
Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191)
(108'-214')];
dímero (230-230'':233-233'')-bisdisulfuro, producido por
células ováricas de hamster chino (CHO), forma glicosilada
alfa
Heavy chain / Chaîne lourde / Cadena pesada
QVQLVQSGAE VKKPGASVKV SCKASGYTFT TAGMQWVRQA PGQGLEWMGW 50
INTHSGVPKY AEDFKGRVTI SADTSTSTAY LQLSSLKSED TAVYYCARSG 100
FGSSYWYFDV WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K 451
Light chain / Chaîne légère / Cadena ligera
DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS 50
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFAVYYCQQ HYITPLTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 148-204 265-325 371-429
22''-96'' 148''-204'' 265''-325'' 371''-429''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (h 5-CL 126) 224-214' 224''-214'''
Inter-H-H (h 11, h 14) 230-230'' 233-233''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
C-terminal lysine clipping:
H CHS K2:
451, 451''
datopotamabum deruxtecanum #
datopotamab deruxtecan immunoglobulin G1-kappa, anti-[Homo sapiens TACSTD2
(tumor-associated calcium signal transducer 2, membrane
component chromosome 1 surface marker 1, M1S1,
gastrointestinal tumor-associated antigen GA7331,
pancreatic carcinoma marker protein GA733-1, epithelial
glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface
glycoprotein Trop-2, TROP2)], humanized monoclonal
antibody conjugated to deruxtecan, comprising a linker and a
camptothecin derivative;
708
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
gamma1 heavy chain humanized (1-451) [VH
(Homo sapiens IGHV1-3*01(79.6%) -(IGHD) -
IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-
58.97-110) (1-121) -Homo sapiens IGHG1*03
(100%) G1m3, nG1m1 (CH1 R120 (218) (122-219),
hinge 1-15 (220-234), CH2 (235-344), CH3 E12
(360), M14 (362) (345-449), CHS (450-451)) (122-
451)], (224-214')-disulfide with kappa light chain
humanized (1'-214') [V-KAPPA (Homo sapiens
IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) CDR-
IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo
sapiens IGKC*01 (100%), Km3 A45.1 (153), V101
(191) (108'-214')];
dimer (230-230'':233-233'')-bisdisulfide; produced in
Chinese hamster ovary (CHO) cells, glycoform alfa,
conjugated, on an average of 4 cysteinyl, to
deruxtecan, comprising a linker and a camptothecin
derivative
datopotamab déruxtécan immunoglobuline G1-kappa, anti-[Homo sapiens
TACSTD2 (transducteur 2 de signaux calciques
associé aux tumeurs, composant membranaire du
chromosome 1 marqueur de surface 1, M1S1,
antigène GA7331 associé aux tumeurs
gastrointestinales, protéine GA733-1 marqueur de
carcinomes pancréatiques, glycoprotéine épithéliale
1, EGP-1, antigène 2 du trophoblaste, glycoprotéine
Trop-2 à la surface des cellules, TROP2)], anticorps
monoclonal humanisé conjugué au déruxtécan,
comprenant un linker et un dérivé de la
camptothécine;
chaîne lourde gamma1 humanisée (1-451) [VH
(Homo sapiens IGHV1-3*01 (79.6%) -(IGHD) -
IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-
58.97-110) (1-121) -Homo sapiens IGHG1*03
(100%) G1m3, nG1m1 (CH1 R120 (218) (122-219),
charnière 1-15 (220-234), CH2 (235-344), CH3 E12
(360), M14 (362) (345-449), CHS (450-451)) (122-
451)], (224-214')-disulfure avec la chaîne légère
kappa humanisée (1'-214') [V-KAPPA (Homo
sapiens IGKV1-39*01 (84.2%) -IGKJ2*01 (100%))
CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -
Homo sapiens IGKC*01 (100%), Km3 A45.1 (153),
V101 (191) (108'-214')];
dimère (230-230'':233-233'')-bisdisulfure; produit
dans des cellules ovariennes de hamster chinois
(CHO), glycoforme alfa, conjugué sur une moyenne
de 4 cystéines au déruxtécan, comprenant un linker
et un dérivé de la camptothécine
datopotamab deruxtecán inmunoglobulina G1-kappa, anti-[Homo sapiens
TACSTD2 (transductor 2 de señales cálcicas
asociado a los tumores, componente membrana del
cromosoma 1 marcador de superficie 1, M1S1,
antígeno GA7331 asociado a los tumores
gastrointestinales, proteína GA733-1 marcador de
carcinomas pancreáticos, glicoproteína epitelial 1,
EGP-1, antígeno 2 del trofoblasto, glicoproteína
Trop-2 en la superficie de las células, TROP2)],
anticuerpo monoclonal humanizado conjugado con
deruxtecán, que comprende un enlace y un
derivado de la camptotecina;
709
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
cadena pesada gamma1 humanizada (1-451) [VH (Homo
sapiens IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01
(93.3%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-
121) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1
(CH1 R120 (218) (122-219), bisagra 1-15 (220-234), CH2
(235-344), CH3 E12 (360), M14 (362) (345-449), CHS
(450-451)) (122-451)], (224-214')-disulfuro con la cadena
ligera kappa humanizada (1'-214') [V-KAPPA (Homo
sapiens IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) CDR-
IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo
sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191)
(108'-214')];
dímero (230-230'':233-233'')-bisdisulfuro; producido por
células ováricas de hamster chino (CHO), forma
glicosilada alfa, conjugado con una media de 4 cisteinas
al deruxtecán, que comprende un enlace y un derivado
de la camptotecina.
Heavy chain / Chaîne lourde / Cadena pesada
QVQLVQSGAE VKKPGASVKV SCKASGYTFT TAGMQWVRQA PGQGLEWMGW 50
INTHSGVPKY AEDFKGRVTI SADTSTSTAY LQLSSLKSED TAVYYCARSG 100
FGSSYWYFDV WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K 451
Light chain / Chaîne légère / Cadena ligera
DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS 50
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFAVYYCQQ HYITPLTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 148-204 265-325 371-429
22''-96'' 148''-204'' 265''-325'' 371''-429''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (h 5-CL 126)* 224-214' 224''-214'''
Inter-H-H (h 11, h 14)* 230-230'' 233-233''
*The four inter-chain disulfide bridges are not present, an average of 4 cysteinyl being
conjugated each via a thioether bond to a drug linker.
*Les quatre ponts disulfures inter-chaînes ne sont pas présents, 4 cystéinyl en moyenne
étant chacun conjugué via une liaison thioéther à un linker-principe actif.
*Faltan los cuatro puentes disulfuro inter-catenarios, una media de 4 cisteinil está
conjugada a conectores de principio activo.
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.
C-terminal lysine clipping:
H CHS K2:
451, 451''
Potential modified residues / résidus modifiés potentiels / restos modificados potenciales
O O
H
Gly Gly Phe Gly N O O
NH
H
N O
C*
O
O N
N CO2H OH
H H3C
S CH3
O
H NH2 F
710
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
demupitamabum #
demupitamab immunoglobulin G1-kappa, anti-[Homo sapiens EGFR
(epidermal growth factor receptor, receptor tyrosine-
protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)],
Homo sapiens monoclonal antibody;
gamma1 heavy chain Homo sapiens (1-449) [VH
(Homo sapiens IGHV4-61*01 (89.9%) -(IGHD) -
IGHJ3*02 (100%)) CDR-IMGT [10.7.11] (26-35.53-
59.98-108) (1-119) -Homo sapiens IGHG1*01 (100%)
G1m17,1 (CH1 K120 (216) (120-217), hinge 1-15
(218-232), CH2 (233-342), CH3 D12 (358), L14 (360)
(343-447), CHS K (448-449)) (120-449)], (222-214')-
disulfide with kappa light chain Homo sapiens (1'-214')
[V-KAPPA (Homo sapiens IGKV1-33*01 (94.7%) -
IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-
52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%),
Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (228-228'':231-231'')-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
démupitamab immunoglobuline G1-kappa, anti-[Homo sapiens
EGFR (récepteur du facteur de croissance
épidermique, récepteur tyrosine-protéine kinase erb-1,
ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal
humanisé;
chaîne lourde gamma1 Homo sapiens (1-449) [VH
(Homo sapiens IGHV4-61*01 (89.9%) -(IGHD) -
IGHJ3*02 (100%)) CDR-IMGT [10.7.11] (26-35.53-
59.98-108) (1-119) -Homo sapiens IGHG1*01 (100%)
G1m17,1 (CH1 K120 (216) (120-217), charnière 1-15
(218-232), CH2 (233-342), CH3 D12 (358), L14 (360)
(343-447), CHS K (448-449)) (120-449)], (222-214')-
disulfure avec la chaîne légère kappa Homo sapiens
(1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01
(94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-
32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01
(100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (228-228'':231-231'')-bisdisulfure, produite
dans des cellules ovariennes de hamster chinois
(CHO), glycoforme alfa
demupitamab inmunoglobulina G1-kappa, anti-[Homo sapiens EGFR
(receptor del factor de crecimiento epidérmico,
receptor tirosina-proteína kinasa erb-1, ERBB1, HER1,
HER-1, ERBB)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 Homo sapiens (1-449) [VH
(Homo sapiens IGHV4-61*01 (89.9%) -(IGHD) -
IGHJ3*02 (100%)) CDR-IMGT [10.7.11] (26-35.53-
59.98-108) (1-119) -Homo sapiens IGHG1*01 (100%)
G1m17,1 (CH1 K120 (216) (120-217), bisagra 1-15
(218-232), CH2 (233-342), CH3 D12 (358), L14 (360)
(343-447), CHS K (448-449)) (120-449)], (222-214')-
disulfuro con la cadena ligera kappa Homo sapiens (1'-
214') [V-KAPPA (Homo sapiens IGKV1-33*01 (94.7%)
-IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-
52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%),
Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (228-228'':231-231'')-bisdisulfuro, producida
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
711
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
docaravimabum #
docaravimab immunoglobulin G2B-kappa, anti-[rabies virus strain
ERA (Evelyn-Rockitniki-Abelseth) glycoprotein
ectodomain epitope G-III], Mus musculus monoclonal
antibody;
gamma2b heavy chain Mus musculus (1-455) [VH
(Mus musculus IGHV2-6-7*01 (92.8%) -(IGHD) -
IGHJ2*01 (100%)) CDR-IMGT [8.7.13] (26-33.51-
57.96-108) (1-119) -Mus musculus IGHG2B*02 (CH1
(120-216), hinge 1-22 (217-238), CH2 (239-348), CH3
(349-453), CHS (454-455)) (120-455)], (134-214')-
disulfide with kappa light chain Mus musculus (1'-214')
[V-KAPPA (Mus musculus IGKV10-96*01 (93.7%) -
IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.99-
107) (1'-106') -Mus musculus IGKC*01 (100%) (108'-
214')];
dimer (228-228":231-231":234-234":237-237")-
tetrakisdisulfide, produced in mouse myeloma cell line
SP2/0-Ag14, glycoform alfa
docaravimab immunoglobuline G2B-kappa, anti-[ectodomaine
épitope G-III glycoprotéine du virus de la rage souche
ERA (Evelyn-Rockitniki-Abelseth)], anticorps
monoclonal Mus musculus;
chaîne lourde gamma2b Mus musculus (1-455) [VH
(Mus musculus IGHV2-6-7*01 (92.8%) -(IGHD) -
IGHJ2*01 (100%)) CDR-IMGT [8.7.13] (26-33.51-
57.96-108) (1-119) -Mus musculus IGHG2B*02 (CH1
(120-216), charnière 1-22 (217-238), CH2 (239-348),
CH3 (349-453), CHS (454-455)) (120-455)], (134-
214')-disulfure avec la chaîne légère kappa Mus
musculus (1'-214') [V-KAPPA (Mus musculus IGKV10-
96*01 (93.7%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9]
(27-32.50-52.99-107) (1'-106') -Mus musculus
IGKC*01 (100%) (108'-214')];
dimère (228-228":231-231":234-234":237-237")-
tétrakisdisulfure, produite dans la lignée cellulaire de
myélome murin SP2/0-Ag14, glycoforme alfa
712
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
docaravimab inmunoglobulina G2B-kappa, anti-[ectodominio epítopo G-III
glicoproteína del virus de la rabia cepa ERA (Evelyn-Rockitniki-
Abelseth)], anticuerpo monoclonal Mus musculus;
cadena pesada gamma2b Mus musculus (1-455) [VH (Mus
musculus IGHV2-6-7*01 (92.8%) -(IGHD) -IGHJ2*01 (100%))
CDR-IMGT [8.7.13] (26-33.51-57.96-108) (1-119) -Mus musculus
IGHG2B*02 (CH1 (120-216), bisagra 1-22 (217-238), CH2 (239-
348), CH3 (349-453), CHS (454-455)) (120-455)], (134-214')-
disulfuro con la cadena ligera kappa Mus musculus (1'-214') [V-
KAPPA (Mus musculus IGKV10-96*01 (93.7%) -IGKJ1*02
(100%)) CDR-IMGT [6.3.9] (27-32.50-52.99-107) (1'-106') -Mus
musculus IGKC*01 (100%) (108'-214')];
dímero (228-228":231-231":234-234":237-237")-tetrakisdisulfuro,
producida en la línea celular de mieloma murino SP2/0-Ag14,
glicoforma alfa
Heavy chain / Chaîne lourde / Cadena pesada
QVQLKESGPG LLAPSQSLSI TCTVSGFSLT GHGVNWVRQP PGKGLEWLGI 50
IWADGTTNYN SALKSRLSIS KDNSKSQVFL KMNSLQTDDT ASYYCAREGD 100
ISGYYFDYWG QGTTLTVSSA KTTPPSVYPL APGCGDTTGS SVTLGCLVKG 150
YFPESVTVTW NSGSLSSSVH TFPALLQSGL YTMSSSVTVP SSTWPSQTVT 200
CSVAHPASST TVDKKLEPSG PISTINPCPP CKECHKCPAP NLEGGPSVFI 250
FPPNIKDVLM ISLTPKVTCV VVDVSEDDPD VQISWFVNNV EVHTAQTQTH 300
REDYNSTIRV VSTLPIQHQD WMSGKEFKCK VNNKDLPSPI ERTISKIKGL 350
VRAPQVYILP PPAEQLSRKD VSLTCLVVGF NPGDISVEWT SNGHTEENYK 400
DTAPVLDSDG SYFIYSKLNM KTSKWEKTDS FSCNVRHEGL KNYYLKKTIS 450
RSPGK 455
Light chain / Chaîne légère / Cadena ligera
DVQMTQTTSS LSASLGDRVT ITCRPSQDIN NYLSWYQQKP DGTVKLLIYY 50
TSRLHSGVPS RFSGSGSGTD YSLTISNLEQ EDFATYFCQQ GNTLPPTFGG 100
GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI 150
DGSERQNGVL NSWTDQDSKD STYSMSSTLT LTKDEYERHN SYTCEATHKT 200
STSPIVKSFN RNEC 214
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-95 146-201 269-329 375-433
22''-95'' 146''-201'' 269''-329'' 375''-433''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (CH1 11-CL 126) 134-214' 134''-214'''
Inter-H-H (h 12, h 15, h 18, h 21) 228-228'' 231-231'' 234-234'' 237-237''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
305, 305''
Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires
complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados
ebopiprantum
ebopiprant (3S)-3-[(2S)-3-([1,1'-biphenyl]-4-sulfonyl)-1,3-thiazolidine-2-
carboxamido]-3-(4-fluorophenyl)propyl L-valinate
ébopiprant L-valinate de (3S)-3-[(2S)-3-([1,1'-biphényl]-4-sulfonyl)-1,3-
thiazolidine-2-carboxamido]-3-(4-fluorophényl)propyle
ebopiprant L-valinato de (3S)-3-[(2S)-3-([1,1'-bifenil]-4-sulfonil)-1,3-
tiazolidina-2-carboxamido]-3-(4-fluorofenil)propilo
C30H34FN3O5S2
713
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
efanesoctocogum alfa #
efanesoctocog alfa human coagulation factor VIII (FVIII, antihemophilic factor, AHF,
procoagulant component) with replaced B-domain (746-1648)-
sequence [FVIII domains A1-a1-A2-a2 (1-740) and N-terminal
B-domain fragment (741-745), fused via a synthetic 291-peptide linker
of 24 repeating 12-peptides (4 types) (746-1033) plus tripeptide ASS
(1034-1036) to the FVIII C-terminal (1649-2332)-domains a3-A3-C1-
C2 (1037-1720)], fused to a human immunoglobulin G1 C-terminal
K>del Fc fragment (1721-1946), (1726-663':1729-666')-bisdisulfide
with the TIL3-D3-TIL4 domain-containing fragment 742-1218 of the
human von Willebrand factor (1'-477') [(C1077>A336',C1120>A379')-mutant]
fused via a synthetic 148-peptide linker of 12 repeating 12-peptides (4
types) plus tetrapeptide GASS (478'-625') to a thrombin cleavable
FVIII fragment 712-743 (626'-657') [thrombin-cleavable acidic region 2
plus B3 domain (1-3)-peptide] fused to a human immunoglobulin G1
C-terminal K>del Fc fragment (658'-883'), produced in human
embryonic kidney 293 (HEK293) cells, glycoform alfa
éfanésoctocog alfa facteur de coagulation VIII humain (FVIII, facteur antihémophilique,
AHF, composant procoagulant) dont le domaine B a été remplacé
(746-1648) [domaines A1-a1-A2-a2 du FVIII (1-740) et fragment
N-terminal du domaine B (741-745), fusionné via un peptide
synthétique de 291 acides aminés, fait de 24 peptides de 12 acides
aminés chacun, se répétant (4 types) (746-1033), et d'un tripeptide
ASS (1034-1036), à la partie C-terminale des domaines a3-A3-C1-C2
1649-2332 du FVIII (1037-1720)], fusionné au fragment Fc C-terminal
K>del de l'immunoglobuline G1 humaine (1721-1946), (1726-
663':1729-666') lié par des ponts disulfure au fragment contenant le
domaine TIL3-D3-TIL4 du facteur de von Willebrand humain 742-1218
(1'-477') [(C1077>A336',C1120>A379')-mutant] fusionné via un peptide
synthétique de 148 acides aminés, fait de 12 peptides de 12 acides
aminés chacun, se répétant (4 types), plus un tétrapeptide GASS
(478'-625'), à un fragment du FVIII clivable par la thrombine 712-743
(626'-657') [région 2 acide clivable par la thrombine plus le (1-3)-
peptide du domaine B3] fusionné au fragment Fc C-terminal K>del de
l'immunoglobuline G1 humaine (658'-883'), produit dans des cellules
rénales embryonnaires humaines 293 (HEK293), glycoforme alfa
efanesoctocog alfa factor de coagulación VIII humano (FVIII, factor antihemofílico, AHF,
componente procoagulante) en el dominio B reemplazado (746-1648)
[dominios A1-a1-A2-a2 del FVIII (1-740) y fragmento N-terminal del
dominio B (741-745), fusionado a través de un péptido sintético de
291 aminoácidos, hecho de 24 péptidos de 12 aminoácidos cada uno,
que se repiten (4 tipos) (746-1033), y de un tripéptido ASS (1034-
1036), con la parte C-terminal de los dominios a3-A3-C1-C2 1649-
2332 del FVIII (1037-1720)], fusionado con el fragmento Fc C-terminal
K>del de la inmunoglobulina G1 humana (1721-1946), (1726-
663':1729-666') unido por puentes disulfuro con el fragmento que
contiene el dominio TIL3-D3-TIL4 del factor de von Willebrand
humano 742-1218 (1'-477') [(C1077>A336',C1120>A379')-mutante]
fusionado a través de un péptido sintético de 148 aminoácidos, hecho
de 12 péptidos de 12 aminoácidos cada uno, que se repiten (4 tipos),
además un tetrapéptido GASS (478'-625'), con un fragmento del FVIII
escindible por la trombina 712-743 (626'-657') [región 2 ácido
escindible por la trombina además el (1-3)-péptido del dominio B3]
fusionado con el fragmento Fc C-terminal K>del de la
inmunoglobulina G1 humana (658'-883'), producido en las células
renales embrionarias humanas 293 (HEK293), glicoforma alfa
714
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
Sequence / Séquence / Secuencia
(a) BddFVIII-Fc chain:
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV 80
YDTVVITLKN MASHPVSLHA VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD PLCLTYSYLS 160
HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR 240
SLPGLIGCHR KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL MDLGQFLLFC HISSHQHDGM 320
EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI 480
TDVRPLYSRR LPKGVKHLKD FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP LLICYKESVD 560
QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL 640
SIGAQTDFLS VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR GMTALLKVSS CDKNTGDYYE 720
DSYEDISAYL LSKNNAIEPR SFSQNGTSES ATPESGPGSE PATSGSETPG TSESATPESG PGSEPATSGS ETPGTSESAT 800
PESGPGTSTE PSEGSAPGSP AGSPTSTEEG TSESATPESG PGSEPATSGS ETPGTSESAT PESGPGSPAG SPTSTEEGSP 880
AGSPTSTEEG TSTEPSEGSA PGTSESATPE SGPGTSESAT PESGPGTSES ATPESGPGSE PATSGSETPG SEPATSGSET 960
PGSPAGSPTS TEEGTSTEPS EGSAPGTSTE PSEGSAPGSE PATSGSETPG TSESATPESG PGTSTEPSEG SAPASSEITR 1040
TTLQSDQEEI DYDDTISVEM KKEDFDIYDE DENQSPRSFQ KKTRHYFIAA VERLWDYGMS SSPHVLRNRA QSGSVPQFKK 1120
VVFQEFTDGS FTQPLYRGEL NEHLGLLGPY IRAEVEDNIM VTFRNQASRP YSFYSSLISY EEDQRQGAEP RKNFVKPNET 1200
KTYFWKVQHH MAPTKDEFDC KAWAYFSDVD LEKDVHSGLI GPLLVCHTNT LNPAHGRQVT VQEFALFFTI FDETKSWYFT 1280
ENMERNCRAP CNIQMEDPTF KENYRFHAIN GYIMDTLPGL VMAQDQRIRW YLLSMGSNEN IHSIHFSGHV FTVRKKEEYK 1360
MALYNLYPGV FETVEMLPSK AGIWRVECLI GEHLHAGMST LFLVYSNKCQ TPLGMASGHI RDFQITASGQ YGQWAPKLAR 1440
LHYSGSINAW STKEPFSWIK VDLLAPMIIH GIKTQGARQK FSSLYISQFI IMYSLDGKKW QTYRGNSTGT LMVFFGNVDS 1520
SGIKHNIFNP PIIARYIRLH PTHYSIRSTL RMELMGCDLN SCSMPLGMES KAISDAQITA SSYFTNMFAT WSPSKARLHL 1600
QGRSNAWRPQ VNNPKEWLQV DFQKTMKVTG VTTQGVKSLL TSMYVKEFLI SSSQDGHQWT LFFQNGKVKV FQGNQDSFTP 1680
VVNSLDPPLL TRYLRIHPQS WVHQIALRME VLGCEAQDLY DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT 1760
CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 1840
GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 1920
NVFSCSVMHE ALHNHYTQKS LSLSPG 1946
(b) vWF fragment-FVIII a2-Fc chain:
SLSCRPPMVK LVCPADNLRA EGLECTKTCQ NYDLECMSMG CVSGCLCPPG MVRHENRCVA LERCPCFHQG KEYAPGETVK 80
IGCNTCVCRD RKWNCTDHVC DATCSTIGMA HYLTFDGLKY LFPGECQYVL VQDYCGSNPG TFRILVGNKG CSHPSVKCKK 160
RVTILVEGGE IELFDGEVNV KRPMKDETHF EVVESGRYII LLLGKALSVV WDRHLSISVV LKQTYQEKVC GLCGNFDGIQ 240
NNDLTSSNLQ VEEDPVDFGN SWKVSSQCAD TRKVPLDSSP ATCHNNIMKQ TMVDSSCRIL TSDVFQDCNK LVDPEPYLDV 320
CIYDTCSCES IGDCAAFCDT IAAYAHVCAQ HGKVVTWRTA TLCPQSCEER NLRENGYEAE WRYNSCAPAC QVTCQHPEPL 400
ACPVQCVEGC HAHCPPGKIL DELLQTCVDP EDCPVCEVAG RRFASGKKVT LNPSDPEHCQ ICHCDVVNLT CEACQEPGTS 480
ESATPESGPG SEPATSGSET PGTSESATPE SGPGSEPATS GSETPGTSES ATPESGPGTS TEPSEGSAPG SPAGSPTSTE 560
EGTSESATPE SGPGSEPATS GSETPGTSES ATPESGPGSP AGSPTSTEEG SPAGSPTSTE EGASSDKNTG DYYEDSYEDI 640
SAYLLSKNNA IEPRSFSDKT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE 720
VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP SRDELTKNQV 800
SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 880
SPG 883
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
(a) 153-179, 248-329, 528-554, 630-711, 1220-1246, 1287-1291, 1409-1557, 1562-1714, 1761-1821, 1867-1925
(Cys-SH: 310, 692, 1388);
(b) 4'-45', 13'-41', 25'-36', 29'-64', 47'-58', 66'-88', 83'-100', 86'-95', 104'-233', 126'-268', 135'-230',
151'-158', 283'-326', 297'-321', 308'-348', 328'-334', 338'-363', 367'-410', 386'-406', 390'-402',
394'-433', 414'-427', 436'-464', 459'-474', 462'-471', 698'-758', 804'-862'
(a)-(b) intermolecular: 1726-663', 1729-666'
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
N41, N239, N1198, N1506, N1797 and N94', N384', N734'
O-glycosylation sites / Sites de O-glycosylation / Posiciones de O-glicosilación
potentially each Ser and Thr in the linker peptides
746-1036 and 478'-625'
Tyr-sulfation sites / Sites de Tyr-sulfation / Posiciones de Tyr-sulfación
346, 718, 719, 723, 729, 1052, 1068 and 632', 633', 637', 643'
eflepedocokinum alfa #
eflepedocokin alfa human interleukin 22 (IL22, cytokine Zcyto18, IL10-
related T-cell-derived inducible factor, IL-TIF) (1-146),
fused via a GSG3S(G4S)2 peptide linker (147-162) to a
human immunoglobulin G2 C-terminal Fc fragment
(163-385), P269>S-mutant S316>A-variant, dimer (165-
165':168-168')-bisdisulfide, produced in Chinese
hamster ovary (CHO) cells, glycoform alfa
715
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
eflépédocokine alfa interleukine 22 humaine (IL22, cytokine Zcyto18,
facteur inductible dérivé des lymphocytes T lié à IL10,
IL-TIF) (1-146), fusionnée via un peptide liant
GSG3S(G4S)2 (147-162) au fragment Fc C-terminal de
l'immunoglobuline G2 humaine (163-385), P269>S-
mutant S366>A-variant, dimère (165-165':168-168')-
bisdisulfure, produit dans des cellules ovariennes de
hamster chinois (CHO), glycoforme alfa
eflepedocokina alfa interleukina 22 humana (IL22, citoquina Zcyto18,
factor inducible derivado de los linfocitos T relacionado
con IL10, IL-TIF) (1-146), fusionada a través de un
péptido que se une a GSG3S(G4S)2 (147-162) con el
fragmento Fc C-terminal de la inmunoglobulina G2
humana (163-385), P269>S-mutante S366>A-variante,
dímero (165-165':168-168')-bisdisulfuro, producido en
las células ováricas de hamster chino (CHO),
glicoforma alfa
Sequence / Séquence / Secuencia
APISSHCRLD KSNFQQPYIT NRTFMLAKEA SLADNNTDVR LIGEKLFHGV 50
SMSERCYLMK QVLNFTLEEV LFPQSDRFQP YMQEVVPFLA RLSNRLSTCH 100
IEGDDLHIQR NVQKLKDTVK KLGESGEIKA IGELDLLFMS LRNACIGSGG 150
GSGGGGSGGG GSVECPPCPA PPVAGPSVFL FPPKPKDTLM ISRTPEVTCV 200
VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV VSVLTVVHQD 250
WLNGKEYKCK VSNKGLPASI EKTISKTKGQ PREPQVYTLP PSREEMTKNQ 300
VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSKLTV 350
DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK 385
Post-translational modifications / Modifications post-traductionnelles / Modificaciones
postraduccionales
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
intramolecular: 7-99 56-145 199-259 305-363
7'-99' 56'-145' 199'-259' 305'-363'
intermolecular: 165-165' 168-168'
Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N21, N35, N64, N235 N21', N35', N64', N235'
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires
complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados
C-terminal lysine clipping / Coupure de la lysine C-terminale / supresión de lisina C-terminal
H CHS K2: 385, 385'
efmarodocokinum alfa #
efmarodocokin alfa human interleukin 22 (IL22, cytokine Zcyto18, IL10-
related T-cell-derived inducible factor, IL-TIF) (1-146),
fused to a human immunoglobulin G4 C-terminal Fc
fragment (147-377), S158>P, N227>G-mutant; dimer
(156-156':159-159')-bisdisulfide, produced in Chinese
hamster ovary (CHO) cells, glycoform alfa
efmarodocokine alfa interleukine 22 humaine (IL22, cytokine Zcyto18,
facteur inductible dérivé des lymphocytes lié à l'IL10,
IL-TIF) (1-146), fusionnée au fragment Fc C-terminal
de l'immunoglobuline G4 humaine (147-377), mutant
S158>P, N227>G, dimère (156-156':159-159')-
bisdisulfure, produit dans des cellules ovariennes de
hamster chinois (CHO), glycoforme alfa
efmarodocokina alfa interleukina 22 humana (IL22, citoquina Zcyto18, IL10-
relacionada factor inducible derivado de células T, IL-
TIF) (1-146), fusionada con el fragmento Fc C-terminal
de la inmunoglobulina G4 humana (147-377), mutante
S158>P, N227>G, dímero (156-156':159-159')-
bisdisulfuro, producido en las células ováricas de
hamster chino (CHO), glicoforma alfa
716
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
Sequence / Séquence / Secuencia
APISSHCRLD KSNFQQPYIT NRTFMLAKEA SLADNNTDVR LIGEKLFHGV 50
SMSERCYLMK QVLNFTLEEV LFPQSDRFQP YMQEVVPFLA RLSNRLSTCH 100
IEGDDLHIQR NVQKLKDTVK KLGESGEIKA IGELDLLFMS LRNACIRVES 150
KYGPPCPPCP APEFLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSQED 200
PEVQFNWYVD GVEVHNAKTK PREEQFGSTY RVVSVLTVLH QDWLNGKEYK 250
CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSLTCLVK 300
GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG 350
NVFSCSVMHE ALHNHYTQKS LSLSLGK 377
Post-translational modifications / Modifications post-traductionnelles / Modificaciones
postraduccionales
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
intramolecular: 7-99 56-145 191-251 297-355
7'-99' 56'-145' 191'-251' 297'-355'
intermolecular: 156-156' 159-159'
Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N21, N35, N64, N143 N21', N35', N64', N143'
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires
complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados
C-terminal lysine clipping / Coupure de la lysine C-terminale / supresión de lisina C-terminal
H CHS K2: 377, 377'
eliapixantum
eliapixant 3-(5-methyl-1,3-thiazol-2-yl)-5-{[(3R)-oxolan-3-yl]oxy}-
N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-
yl]ethyl}benzamide
éliapixant 3-(5-méthyl-1,3-thiazol-2-yl)-5-{[(3R)-oxolan-3-yl]oxy}-
N-{(1R)-1-[2-(trifluorométhyl)pyrimidin-5-
yl]éthyl}benzamide
eliapixant 3-(5-metil-1,3-tiazol-2-il)-5-{[(3R)-oxolan-3-il]oxi}-N-
{(1R)-1-[2-(trifluorometil)pirimidin-5-il]etil}benzamida
C22H21F3N4O3S
elinzanetantum
elinzanetant 2-[3,5-bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-
methylphe-nyl)-6-[(7S,9aS)-7-
(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-
8(1H)-yl]pyridin-3-yl}-N,2-dimethylpropanamide
élinzanétant 2-[3,5-bis(trifluorométhyl)phényl]-N-{4-(4-fluoro-2-
méthylphényl)-6-[(7S,9aS)-7-
(hydroxyméthyl)hexahydropyrazino[2,1-c][1,4]oxazin-
8(1H)-yl]pyridin-3-yl}-N,2-diméthylpropanamide
elinzanetant 2-[3,5-bis(trifluorometil)fenil]-N-{4-(4-fluoro-2-
metilfenil)-6-[(7S,9aS)-7-
(hidroximetil)hexahidropirazino[2,1-c][1,4]oxazin-
8(1H)-il]piridin-3-il}-N,2-dimetilpropanamida
717
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
C33H35F7N4O3
F
H3C CH3 CH3 CH3
F3C N
H
O
N N O
H
CF3 HO N
enflicoxibum
enflicoxib rac-4-[(5R)-5-(2,4-difluorophenyl)-3-(trifluoromethyl)-
4,5-dihydro-1H-pyrazol-1-yl]benzene-1-sulfonamide
enflicoxib rac-4-[(5R)-5-(2,4-difluorophényl)-3-(trifluorométhyl)-
4,5-dihydro-1H-pyrazol-1-yl]benzène-1-sulfonamide
enflicoxib rac-4-[(5R)-5-(2,4-difluorofenil)-3-(trifluorometil)-4,5-
dihidro-1H-pirazol-1-il]benceno-1-sulfonamida
C16H12F5N3O2S
esamisulpridum
esamisulpride 4-amino-5-(ethanesulfonyl)-N-{[(2S)-1-ethylpyrrolidin-
2-yl]methyl}-2-methoxybenzamide
ésamisulpride 4-amino-5-(éthanesulfonyl)-N-{[(2S)-1-éthylpyrrolidin-
2-yl]méthyl}-2-méthoxybenzamide
esamisulprida 4-amino-5-(etanosulfonil)-N-{[(2S)-1-etilpirrolidin-2-
il]metil}-2-metoxibenzamida
C17H27N3O4S
exalurenum
exaluren 4-O-(2-amino-2,7-dideoxy-D-glycero-α-D-gluco-
heptopyranosyl)-5-O-(5-amino-5,6-dideoxy-α-L-
talofuranosyl)-2-deoxy-D-streptamine
exalurène 4-O-(2-amino-2,7-didésoxy-D-glycéro-α-D-gluco-
heptopyranosyl)-5-O-(5-amino-5,6-didésoxy-α-L-
talofuranosyl)-2-désoxy-D-streptamine
718
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
exalureno 4-O-(2-amino-2,7-didesoxi-D-glicero-α-D-gluco-
heptopiranosil)-5-O-(5-amino-5,6-didesoxi-α-L-
talofuranosil)-2-desoxi-D-estreptamina
C19H38N4O10
NH2 H2N OH
H2N O OH
O H
HO O OH CH3
HO
O
OH
H
H3C NH2
ezabenlimabum #
ezabenlimab immunoglobulin G4-kappa, anti-[Homo sapiens
PDCD1 (programmed cell death 1, PD-1, PD1,
CD279)], humanized monoclonal antibody;
gamma4 heavy chain humanized (1-446) [VH (Homo
sapiens IGHV3-23*04 (86.7%) -(IGHD) -IGHJ4*01
(100%)) [8.8.13] (1-120)-Homo sapiens IGHG4*01,
G4v5 h P10 (CH1 (121-218), hinge 1-12 S10>P (228)
(219-230), CH2 (231-340), CH3 (341-445), CHS
K2>del (446)) (121-446)], (134-218')-disulfide with
kappa light chain humanized (1'-218') [V-KAPPA
(Homo sapiens IGKV3D-11*01 (79.8%) -IGKJ2*02
(100%)) [10.3.9] (1'-111') -Homo sapiens IGKC*01
(100%), Km3 A45.1 (157), V101 (195) (112'-218')];
dimer (226-226":229-229")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
ézabenlimab immunoglobuline G4-kappa, anti-[Homo sapiens
PDCD1 (protéine 1 de mort cellulaire programmée,
PD-1, PD1, CD279)], anticorps monoclonal humanisé;
chaîne lourde gamma4 humanisée (1-446) [VH (Homo
sapiens IGHV3-23*04 (86.7%) -(IGHD) -IGHJ4*01
(100%)) [8.8.13] (1-120) -Homo sapiens IGHG4*01,
G4v5 h P10 (CH1 (121-218), charnière 1-12 S10>P
(228) (219-230), CH2 (231-340), CH3 (341-445), CHS
K2>del (446)) (121-446)], (134-218')-disulfure avec la
chaîne légère kappa humanisée (1'-218') [V-KAPPA
(Homo sapiens IGKV3D-11*01 (79.8%) -IGKJ2*02
(100%)) [10.3.9] (1'-111') -Homo sapiens IGKC*01
(100%), Km3 A45.1 (157), V101 (195) (112'-218')];
dimère (226-226":229-229")-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
ezabenlimab inmunoglobulina G4-kappa, anti-[Homo sapiens
PDCD1 (proteína 1 de muerte celular programada,
PD-1, PD1, CD279)], anticuerpo monoclonal
humanizado;
719
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
cadena pesada gamma4 humanizada (1-446) [VH
(Homo sapiens IGHV3-23*04 (86.7%) -(IGHD) -
IGHJ4*01 (100%)) [8.8.13] (1-120) -Homo sapiens
IGHG4*01, G4v5 h P10 (CH1 (121-218), bisagra 1-12
S10>P (228) (219-230), CH2 (231-340), CH3 (341-
445), CHS K2>del (446)) (121-446)], (134-218')-
disulfuro con la cadena ligera kappa humanizada (1'-
218') [V-KAPPA (Homo sapiens IGKV3D-11*01
(79.8%) -IGKJ2*02 (100%)) [10.3.9] (1'-111') -Homo
sapiens IGKC*01 (100%), Km3 A45.1 (157), V101
(195) (112'-218')];
dímero (226-226":229-229")-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
ezeprogindum
ezeprogind N-[3-(4-{3-[bis(2-methylpropyl)amino]propyl}piperazin-
1-yl)propyl]-1H-benzimidazol-2-amine
ézéprogind N-[3-(4-{3-[bis(2-méthylpropyl)amino]propyl}pipérazin-
1-yl)propyl]-1H-benzimidazol-2-amine
ezeprogind N-[3-(4-{3-[bis(2-metilpropil)amino]propil}piperazin-1-
il)propil]-1H-benzimidazol-2-amino
C25H44N6
720
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
feladilimabum #
feladilimab immunoglobulin G4-kappa, anti-[Homo sapiens ICOS
(inducible T-cell costimulator, activation-inducible
lymphocyte immunomediatory molecule, AILIM,
CD278)], humanized monoclonal antibody;
gamma4 heavy chain humanized (1-448) [VH (Homo
sapiens IGHV1-69*04 (84.7%) -(IGHD) -IGHJ6*01
(100%)) [8.8.14] (1-121) -Homo sapiens IGHG4*01,
G4v5 h P10, G4v3 CH2 E1.2 (CH1 (122-219), hinge 1-
12 S10>P (229)(220-231), CH2 L1.2>E (236) (232-
341), CH3 (342-446), CHS (447-448)) (122-448)],
(135-213')-disulfide with kappa light chain humanized
(1'-213') [V-KAPPA (Homo sapiens IGKV3-11*01
(85.3%) -IGKJ2*01 (100%)) [5.3.9] (1'-106') -Homo
sapiens IGKC*01 (100%), Km3 A45.1 (152), V101
(190) (107'-213')];
dimer (227-227'':230-230'')-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
féladilimab immunoglobuline G4-kappa, anti-[Homo sapiens ICOS
(costimulateur inductible du lymphocyte T, molécule
immunomédiateur lymphocytaire inductible par
activation, AILIM, CD278)], anticorps monoclonal
humanisé;
chaîne lourde gamma4 humanisée (1-448) [VH (Homo
sapiens IGHV1-69*04 (84.7%) -(IGHD) - IGHJ6*01
(100%)) [8.8.14] (1-121) -Homo sapiens IGHG4*01,
G4v5 h P10, G4v3 CH2 E1.2 (CH1 (122-219),
charnière 1-12 S10>P (229) (220-231), CH2 L1.2>E
(236) (232-341), CH3 (342-446), CHS (447-448)) (122-
448)], (135-213')-disulfure avec la chaîne légère kappa
humanisée (1'-213') [V-KAPPA (Homo sapiens IGKV3-
11*01 (85.3%) -IGKJ2*01 (100%)) [5.3.9] (1'-106') -
Homo sapiens IGKC*01 (100%), Km3 A45.1 (152),
V101 (190) (107'-213')];
dimère (227-227'':230-230'')-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
feladilimab inmunoglobulina G4-kappa, anti-[Homo sapiens ICOS
(coestimulador inducible del linfocito T, molécula
inmunomediadora linfocitaria inducible para activación,
AILIM, CD278)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 humanizada (1-448) [VH
(Homo sapiens IGHV1-69*04 (84.7%) -(IGHD) -
IGHJ6*01 (100%)) [8.8.14] (1-121) -Homo sapiens
IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (122-
219), bisagra 1-12 S10>P (229) (220-231), CH2
L1.2>E (236) (232-341), CH3 (342-446), CHS (447-
448)) (122-448)], (135-213')-disulfuro con la cadena
ligera kappa humanizada (1'-213') [V-KAPPA (Homo
sapiens IGKV3-11*01 (85.3%) -IGKJ2*01 (100%))
[5.3.9] (1'-106') -Homo sapiens IGKC*01 (100%), Km3
A45.1 (152), V101 (190) (107'-213')];
dímero (227-227'':230-230'')-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
721
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
felzartamabum #
felzartamab immunoglobulin G1-lambda, anti-[Homo sapiens CD38
(ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1,
cADPr hydrolase 1, T10)], humanized monoclonal
antibody;
gamma1 heavy chain (1-450) [VH (Homo sapiens
IGHV3-30*01 (90.8%) -(IGHD) -IGHJ4*01 (92.9%))
CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) -
Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1
R120 (217) (121-218), hinge 1-15 (219-233), CH2
(234-343), CH3 E12 (359), M14 (361) (344-448), CHS
(449-450)) (121-450)], (223-212')-disulfide with lambda
light chain (1'-213') [V-LAMBDA (Homo sapiens
IGLV3-1*01 (84.1%) -IGLJ3*02 (100%)) CDR-IMGT
[6.3.10] (26-31.49-51.88-97) (1'-107') -Homo sapiens
IGLC2*01 (100%) (108'-213')];
dimer (229-229'':232-232'')-bisdisulfide, produced in
human cell line PER.C6, glycoform alfa
felzartamab immunoglobuline G1-lambda, anti-[Homo sapiens
CD38 (ADP-ribosyl cyclase 1, ADP-ribose cyclique
hydrolase 1, cADPr hydrolase 1, T10)], anticorps
monoclonal humanisé ;
chaîne lourde gamma1 (1-450) [VH (Homo sapiens
IGHV3-30*01 (90.8%) -(IGHD) - IGHJ4*01 (92.9%))
CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) -
Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1
R120 (217) (121-218), charnière 1-15 (219-233), CH2
(234-343), CH3 E12 (359), M14 (361) (344-448), CHS
(449-450)) (121-450)], (223-212')-disulfure avec la
chaîne légère lambda (1'-213') [V-LAMBDA (Homo
sapiens IGLV3-1*01 (84.1%) -IGLJ3*02 (100%)) CDR-
IMGT [6.3.10] (26-31.49-51.88-97) (1'-107') -Homo
sapiens IGLC2*01 (100%) (108'-213')];
dimère (229-229'':232-232'')-bisdisulfure, produite
dans des cellules humaines PER.C6, glycoforme alfa
722
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
felzartamab inmunoglobulina G1-lambda, anti-[Homo sapiens CD38 (ADP-
ribosil ciclasa 1, ADP-ribosa cíclica hidrolasa 1, cADPr hidrolasa
1, T10)], anticuerpo monoclonal humanizado ;
cadena pesada gamma1 (1-450) [VH (Homo sapiens IGHV3-
30*01 (90.8%) -(IGHD) - IGHJ4*01 (92.9%)) CDR-IMGT [8.8.13]
(26-33.51-58.97-109) (1-120) -Homo sapiens IGHG1*03 (100%)
G1m3, nG1m1 (CH1 R120 (217) (121-218), bisagra 1-15 (219-
233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS
(449-450)) (121-450)], (223-212')-disulfuro con la cadena ligera
lambda (1'-213') [V-LAMBDA (Homo sapiens IGLV3-1*01 (84.1%)
-IGLJ3*02 (100%)) CDR-IMGT [6.3.10] (26-31.49-51.88-97) (1'-
107') -Homo sapiens IGLC2*01 (100%) (108'-213')];
dímero (229-229'':232-232'')-bisdisulfuro, producida por células
humanas PER.C6, glicoforma alfa
Heavy chain / Chaîne lourde / Cadena pesada
QVQLVESGGG LVQPGGSLRL SCAASGFTFS SYYMNWVRQA PGKGLEWVSG 50
ISGDPSNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDL 100
PLVYTGFAYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
Light chain / Chaîne légère / Cadena ligera
DIELTQPPSV SVAPGQTARI SCSGDNLRHY YVYWYQQKPG QAPVLVIYGD 50
SKRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQTY TGGASLVFGG 100
GTKLTVLGQP KAAPSVTLFP PSSEELQANK ATLVCLISDF YPGAVTVAWK 150
ADSSPVKAGV ETTTPSKQSN NKYAASSYLS LTPEQWKSHR SYSCQVTHEG 200
STVEKTVAPT ECS 213
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22''-96'' 147''-203'' 264''-324'' 370''-428''
Intra-L (C23-C104) 22'-87' 135'-194'
22'''-87''' 135'''-194'''
Inter-H-L (h 5-CL 126) 223-212' 223''-212'''
Inter-H-H (h 11, h 14) 229-229'' 232-232''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300''
Fucosylated complex bi-antennary PER.C6-type glycans / glycanes de type PER.C6
bi-antennaires complexes fucosylés / glicanos de tipo PER.C6 biantenarios complejos
fucosilados
filapixantum
filapixant 3-{[(2R)-4-methylmorpholin-2-yl]methoxy}-5-(5-methyl-1,3-thiazol-
2-yl)-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide
filapixant 3-{[(2R)-4-méthylmorpholin-2-yl]méthoxy}-5-(5-méthyl-1,3-thiazol-
2-yl)-N-{(1R)-1-[2-(trifluorométhyl)pyrimidin-5-yl]éthyl}benzamide
filapixant 3-{[(2R)-4-metilmorfolin-2-il]metoxi}-5-(5-metil-1,3-tiazol-2-il)-N-
{(1R)-1-[2-(trifluorometil)pirimidin-5-il]etil}benzamida
C24H26F3N5O3S
723
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
fosciclopiroxum
fosciclopirox [(6-cyclohexyl-4-methyl-2-oxopyridin-1(2H)-
yl)oxy]methyl dihydrogen phosphate
fosciclopirox dihydrogénophosphate de [(6-cyclohexyl-4-méthyl-2-
oxopyridin-1(2H)-yl)oxy]méthyle
fosciclopirox dihidrogenofosfato de [(6-ciclohexil-4-metil-2-
oxopiridin-1(2H)-il)oxi]metilo
C13H20NO6P
H3C
HO OH
N P
O O O
O
fosifidancitinibum
fosifidancitinib (5-{[2-(4-fluoro-3-methoxy-5-methylanilino)-5-
methylpyrimidin-4-yl]amino}-2-oxo-1,3-benzoxazol-
3(2H)-yl)methyl dihydrogen phosphate
fosifidancitinib dihydrogénophosphate de (5-{[2-(4-fluoro-3-methoxy-
5-methylanilino)-5-methylpyrimidin-4-yl]amino}-2-oxo-
1,3-benzoxazol-3(2H)-yl)méthyle
fosifidancitinib dihidrogenofosfato de (5-{[2-(4-fluoro-5-metilanilino-3-
metoxi)-5-metilpirimidin-4-il]amino}-2-oxo-1,3-
benzoxazol-3(2H)-il)metilo
C21H21FN5O7P
O
OH
P
O
O OH
N OCH3
O H3C F
N
N N N CH3
H H
genisteinum
genistein 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
génistéine 5,7-dihydroxy-3-(4-hydroxyphényl)-4H-chromén-4-one
genisteína 5,7-dihidroxi-3-(4-hidroxifenil)-4H-cromen-4-ona
C15H10O5
HO O
OH O
OH
724
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
giloralimabum #
giloralimab immunoglobulin G1-kappa, anti-[Homo sapiens CD40
(tumor necrosis factor receptor super family member 5,
TNFRSF5)], monoclonal antibody;
gamma1 heavy chain (1-442) [VH (Homo sapiens
IGHV4-59*01 (88.8%) -(IGHD) -IGHJ4*01 (85.7%))
CDR-IMGT [9.7.5] (26-34.52-58.97-101) (1-112) -
Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1
(CH1 R120>K (209) (113-210), hinge 1-15 (211-225),
CH2 V37>E (268) (226-335), CH3 E12 (351), M14
(353) (336-440), CHS (441-442)) (113-442)], (215-
219')-disulfide with kappa light chain (1'-219') [V-
KAPPA (Mus musculus IGKV1-122*01 (89.0%) -
IGKJ4*01 (91.7%)/Homo sapiens IGKV2-29*02
(86.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27-
37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01
(100%) Km3 A45.1 (158), V101 (196) (113'-219')];
dimer (221-221":224-224")-bisdisulfide
giloralimab immunoglobuline G1-kappa, anti-[Homo sapiens CD40
(membre 5 de la superfamille des récepteurs du TNF,
TNFRSF5)], anticorps monoclonal;
chaîne lourde gamma1 (1-442) [VH (Homo sapiens
IGHV4-59*01 (88.8%) -(IGHD) -IGHJ4*01 (85.7%))
CDR-IMGT [9.7.5] (26-34.52-58.97-101) (1-112) -
Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1
(CH1 R120>K (209) (113-210), charnière 1-15 (211-
225), CH2 V37>E (268) (226-335), CH3 E12 (351),
M14 (353) (336-440), CHS (441-442)) (113-442)],
(215-219')-disulfure avec la chaîne légère kappa (1'-
219') [V-KAPPA (Mus musculus IGKV1-122*01 (89.0%
-IGKJ4*01 (91.7%)/Homo sapiens IGKV2-29*02
(86.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27-
37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01
(100%) Km3 A45.1 (158), V101 (196) (113'-219')];
dimère (221-221":224-224")-bisdisulfure
giloralimab inmunoglobulina G1-kappa, anti-[Homo sapiens CD40
(miembro 5 de la superfamilia de los receptores del
TNF, TNFRSF5)], anticuerpo monoclonal;
cadena pesada gamma1 (1-442) [VH (Homo sapiens
IGHV4-59*01 (88.8%) -(IGHD) -IGHJ4*01 (85.7%))
CDR-IMGT [9.7.5] (26-34.52-58.97-101) (1-112) -
Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1
(CH1 R120>K (209) (113-210), bisagra 1-15 (211-
225), CH2 V37>E (268) (226-335), CH3 E12 (351),
M14 (353) (336-440), CHS (441-442)) (113-442)],
(215-219')-disulfuro con la cadena ligera kappa (1'-
219') [V-KAPPA (Mus musculus IGKV1-122*01 (89.0%
-IGKJ4*01 (91.7%)/Homo sapiens IGKV2-29*02
(86.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27-
37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01
(100%) Km3 A45.1 (158), V101 (196) (113'-219')];
dímero (221-221":224-224")-bisdisulfuro
725
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
giredestrantum
giredestrant 3-[(1R,3R)-1-(2,6-difluoro-4-{[1-(3-
fluoropropyl)azetidin-3-yl]amino}phenyl)-3-methyl-
1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]-2,2-
difluoropropan-1-ol
girédestrant 3-[(1R,3R)-1-(2,6-difluoro-4-{[1-(3-
fluoropropyl)azétidin-3-yl]amino}phényl)-3-méthyl-
1,3,4,9-tétrahydro-2H-pyrido[3,4-b]indol-2-yl]-2,2-
difluoropropan-1-ol
giredestrant 3-[(1R,3R)-1-(2,6-difluoro-4-{[1-(3-fluoropropil)azetidin-
3-il]amino}fenil)-3-metil-1,3,4,9-tetrahidro-2H-
pirido[3,4-b]indol-2-il]-2,2-difluoropropan-1-ol
C27H31F5N4O
726
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
icenticaftorum
icenticaftor 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-
methylpropyl]-5-(trifluoromethyl)pyridine-2-
carboxamide
icenticaftor 3-amino-6-méthoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-
méthylpropyl]-5-(trifluorométhyl)pyridine-2-
carboxamide
icenticaftor 3-amino-6-metoxi-N-[(2S)-3,3,3-trifluoro-2-hidroxi-2-
metilpropil]-5-(trifluorometil)piridina-2-carboxamida
C12H13F6N3O3
icerguastatum
icerguastat (2E)-2-[(2-chlorophenyl)methylidene]hydrazine-1-
carboximidamide
icerguastat (2E)-2-[(2-chlorophényl)méthylidène]hydrazine-1-
carboximidamide
icerguastat (2E)-2-[(2-clorofenil)metilideno]hidrazina-1-
carboximidamida
C8H9ClN4
idetrexedum
idetrexed N-(4-{[(6S)-2-(hydroxymethyl)-4-oxo-4,6,7,8-
tetrahydro-1H-cyclopenta[g]quinazolin-6-yl](prop-2-yn-
1-yl)amino}benzoyl)-L-γ-glutamyl-D-glutamic acid
idétrexed acide N-(4-{[(6S)-2-(hydroxyméthyl)-4-oxo-4,6,7,8-
tétrahydro-1H-cyclopenta[g]quinazolin-6-yl](prop-2-yn-
1-yl)amino}benzoyl)-L-γ-glutamyl-D-glutamique
idetrexed ácido N-(4-{[(6S)-2-(hidroximetil)-4-oxo-4,6,7,8-
tetrahidro-1H-ciclopenta[g]quinazolin-6-il](prop-2-in-1-
il)amino}benzoil)-L-γ-glutamil-D-glutámico
C32H33N5O10
O CO2H
CH
N
H H
N CO2H
O N
H
O
N
HO CO2H
N
H
727
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
ifidancitinibum
ifidancitinib 5-{[2-(4-fluoro-3-methoxy-5-methylanilino)-5-
methylpyrimidin-4-yl]amino}-1,3-benzoxazol-2(3H)-one
ifidancitinib 5-{[2-(4-fluoro-3-méthoxy-5-méthylanilino)-5-
méthylpyrimidin-4-yl]amino}-1,3-benzoxazol-2(3H)-one
ifidancitinib 5-{[2-(4-fluoro-5-metilanilino-3-metoxi)-5-metilpirimidin-
4-il]amino}-1,3-benzoxazol-2(3H)-ona
C20H18FN5O3
imaradenantum
imaradenant 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-
1,2,4-triazin-3-amine
imaradénant 6-(2-chloro-6-méthylpyridin-4-yl)-5-(4-fluorophényl)-
1,2,4-triazin-3-amine
imaradenant 6-(2-cloro-6-metilpiridin-4-il)-5-(4-fluorofenil)-1,2,4-
triazin-3-amina
C15H11ClFN5
N NH2
N
Cl N
N
CH3
F
inavolisibum
inavolisib (2S)-2-({2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-
oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-
d][1,4]benzoxazepin-9-yl}amino)propenamide
inavolisib (2S)-2-({2-[(4S)-4-(difluorométhyl)-2-oxo-1,3-
oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-
d][1,4]benzoxazépin-9-yl}amino)propenamide
inavolisib (2S)-2-({2-[(4S)-4-(difluorometil)-2-oxo-1,3-oxazolidin-
3-il]-5,6-dihidroimidazo[1,2-d][1,4]benzoxazepin-9-
il}amino)propanamida
728
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
C18H19F2N5O4
O O
N
O N H CH3
N
H NH2
N
F H
F O
insulinum efsitorum alfa #
insulin efsitora alfa human insulin B-chain (1-30) variant (Y16>E, F25>H,
T27>G, P28>G, K29>G, T30>G) fused via a G2SG4
peptide linker (31-37) to human insulin A-chain (38-58)
variant (I10>T47, Y14>D51, N21>G58) and via a (G4Q)3G5
peptide linker (59-78) to a human immunoglobulin G2
C-terminal K>del Fc fragment (79-299), dimer (80-
80':83-83')-bisdisulfide, produced in Chinese hamster
ovary (CHO) cells, glycoform alfa
insuline efsitora alfa chaîne B de l'insuline humaine (1-30) variant (Y16>E,
F25>H, T27>G, P28>G, K29>G, T30>G) fusionné via un
peptide liant G2SG4 (31-37) à la chaîne A de l'insuline
humaine (38-58) variant (I10>T47, Y14>D51, N21>G58) et
via un peptide liant (G4Q)3G5 (59-78) au fragment Fc
C-terminal K>del de l'immunoglobuline G2 humaine
(IgG2) (79-299), dimère (80-80':83-83')-bisdisulfure,
produit par des cellules ovariennes de hamster chinois
(CHO), glycoforme alfa
insulina efsitora alfa cadena B de la insulina humana (1-30) variante
(Y16>E, F25>H, T27>G, P28>G, K29>G, T30>G) fusionada
a través de un péptido que se une G2SG4 (31-37) a la
cadena A de la insulina humana (38-58) variante
(I10>T47, Y14>D51, N21>G58) y a través de un péptido
que se une (G4Q)3G5 (59-78) al fragmento Fc C-
terminal K>del de la inmunoglobulina G2 humana
(IgG2) (79-299), dímero (80-80':83-83')-bisdisulfuro,
producido por las células ováricas de hamster chino
(CHO), glicoforma alfa
Sequence / Séquence / Secuencia
FVNQHLCGSH LVEALELVCG ERGFHYGGGG GGSGGGGGIV EQCCTSTCSL 50
DQLENYCGGG GGQGGGGQGG GGQGGGGGEC PPCPAPPVAG PSVFLFPPKP 100
KDTLMISRTP EVTCVVVDVS HEDPEVQFNW YVDGVEVHNA KTKPREEQFN 150
STFRVVSVLT VVHQDWLNGK EYKCKVSNKG LPAPIEKTIS KTKGQPREPQ 200
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPM 250
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG 299
Post-translational modifications / Modifications post-traductionnelles / Modificaciones
postraduccionales
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
B-A 7-44 19-57 B'-A' 7'-44' 19'-57'
A-A 43-48 A'-A' 43'-48'
Intra-Fc 114-174 220-278 114'-174' 220'-278'
Inter-Fc 80-80' 83-83'
Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N150, N150'
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires
complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados
iptacopanum
iptacopan 4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-
4-yl)methyl]piperidin-2-yl}benzoic acid
729
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
iptacopan acide 4-{(2S,4S)-4-éthoxy-1-[(5-méthoxy-7-méthyl-1H-
indol-4-yl)méthyl]pipéridin-2-yl}benzoïque
iptacopán ácido 4-{(2S,4S)-4-etoxi-1-[(7-metil-5-metoxi-1H-indol-4-
il)metil]piperidin-2-il}benzoico
C25H30N2O4
CO2H
HN
N
H3C OCH3 O CH3
isecarosmabum #
isecarosmab immunoglobulin single chain VH-VH', anti-[Homo sapiens
ADAMTSL5 (ADAMTS like 5, THSD6, thrombospondin
type I domain 6)] and anti-[Homo sapiens ALB (albumin,
human serum albumin, HSA)], Lama glama and
humanized monoclonal antibody, bispecific bivalent;
sc VH-VH'(1-275) [Lama glama VH anti-ADAMTSL5
(Lama glama IGHV3S1*01 (81.4%) -(IGHD) -IGHJ2*01
(100%)/Homo sapiens IGHV3-23*04 (80.2%) -(IGHD) -
IGHJ1*01 (100%) [8.8.17] (1-124)) -35-mer (GGGGS)7
linker (125-159)-humanized VH anti-ALB (Homo sapiens
IGHV3-23*04 (87.5%) -(IGHD) -IGHJ1*01 (100%) [8.8.8]
(160-275),
produced in Pichia pastoris yeast, non-glycosylated
isécarosmab immunoglobuline single chaîne VH-VH', anti-[Homo
sapiens ADAMTSL5 (ADAMTS like 5, thrombospondine
type I domaine 6)] et anti-[Homo sapiens ALB (albumine,
sérum albumine humaine, SAH)], anticorps monoclonal
Lama glama et humanisé, bispécifique bivalent;
sc VH-VH' (1-275) [Lama glama VH anti-ADAMTSL5
(Lama glama IGHV3S1*01 (81.4%) -(IGHD) -IGHJ2*01
(100%)/Homo sapiens IGHV3-23*04 (80.2%) -(IGHD) -
IGHJ1*01 (100%) [8.8.17] (1-124)) -35-mer (GGGGS)7
linker (125-159)-VH humanisé anti-ALB (Homo sapiens
IGHV3-23*04 (87.5%) -(IGHD) -IGHJ1*01 (100%) [8.8.8]
(160-275),
produit dans la levure Pichia pastoris, non-glycosylé
isecarosmab inmunoglobulina cadena simple VH-VH', anti-[Homo
sapiens ADAMTSL5 (ADAMTS like 5, trombospondina
tipo I dominio 6)] y anti-[Homo sapiens ALB (albúmina,
sero albúmina humana, SAH)], anticuerpo monoclonal
Lama glama y humanizado, biespecífico bivalente;
sc VH-VH' (1-275) [Lama glama VH anti-ADAMTSL5
(Lama glama IGHV3S1*01 (81.4%) -(IGHD) -IGHJ2*01
(100%)/Homo sapiens IGHV3-23*04 (80.2%) -(IGHD) -
IGHJ1*01 (100%) [8.8.17] (1-124)) -linker 35-mer
(GGGGS)7 (125-159)-VH humanizado anti-ALB (Homo
sapiens IGHV3-23*04 (87.5%) -(IGHD) -IGHJ1*01
(100%) [8.8.8] (160-275),
producido en la levadura Pichia pastoris, no glicosilado
730
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
itacnosertibum
itacnosertib N4-([2,2'-bipyridin]-3-yl)-N2-[3-methoxy-4-(4-methylpiperazin-1-
yl)phenyl]pyrimidine-2,4-diamine
itacnosertib N4-([2,2'-bipyridin]-3-yl)-N2-[3-méthoxy-4-(4-méthylpipérazin-1-
yl)phényl]pyrimidine-2,4-diamine
itacnosertib N4-([2,2'-bipiridin]-3-il)-N2-[4-(4-metilpiperazin-1-il)-3-
metoxifenil]pirimidina-2,4-diamina
C26H28N8O
itepekimabum #
itepekimab immunoglobulin G4-kappa, anti-[Homo sapiens IL33 (interleukin
33, interleukin-1 family member 11, IL1F11, nuclear factor for high
endothelial venules, NF-HEV)], monoclonal antibody;
gamma4 heavy chain (1-449) [VH (Homo sapiens IGHV3-23*04
(88.8%) -(IGHD) -IGHJ6*03 (91.0%)) [8.8.15] (1-122) -Homo
sapiens IGHG4*01, G4v5 h P10 (CH1 (123-220), hinge 1-12
S10>P (230)(221-232), CH2 (233-342), CH3 (343-447), CHS
(448-449)) (123-449)], (136-214')-disulfide with kappa light chain
Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01
(96.8%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese
hamster ovary (CHO) cells, glycoform alfa
itépékimab immunoglobuline G4-kappa, anti-[Homo sapiens IL33 (interleukine
33, membre 11 de la famille 1 d'interleukines, IL1F11, facteur
nucléaire des veinules à haut endothélium, NF-HEV)], anticorps
monoclonal;
chaîne lourde gamma4 (1-449) ) [VH (Homo sapiens IGHV3-
23*04 (88.8%) -(IGHD) -IGHJ6*03 (91.0%)) [8.8.15] (1-122) -
Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (123-220), charnière
1-12 S10>P (230)(221-232), CH2 (233-342), CH3 (343-447), CHS
(448-449)) (123-449)], (136-214')-disulfure avec la chaîne légère
kappa (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (96.8%) -
IGKJ5*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01
(100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (228-228'':231-231'')-bisdisulfure, produit dans des cellules
ovariennes de hamster chinois (CHO), glycoforme alfa
731
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
itepekimab inmunoglobulina G4-kappa, anti-[Homo sapiens IL33
(interleukina 33, miembro 11 de la familia 1 de
interleukinas, IL1F11, factor nuclear de las vénulas del
endotelio alto, NF-HEV)], anticuerpo monoclonal;
cadena pesada gamma4 (1-449) ) [VH (Homo sapiens
IGHV3-23*04 (88.8%) -(IGHD) -IGHJ6*03 (91.0%))
[8.8.15] (1-122) -Homo sapiens IGHG4*01, G4v5 h
P10 (CH1 (123-220), bisagra 1-12 S10>P (230)(221-
232), CH2 (233-342), CH3 (343-447), CHS (448-449))
(123-449)], (136-214')-disulfuro con la cadena ligera
kappa (1'-214') [V-KAPPA (Homo sapiens IGKV1-
12*01 (96.8%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') -
Homo sapiens IGKC*01 (100%), Km3 A45.1 (153),
V101 (191) (108'-214')];
dímero (228-228'':231-231'')-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
izaflortaucipirum (18F)
izaflortaucipir (18F) 2-(2-(18F)fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-
c']dipyridine
izaflortaucipir (18F) 2-(2-(18F)fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-
c']dipyridine
izaflortaucipir (18F) 2-(2-(18F)fluoropiridin-4-il)-9H-pirrolo[2,3-b:4,5-
c']dipiridina
732
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
C15H918FN4
izokibepum #
izokibep fusion protein composed of 3 binding domains
consisting of three-alpha-helix motifs, each derived
from the immunoglobulin (Ig)-binding Z-domain of
staphylococcal protein A (SpA), engineered for binding
to two homodimer subunits of human interleukin 17A
(IL17A) with the two identical N- and C-terminal
domains (1-58, 116-173) and to the domain II of
human serum albumin (HSA) with the central domain
(59-110), connected via a G4S peptide linker (111-
115);
[IL17A-binding engineered SpA peptide (1-58)]-[HSA-
binding engineered SpA peptide (59-110)]-[G4S linker
(111-115)]-[IL17A-binding engineered SpA peptide
(116-173] fusion protein;
produced in Escherichia coli
izokibep protéine de fusion composée de 3 domaines liants,
chacun consistant en un motif à 3 hélices alpha dérivé
du domaine Z de la protéine staphylococcique A (SpA)
se liant à l'immunoglobuline (Ig), mis au point pour se
lier aux deux homodimères des sous-unités de
l'interleukine 17A humaine (IL17A) avec les deux
domaines N- et C-terminaux identiques (1-58, 116-
173), et au domaine II de l'albumine sérique humaine
(ASH, HSA) avec le domaine central (59-110),
connecté via un peptide liant G4S (111-115);
protéine de fusion [peptide SpA mis au point pour se
lier à l'IL17A (1-58)]-[peptide SpA mis au point pour se
lier au HSA (59-110)]-[peptide liant G4S (111-115)]-
[peptide SpA mis au point pour se lier à l'IL17A (116-
173)];
produite par Escherichia coli
izokibep proteína de fusión compuesta de 3 dominios de unión,
cada uno consistente en un motivo con 3 hélices alfa
derivado del dominio Z de la proteína estafilocócica A
(SpA) que se une a la inmunoglobulina (Ig), diseñado
para unirse a los dos homodímeros de las sub-
unidades de la interleukina 17A humana (IL17A) con
los dos dominios N- y C-terminal idénticos (1-58, 116-
173), y con el dominio II de la albúmina sérica humana
(ASH, HSA) con el dominio central (59-110),
conectado a través de un péptido que se une a G4S
(111-115);
proteína de fusión [péptido SpA diseñado para unirse
a la IL17A (1-58)]-[péptido SpA diseñado para unirse
al HSA (59-110)]-[G4S linker (111-115)]-[péptido SpA
diseñado para unirse a la IL17A (116-173)];
producida por Escherichia coli
733
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
lazuvapagonum
lazuvapagon (4S)-N-[(2S)-1-hydroxypropan-2-yl]-methyl-1-[2-methyl-4-(3-methyl-
1H-pyrazol-1-yl)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine-4-
carboxamide
lazuvapagon (4S)-N-[(2S)-1-hydroxypropan-2-yl]-méthyl-1-[2-méthyl-4-(3-méthyl-
1H-pyrazol-1-yl)benzoyl]-2,3,4,5-tétrahydro-1H-1-benzazépine-4-
carboxamide
lazuvapagón (4S)-N-[(2S)-1-hidroxipropan-2-il]-metil-1-[2-metil-4-(3-metil-1H-
pirazol-1-il)benzoil]-2,3,4,5-tetrahidro-1H-1-benzazepina-4-
carboxamida
C27H32N4O3
O CH3
H3C
OH
H3C N
N H
N
N
CH3 O
lecanemabum #
lecanemab immunoglobulin G1-kappa, anti-[Homo sapiens APP (amyloid beta
A4 precursor protein) soluble beta-amyloid protofibril], monoclonal
antibody;
gamma1 heavy chain (1-454) [VH (Homo sapiens IGHV3-48*01
(89.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.17] (26-
33.51-58.97-113) (1-124) -Homo sapiens IGHG1*03 (100%) G1m3,
nG1m1 (CH1 R120 (221) (125-222), hinge 1-15 (223-237), CH2
(238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454))
(125-454)], (227-219')-disulfide with kappa light chain (1'-219') [V-
KAPPA (Mus musculus IGKV1-117*01 (91%) -IGKJ1*02
(90.9%)/Homo sapiens IGKV2-30*02 (84.0%) -IGKJ2*01 (90.9%))
CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (227'-219')];
dimer (233-233'':236-236'')-bisdisulfide, produced in Chinese
hamster ovary (CHO) cells, glycoform alfa
lécanémab immunoglobuline G1-kappa, anti-[Homo sapiens APP (protéine
précurseur amyloïde bêta A4) protofibrille bêta amyloïde soluble],
anticorps monoclonal;
chaîne lourde gamma1 (1-454) [VH (Homo sapiens IGHV3-48*01
(89.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.17] (26-
33.51-58.97-113) (1-124) -Homo sapiens IGHG1*03 (100%) G1m3,
nG1m1 (CH1 R120 (221) (125-222), charnière 1-15 (223-237), CH2
(238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454))
(125-454)], (227-219')-disulfure avec la chaîne légère kappa
734
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
(1'-219') [V-KAPPA (Mus musculus IGKV1-117*01 (91%) -
IGKJ1*02 (90.9%)/Homo sapiens IGKV2-30*02 (84.0%) -IGKJ2*01
(90.9%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -Homo
sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (227'-
219')];
dimère (233-233'':236-236'')-bisdisulfure, produite dans des cellules
ovariennes de hamster chinois (CHO), glycoforme alfa
lecanemab inmunoglobulina G1-kappa, anti-[Homo sapiens APP (proteína
precusor amiloide beta A4) protofibrilla beta amiloide soluble],
anticuerpo monoclonal;
cadena pesada gamma1 (1-454) [VH (Homo sapiens IGHV3-48*01
(89.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.17] (26-
33.51-58.97-113) (1-124) -Homo sapiens IGHG1*03 (100%) G1m3,
nG1m1 (CH1 R120 (221) (125-222), bisagra 1-15 (223-237), CH2
(238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454))
(125-454)], (227-219')-disulfuro con la cadena ligera kappa (1'-219')
[V-KAPPA (Mus musculus IGKV1-117*01 (91%) -IGKJ1*02
(90.9%)/Homo sapiens IGKV2-30*02 (84.0%) -IGKJ2*01 (90.9%))
CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (227'-219')];
dímero (233-233'':236-236'')-bisdisulfuro, producida por células
ováricas de hamster chino (CHO), forma glicosilada alfa
lorpucitinibum
lorpucitinib 2-{1-[trans-4-(cyanomethyl)cyclohexyl]-1,6-dihydroimidazo[4,5-
d]pyrrolo[2,3-b]pyridin-2-yl}-N-(2-hydroxy-2-methylpropyl)acetamide
lorpucitinib 2-{1-[trans-4-(cyanométhyl)cyclohexyl]-1,6-dihydroimidazo[4,5-
d]pyrrolo[2,3-b]pyridin-2-yl}-N-(2-hydroxy-2-méthylpropyl)acetamide
lorpucitinib 2-{1-[trans-4-(cianometil)ciclohexil]-1,6-dihidroimidazo[4,5-
d]pirrolo[2,3-b]piridin-2-il}-N-(2-hidroxi-2-metilpropil)acetamida
735
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
C22H28N6O2
luvadaxistatum
luvadaxistat 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-
3(2H)-one
luvadaxistat 4-hydroxy-6-{2-[4-(trifluorométhyl)phényl]éthyl}pyridazin-
3(2H)-one
luvadaxistat 4-hidroxi-6-{2-[4-(trifluorometil)fenil]etil}piridazin-3(2H)-ona
C13H11F3N2O2
miptenalimabum #
miptenalimab immunoglobulin G4-kappa, anti-[Homo sapiens LAG3
(lymphocyte activating 3, lymphocyte-activation 3, CD223)],
monoclonal antibody;
gamma4 heavy chain (1-448) [VH (Homo sapiens IGHV3-
33*01 (77.0%) -(IGHD) -IGHJ4*01 (93.3%)) [10.7.14] (1-122)-
Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (123-220), hinge
1-12 S10>P (230) (221-232), CH2 (233-342), CH3 (343-447),
CHS K2>del (448)) (123-448)], (136-214')-disulfide with kappa
light chain (1'-214') [V-KAPPA (Mus musculus IGKV6-17
(85.3%) -IGKJ2*03 (90.9%)/Homo sapiens IGKV1-39*01
(82.1%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (228-228":231-231")-bisdisulfide, produced in Chinese
hamster ovary (CHO) cells, glycoform alfa
mipténalimab immunoglobuline G4-kappa, anti-[Homo sapiens LAG3
(activateur 3 des lymhocytes, lymphocyte-activation 3,
CD223)], anticorps monoclonal;
chaîne lourde gamma4 (1-448) [VH (Homo sapiens IGHV3-
33*01 (77.0%) -(IGHD) -IGHJ4*01 (93.3%)) [10.7.14] (1-122) -
Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (123-220),
charnière 1-12 S10>P (230) (221-232), CH2 (233-342), CH3
(343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfure
avec la chaîne légère kappa (1'-214') [V-KAPPA (Mus
musculus IGKV6-17 (85.3%) -IGKJ2*03 (90.9%)/Homo
sapiens IGKV1-39*01 (82.1%) -IGKJ2*01 (100%)) [6.3.9] (1'-
107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153),
V101 (191) (108'-214')];
dimère (228-228":231-231")-bisdisulfure, produit dans des
cellules ovariennes de hamster chinois (CHO), glycoforme alfa
736
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
miptenalimab inmunoglobulina G4-kappa, anti-[Homo sapiens LAG3
(activador 3 de los linfocitos, linfocito-activación 3, CD223)],
anticuerpo monoclonal;
cadena pesada gamma4 (1-448) [VH (Homo sapiens IGHV3-
33*01 (77.0%) -(IGHD) -IGHJ4*01 (93.3%)) [10.7.14] (1-122) -
Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (123-220), bisagra
1-12 S10>P (230) (221-232), CH2 (233-342), CH3 (343-447),
CHS K2>del (448)) (123-448)], (136-214')-disulfuro con la
cadena ligera kappa (1'-214') [V-KAPPA (Mus musculus
IGKV6-17 (85.3%) -IGKJ2*03 (90.9%)/Homo sapiens IGKV1-
39*01 (82.1%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -Homo
sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-
214')];
dímero (228-228":231-231")-bisdisulfuro, producido por células
ováricas de hamster chino (CHO), forma glicosilada alfa
mirdametinibum
mirdametinib N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-
iodoanilino)benzamide
mirdamétinib N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-
iodoanilino)benzamide
mirdametinib N-[(2R)-2,3-dihidroxipropoxi]-3,4-difluoro-2-(2-fluoro-4-
iodoanilino)benzamide
C16H14F3IN2O4
737
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
miromavimabum #
miromavimab immunoglobulin G1-kappa, anti-[rabies virus strain
ERA (Evelyn-Rockitniki-Abelseth) glycoprotein
ectodomain epitope G-II], Mus musculus monoclonal
antibody;
gamma1 heavy chain Mus musculus (1-445) [VH (Mus
musculus IGHV1S130*01 (93.9%) -(IGHD) -IGHJ1*01
(88.2%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-
121) -Mus musculus IGHG1*02 (CH1 Q100>E (199)
(122-218), hinge 1-13 (219-231), CH2 K81>Q (288),
I84.3>F (294) (232-338), CH3 N27>D (369) (339-443),
CHS (444-445)) (122-445)], (223-214')-disulfide with
kappa light chain Mus musculus (1'-214') [V-KAPPA
(Mus musculus IGKV6-17*01 (98.9%) -IGKJ1*02
(100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-
107') -Mus musculus IGKC*01 (100%) (108'-214')];
dimer (225-225":228-228":230-230")-trisdisulfide,
produced in mouse myeloma cell line SP2/0-Ag14,
glycoform alfa
miromavimab immunoglobuline G1-kappa, anti-[épitope G-II de
l'ectodomaine de la glycoprotéine de la souche ERA
(Evelyn-Rockitniki-Abelseth) du virus de la rage],
anticorps monoclonal Mus musculus;
chaîne lourde gamma1 Mus musculus (1-445) [VH
(Mus musculus IGHV1S130*01 (93.9%) -(IGHD) -
IGHJ1*01 (88.2%)) CDR-IMGT [8.8.14] (26-33.51-
58.97-110) (1-121) -Mus musculus IGHG1*02 (CH1
Q100>E (199) (122-218), charnière 1-13 (219-231),
CH2 K81>Q (288), I84.3>F (294) (232-338), CH3
N27>D (369) (339-443), CHS (444-445)) (122-445)],
(223-214')-disulfure avec la chaîne légère kappa Mus
musculus (1'-214') [V-KAPPA (Mus musculus IGKV6-
17*01 (98.9%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9]
(27-32.50-52.89-97) (1'-107') -Mus musculus IGKC*01
(100%) (108'-214')];
dimère (225-225":228-228":230-230")-trisdisulfure,
produite dans la lignée cellulaire de myélome murin
SP2/0-Ag14, glycoforme alfa
miromavimab inmunoglobulina G1-kappa, anti-[epítopo G-II del
ectodominio de la glicoproteína de la cepa ERA
(Evelyn-Rockitniki-Abelseth) del virus de la rabia],
anticuerpo monoclonal Mus musculus;
cadena pesada gamma1 Mus musculus (1-445) [VH
(Mus musculus IGHV1S130*01 (93.9%) -(IGHD) -
IGHJ1*01 (88.2%)) CDR-IMGT [8.8.14] (26-33.51-
58.97-110) (1-121) -Mus musculus IGHG1*02 (CH1
Q100>E (199) (122-218), bisagra 1-13 (219-231), CH2
K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D
(369) (339-443), CHS (444-445)) (122-445)], (223-
214')-disulfuro con la cadena ligera kappa Mus
musculus (1'-214') [V-KAPPA (Mus musculus IGKV6-
17*01 (98.9%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9]
(27-32.50-52.89-97) (1'-107') -Mus musculus IGKC*01
(100%) (108'-214')];
dímero (225-225":228-228":230-230")-trisdisulfuro,
producida en la línea celular de mieloma murino
SP2/0-Ag14, glicoforma alfa
738
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
modakafuspum alfa #
modakafusp alfa immunoglobulin G4-kappa, anti-[human ADP-ribosyl cyclase/cyclic ADP-
ribose hydrolase 1 (EC:3.2.2.6) (ADPRC 1/cADRp hydrolase 1, cell surface
antigen CD38)], humanized monoclonal antibody, fused at each C-terminus
of the heavy chains (1-447, 1''-447'') to attenuated human interferon α-2b
(IFNα2b) variant (K23>R470, T106>A553, A145>D592) (448-612, 448''-612'');
gamma4 heavy chain humanized fused to IFNα2b (1-612) [VH (Homo
sapiens IGHV1-69-2*01 (90.7%) -(IGHD)- IGHJ4*01 (85.7%)) CDR-IMGT
[8.8.13] (26-33.51-58.97-109) (1-120)-Homo sapiens IGHG4*01, G4v5 h
P10 (CH1 (121-218), hinge 1-12 S10>P (228) (219-230), CH2 (231-340),
CH3 (341-445), CHS (446-447))(121-447), fused to IFNα2b K23>R (470),
T106>A (553), A145>D (592) (448-612)],(134-214')-disulfide with kappa light
chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01 (83.2%)
-IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo
sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer
(226-226":229-229")-bisdisulfide;
produced in Chinese hamster ovary (CHO) K1SV cells, glycoform alfa
modakafusp alfa immunoglobuline G4-kappa, anti-[ADP-ribosyl cyclase/ ADP cyclique -
ribose hydrolase 1 humaine (EC:3.2.2.6) (ADPRC 1/cADRp hydrolase 1,
antigène de surface cellulaire CD38)], anticorps monoclonal humain
fusionné à chaque partie C-terminale des chaînes lourdes (1-447, 1''-447'')
à un variant (K23>R470, T106>A553, A145>D592) de l'interféron α-2b humain
(IFNα2b) atténué, (448-612, 448''-612'');
chaîne lourde gamma4 humanisée fusionnée à IFNα2b (1-612) [VH (Homo
sapiens IGHV1-69-2*01 (90.7%) -(IGHD)- IGHJ4*01 (85.7%)) CDR-IMGT
[8.8.13] (26-33.51-58.97-109) (1-120)-Homo sapiens IGHG4*01, G4v5 h
P10 (CH1 (121-218), charnière 1-12 S10>P (228) (219-230), CH2 (231-
340), CH3 (341-445), CHS (446-447))(121-447), fusionné à IFNα2b K23>R
(470), T106>A (553), A145>D (592) (448-612)],(134-214')-disulfure avec la
chaîne légère kappa humanisée (1'-214') [V-KAPPA (Homo sapiens
IGKV1-33*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-
52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101
(191) (108'-214')]; dimère (226-226":229-229")-bisdisulfure ;
produit dans des cellules ovariennes de hamster chinois (CHO) K1SV,
glycoforme alfa
739
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
modakafusp alfa inmunoglobulina G4-kappa, anti-[ADP-ribosil ciclasa/
ADP cíclica -ribosa hidrolasa 1 humana (EC:3.2.2.6)
(ADPRC 1/cADRp hidrolasa 1, antígeno de superficie
celular CD38)], anticuerpo monoclonal humano
fusionado a cada parte C-terminal de las cadenas
pesadas (1-447, 1''-447'') a una variante (K23>R470,
T106>A553, A145>D592) del interferón α-2b humano
(IFNα2b) atenuado, (448-612, 448''-612'');
cadena pesada gamma4 humanizada fusionada al
IFNα2b (1-612) [VH (Homo sapiens IGHV1-69-2*01
(90.7%) -(IGHD)- IGHJ4*01 (85.7%)) CDR-IMGT
[8.8.13] (26-33.51-58.97-109) (1-120)-Homo sapiens
IGHG4*01, G4v5 h P10 (CH1 (121-218), bisagra 1-12
S10>P (228) (219-230), CH2 (231-340), CH3 (341-
445), CHS (446-447))(121-447), fusionado con IFNα2b
K23>R (470), T106>A (553), A145>D (592) (448-
612)],(134-214')-disulfuro con la cadena ligera kappa
humanizada (1'-214') [V-KAPPA (Homo sapiens
IGKV1-33*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT
[6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-
214')]; dímero (226-226":229-229")-bisdisulfuro ;
producido en las células ováricas de hamster chino
(CHO) K1SV, glicoforma alfa
Sequence / Séquence / Secuencia
Heavy chain / Chaîne lourde / Cadena pesada (anti-CD38 4-IFN 2b)
EVQLVQSGAE VKKPGATVKI SCKVSGYTFT DSVMNWVQQA PGKGLEWMGW 50
IDPEYGRTDV AEKFQGRVTI TADTSTDTAY MELSSLRSED TAVYYCARTK 100
YNSGYGFPYW GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200
YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGKCDL 450
PQTHSLGSRR TLMLLAQMRR ISLFSCLKDR HDFGFPQEEF GNQFQKAETI 500
PVLHEMIQQI FNLFSTKDSS AAWDETLLDK FYTELYQQLN DLEACVIQGV 550
GVAETPLMKE DSILAVRKYF QRITLYLKEK KYSPCAWEVV RDEIMRSFSL 600
STNLQESLRS KE 612
Light chain / chaîne légère / cadena ligera
DIQMTQSPSS LSASVGDRVT ITCKASQNVD SDVDWYQQKP GKAPKLLIYK 50
ASNDYTGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCMQ SNTHPRTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-96 147-203 261-321 367-425
22''-96'' 147''-203'' 261''-321'' 367''-425''
Intra-IFN 448-545 476-585 448''-545'' 476''-585''
Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194'''
Inter-H-L 134-214' 134''-214'''
Inter-H-H 226-226'' 229-229''
Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
H CH2 N84.4: N297, N297''
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires
complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados
murizatoclaxum
murizatoclax (13S,31R,32R,4R,5E,8S,9R)-6'-chloro-4-methoxy-8,9-
dimethyl-4-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-
2-yl]methyl}-3',4'-dihydro-12H,14H,2'H-spiro[10λ6-thia-
11-aza-1(5,7)-[1,5]benzoxazepina-3(1,2)-
cyclobutanacyclododecaphan-5-ene-13,1'-
naphthalene]-10,10,12-trione
740
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
murizatoclax (13S,31R,32R,4R,5E,8S,9R)-6'-chloro-4-méthoxy-8,9-
diméthyl-4-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-
2-yl]méthyl}-3',4'-dihydro-12H,14H,2'H-spiro[10λ6-thia-
11-aza-1(5,7)-[1,5]benzoxazépina-3(1,2)-
cyclobutanacyclododécaphan-5-ène-13,1'-naphtalène]-
10,10,12-trione
murizatoclax (13S,31R,32R,4R,5E,8S,9R)-6'-cloro-4-metoxi-8,9-
dimetil-4-{[(9aR)-octahidro-2H-pirido[1,2-a]pirazin-2-
il]metil}-3',4'-dihidro-12H,14H,2'H-spiro[10λ6-thia-11-
aza-1(5,7)-[1,5]benzoxazepina-3(1,2)-
ciclobutanaciclododecafan-5-eno-13,1'-naftaleno]-
10,10,12-triona
C42H57ClN4O5S
nadunolimabum #
nadunolimab immunoglobulin G1-kappa, anti-[Homo sapiens
IL1RAP (interleukin-1 receptor accessory protein)],
humanized monoclonal antibody;
gamma1 heavy chain humanized (1-446) [VH (Homo
sapiens IGHV1-69*02 (85.4%) -(IGHD) -IGHJ4*01
(100%)) [8.8.10] (1-117) -Homo sapiens IGHG1*03v,
G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-
215), hinge (216-230), CH2 (231-340), CH3 E12 (356),
M14 (358) (341-445), CHS K2>del (446)) (118-446)],
(220-214')-disulfide with kappa light chain humanized
(1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01
(85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo
sapiens IGKC*01 (100%), Km3 A45.1 (153), V101
(191) (108'-214')]; dimer (226-226'':229-229'')-
bisdisulfide
nadunolimab immunoglobulin G1-kappa, anti-[Homo sapiens
IL1RAP (interleukin-1 receptor accessory protein)],
humanized monoclonal antibody;
gamma1 heavy chain humanized (1-446) [VH (Homo
sapiens IGHV1-69*02 (85.4%) -(IGHD) -IGHJ4*01
(100%)) [8.8.10] (1-117) -Homo sapiens IGHG1*03v,
G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-
215), hinge (216-230), CH2 (231-340), CH3 E12 (356),
M14 (358) (341-445), CHS K2>del (446)) (118-446)],
(220-214')-disulfide with kappa light chain humanized
(1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01
(85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo
sapiens IGKC*01 (100%), Km3 A45.1 (153), V101
(191) (108'-214')]; dimer (226-226'':229-229'')-
bisdisulfide
741
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
nadunolimab immunoglobulin G1-kappa, anti-[Homo sapiens
IL1RAP (interleukin-1 receptor accessory protein)],
humanized monoclonal antibody;
gamma1 heavy chain humanized (1-446) [VH (Homo
sapiens IGHV1-69*02 (85.4%) -(IGHD) -IGHJ4*01
(100%)) [8.8.10] (1-117) -Homo sapiens IGHG1*03v,
G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-
215), hinge (216-230), CH2 (231-340), CH3 E12 (356),
M14 (358) (341-445), CHS K2>del (446)) (118-446)],
(220-214')-disulfide with kappa light chain humanized
(1'-214') [V-KAPPA (Homo sapiens IGKV1-33*01
(85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -Homo
sapiens IGKC*01 (100%), Km3 A45.1 (153), V101
(191) (108'-214')]; dimer (226-226'':229-229'')-
bisdisulfide
Heavy chain / Chaîne lourde / Cadena pesada
QVQLVQSGAE VKKPGSSVKV SCKASGYAFT SSWMNWVRQA PGQGLEWMGR 50
IYPGDGNTHY AQKFQGRVTL TADKSTSTAY MELSSLRSED TAVYYCGEGY 100
LDPMDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG 446
Light chain / Chaîne légère / Cadena ligera
DIQMTQSPSS LSASVGDRVT ITCQASQGIN NYLNWYQQKP GKAPKLLIHY 50
TSGLHAGVPS RFSGSGSGTD YTLTISSLEP EDVATYYCQQ YSILPWTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfur
Intra-H (C23-C104) 22-96 144-200 261-321 367-425
22''-96'' 144''-200'' 261''-321'' 367''-425''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (h 5-CL 126) 220-214' 220''-214'''
Inter-H-H (h 11, h 14) 226-226" 229-229"
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297'
Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennai
complexes afucosylés / glicanos de tipo CHO biantenarios complejos afucosilados.
nesolicaftorum
nesolicaftor N-(trans-3-{5-[(1R)-1-hydroxyethyl]-1,3,4-oxadiazol-2-
yl}cyclobutyl)-3-phenyl-1,2-oxazole-5-carboxamide
nésolicaftor N-(trans-3-{5-[(1R)-1-hydroxyéthyl]-1,3,4-oxadiazol-2-
yl}cyclobutyl)-3-phenyl-1,2-oxazole-5-carboxamide
nesolicaftor 3-fenil-N-(trans-3-{5-[(1R)-1-hidroxietil]-1,3,4-
oxadiazol-2-il}ciclobutil)-1,2-oxazolo-5-carboxamida
C18H18N4O4
742
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
nipocalimabum #
nipocalimab immunoglobulin G1-lambda, anti-[Homo sapiens
FCGRT (Fc fragment of IgG receptor and transporter,
neonatal Fc receptor, FcRn, transmembrane alpha
chain of the neonatal receptor)], Homo sapiens
monoclonal antibody;
gamma1 heavy chain Homo sapiens (1-445) [VH
(Homo sapiens IGHV3-23*01 (90.8%) -(IGHD) -
IGHJ3*01 (100%)) CDR-IMGT [8.8.9] (26-33.51-58.97-
105) (1-116) -Homo sapiens IGHG1*03
G1m3>G1m17, nG1m1, G1v29 CH2 A84.4 (CH1
R120>K (213) (117-214), hinge 1-15 (215-229), CH2
N84.4>A (296) (230-339), CH3 E12 (355), M14 (357)
(340-444), CHS K2>del (445)) (117-445)], (219-215')-
disulfide with lambda light chain Homo sapiens (1'-
216') [V-LAMBDA (Homo sapiens IGLV2-23*01
(94.8%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.10] (26-
34.52-54.91-100) (1'-110') -Homo sapiens IGLC3*03
(100%) (111'-216')];
dimer (225-225'':228-228'')-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
nipocalimab immunoglobuline G1-lambda, anti-[Homo sapiens
FCGRT (transporteur et récepteur du fragment Fc des
IgG, récepteur Fc néonatal, FcRn, chaîne alpha
transmembranaire du récepteur néonatal)], anticorps
monoclonal Homo sapiens;
chaîne lourde gamma1 Homo sapiens (1-445) [VH
(Homo sapiens IGHV3-23*01 (90.8%) -(IGHD) -
IGHJ3*01 (100%)) CDR-IMGT [8.8.9] (26-33.51-58.97-
105) (1-116) -Homo sapiens IGHG1*03
G1m3>G1m17, nG1m1, G1v29 CH2 A84.4 (CH1
R120>K (213) (117-214), charnière 1-15 (215-229),
CH2 N84.4>A (296) (230-339), CH3 E12 (355), M14
(357) (340-444), CHS K2>del (445)) (117-445)], (219-
215')-disulfure avec la chaîne légère lambda Homo
sapiens (1'-216') [V-LAMBDA (Homo sapiens IGLV2-
23*01 (94.8%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.10]
(26-34.52-54.91-100) (1'-110') -Homo sapiens
IGLC3*03 (100%) (111'-216')];
dimère (225-225'':228-228'')-bisdisulfure, produite
dans des cellules ovariennes de hamster chinois
(CHO), glycoforme alfa
nipocalimab inmunoglobulina G1-lambda, anti-[Homo sapiens
FCGRT (transportador y receptor del fragmento Fc de
las IgG, receptor Fc neonatal, FcRn, cadena alfa
transmembranaria del receptor neonatal)], anticuerpo
monoclonal Homo sapiens;
cadena pesada gamma1 Homo sapiens (1-445) [VH
(Homo sapiens IGHV3-23*01 (90.8%) -(IGHD) -
IGHJ3*01 (100%)) CDR-IMGT [8.8.9] (26-33.51-58.97-
105) (1-116) -Homo sapiens IGHG1*03
G1m3>G1m17, nG1m1, G1v29 CH2 A84.4 (CH1
R120>K (213) (117-214), bisagra 1-15 (215-229), CH2
N84.4>A (296) (230-339), CH3 E12 (355), M14 (357)
(340-444), CHS K2>del (445)) (117-445)], (219-215')-
disulfuro con la cadena ligera lambda Homo sapiens
(1'-216') [V-LAMBDA (Homo sapiens IGLV2-23*01
(94.8%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.10] (26-
34.52-54.91-100) (1'-110') -Homo sapiens IGLC3*03
(100%) (111'-216')];
dímero (225-225'':228-228'')-bisdisulfuro, producida
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
743
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
Heavy chain / Chaîne lourde / Cadena pesada
EVQLLESGGG LVQPGGSLRL SCAASGFTFS TYAMGWVRQA PGKGLEWVSS 50
IGASGSQTRY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARLA 100
IGDSYWGQGT MVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYASTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPG 445
Light chain / Chaîne légère / Cadena ligera
QSALTQPASV SGSPGQSITI SCTGTGSDVG SYNLVSWYQQ HPGKAPKLMI 50
YGDSERPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYAGSGIYV 100
FGTGTKVTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHKSYSCQVT 200
HEGSTVEKTV APTECS 216
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 143-199 260-320 366-424
22''-96'' 143''-199'' 260''-320'' 366''-424''
Intra-L (C23-C104) 22'-90' 138'-197'
22'''-90''' 138'''-197'''
Inter-H-L (h 5-CL 126) 219-215' 219''-215'''
Inter-H-H (h 11, h 14) 225-225'' 228-228''
No N-glycosylation sites / pas de sites de N-glycosylation / ningún posición de N-glicosilación
H CH2 N84.4>A:
296, 296''
olverembatinibum
olverembatinib 4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-
(trifluoromethyl)phenyl}-3-[(1H-pyrazolo[3,4-b]pyridin-
5-yl)ethynyl]benzamide
olvérembatinib 4-méthyl-N-{4-[(4-méthylpipérazin-1-yl)méthyl]-3-
(trifluorométhyl)phényl}-3-[(1H-pyrazolo[3,4-b]pyridin-
5-yl)éthynyl]benzamide
olverembatinib 4-metil-N-{4-[(4-metilpiperazin-1-il)metil]-3-
(trifluorometil)fenil}-3-[(1H-pirazolo[3,4-b]piridin-5-
il)etinil]benzamide
C29H27F3N6O
olvimulogenum nanivacirepvecum #
olvimulogene nanivacirepvec A recombinant replication-competent oncolytic vaccinia
virus (strain LIVP) comprising the genes encoding a
Renilla luciferase - green fluorescent protein fusion
protein (ruc-gfp) and enzymes beta-galactosidase
(lacZ) and beta-glucuronidase (gusA), inserted into the
F14.5L, J2R (thymidine kinase) and A56R
(hemagglutinin) loci, respectively. Expression of the
three proteins is driven by a synthetic early/late
promoter (pSEL), a vaccinia virus strain Western
Reserve early/late p7.5 promoter and a vaccinia virus
strain Western Reserve late p11 promoter,
respectively. A human transferrin receptor gene has
also been inserted in the J2R locus but is not
expressed.
744
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
olvimulogène nanivacirépvec virus de la vaccine recombinant répliquant oncolytique
(souche LIVP) contenant les gènes codant pour une
protéine de fusion luciférase de Renilla - protéine
fluorescente verte (ruc-gfp) et des enzymes
galactosidase bêta (lacZ) et glucuronidase bêta
(gusA), insérés dans les loci F14.5L, J2R (thymidine
kinase) and A56R (hémagglutinine), respectivement.
L'expression des trois protéines est sous le contrôle
d'un promoteur synthétique précoce/tardif (pSEL), d'un
promoteur p7.5 précoce/tardif du virus de la vaccine
souche Western Reserve et d'un promoteur p11 tardif
du virus de la vaccine souche Western Reserve,
respectivement. Un gène du récepteur de transférine
humain a aussi été inséré dans le locus J2R mais n'est
pas exprimé.
olvimulogén nanivacirepvec Un virus vaccinia recombinante (cepa LIVP)
competente para replicación, oncolítico, que contiene
los genes que codifican para una proteína de fusión de
la luciferasa de Renilla y la proteína fluorescente verde
(ruc-gfp) y para las enzimas beta-galactosidasa (LacZ)
y beta-glucuronidasa (gusA), insertados en los loci
F14.5L, J2R (timidina quinasea) y A56R
(hemaglutinina), respectivamente. La expresión de las
tres proteínas está dirigida por un promotor
temprano/tardío sintético (pSEL), un promotor p7.5
precoz/tardío de la cepa Western Reserve del virus
vaccinia y un promotor p11 tardío de la cepa Western
Reserve del virus vaccinia, respectivamente. Se ha
insertado también un gen del receptor de transferrina
humano en el locus J2R pero éste no se expresa.
omfiloctocogum alfa #
omfiloctocog alfa human coagulation factor VIII (FVIII, antihemophilic
factor, AHF, procoagulant component) with deleted B-
domain (746-1639)-sequence:
single-chain recombinant FVIII composed of domains
A1-a1-A2-a2 (1-740), the B-domain N- and C-terminal
fragments (741-745) and 1640-1648 (746-754) and
domains a3-A3-C1-C2 1649-2332 (755-1438),
produced in Chinese hamster ovary (CHO) cells,
glycoform alfa
omfiloctocog alfa facteur de coagulation VIII humain (FVIII, facteur
antihémophilique, AHF, composant procoagulant) dont
le domaine B a été supprimé (746-1639):
chaîne unique du FVIII humain recombinant composé
des domaines A1-a1-A2-a2 (1-740), des fragments N-
and C-terminaux du domaine B (741-745) et 1640-
1648 (746-754) et des domaines a3-A3-C1-C2 1649-
2332 (755-1438), produit par des cellules ovariennes
de hamster chinois (CHO), glycoforme alfa
omfiloctocog alfa factor de coagulación VIII humano (FVIII, factor
antihemofílico, AHF, componente procoagulante) con
el dominio B que ha sido suprimido (746-1639):
745
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
cadena única del FVIII humano recombinante
compuesto de los dominios A1-a1-A2-a2 (1-740), de
los fragmentos N- y C-terminal del dominio B (741-
745) y 1640-1648 (746-754) y de los dominios a3-A3-
C1-C2 1649-2332 (755-1438), producido por las
células ováricas de hamster chino (CHO), glicoforma
alfa
Sequence / Séquence / Secuencia
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50
FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350
TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450
PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650
VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700
GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SFSQNPPVLK 750
RHQREITRTT LQSDQEEIDY DDTISVEMKK EDFDIYDEDE NQSPRSFQKK 800
TRHYFIAAVE RLWDYGMSSS PHVLRNRAQS GSVPQFKKVV FQEFTDGSFT 850
QPLYRGELNE HLGLLGPYIR AEVEDNIMVT FRNQASRPYS FYSSLISYEE 900
DQRQGAEPRK NFVKPNETKT YFWKVQHHMA PTKDEFDCKA WAYFSDVDLE 950
KDVHSGLIGP LLVCHTNTLN PAHGRQVTVQ EFALFFTIFD ETKSWYFTEN 1000
MERNCRAPCN IQMEDPTFKE NYRFHAINGY IMDTLPGLVM AQDQRIRWYL 1050
LSMGSNENIH SIHFSGHVFT VRKKEEYKMA LYNLYPGVFE TVEMLPSKAG 1100
IWRVECLIGE HLHAGMSTLF LVYSNKCQTP LGMASGHIRD FQITASGQYG 1150
QWAPKLARLH YSGSINAWST KEPFSWIKVD LLAPMIIHGI KTQGARQKFS 1200
SLYISQFIIM YSLDGKKWQT YRGNSTGTLM VFFGNVDSSG IKHNIFNPPI 1250
IARYIRLHPT HYSIRSTLRM ELMGCDLNSC SMPLGMESKA ISDAQITASS 1300
YFTNMFATWS PSKARLHLQG RSNAWRPQVN NPKEWLQVDF QKTMKVTGVT 1350
TQGVKSLLTS MYVKEFLISS SQDGHQWTLF FQNGKVKVFQ GNQDSFTPVV 1400
NSLDPPLLTR YLRIHPQSWV HQIALRMEVL GCEAQDLY 1438
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179, 248-329, 528-554, 630-711, 938-964, 1005-1009, 1127-1275, 1280-1432
(Cys-SH: 310, 692, 1106)
Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N41, N239, N916, N1224
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires
complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados
Tyr-sulfation sites / Sites de Tyr-sulfation / Posiciones de Tyr-sulfación
346, 718, 719, 723, 770, 786
onatasertibum
onatasertib 7-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-(trans-4-
methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-
2(1H)-one
onatasertib 7-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-(trans-4-
méthoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-
2(1H)-one
onatasertib 7-[6-(2-hidroxipropan-2-il)piridin-3-il]-1-(trans-4-
metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pirazin-
2(1H)-ona
C21H27N5O3
746
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
ongericimabum #
ongericimab immunoglobulin G4-kappa, anti-[Homo sapiens
PCSK9 (proprotein convertase subtilisin/kexin type 9,
neural apoptosis-regulated convertase 1, NARC1,
NARC-1, proprotein convertase 9, PC9)], humanized
monoclonal antibody;
gamma4 heavy chain (1-438) [VH (Homo sapiens
IGHV4-59*01 (79.2%) -(IGHD) -IGHJ1*01 (100%))
CDR-IMGT [8.7.5] (26-33.51-57.96-100) (1-111) -
Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (112-
209), hinge 1-12 S10>P (219) (210-221), CH2 (222-
331), CH3 (332-436), CHS (437-438)) (112-438)],
(125-213')-disulfide with kappa light chain (1'-213') [V-
KAPPA (Homo sapiens IGKV1-33*01 (85.1%) -
IGKJ1*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-
96) (1'-106') -Homo sapiens IGKC*01 (100%) Km3
A45.1 (152), V101 (190) (107'-213')];
dimer (217-217'':220-220'')-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
ongéricimab immunoglobuline G4-kappa, anti-[Homo sapiens
PCSK9 (proprotéine convertase subtilisine/kexine type
9, convertase 1 régulée par l'apoptose neuronale,
NARC1, NARC-1, proprotéine convertase 9, PC9)],
anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-438) [VH (Homo sapiens
IGHV4-59*01 (79.2%) -(IGHD) - IGHJ1*01 (100%))
CDR-IMGT [8.7.5] (26-33.51-57.96-100) (1-111) -
Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (112-
209), charnière 1-12 S10>P (219) (210-221), CH2
(222-331), CH3 (332-436), CHS (437-438)) (112-438)],
(125-213')-disulfure avec la chaîne légère kappa (1'-
213') [V-KAPPA (Homo sapiens IGKV1-33*01 (85.1%)
-IGKJ1*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-
52.89-96) (1'-106') -Homo sapiens IGKC*01 (100%)
Km3 A45.1 (152), V101 (190) (107'-213')];
dimère (217-217'':220-220'')-bisdisulfure, produite
dans des cellules ovariennes de hamster chinois
(CHO), glycoforme alfa
ongericimab inmunoglobulina G4-kappa, anti-[Homo sapiens
PCSK9 (proproteína convertasa subtilisina/kexina tipo
9, convertasa 1 regulada por la apoptosa neuronal,
NARC1, NARC-1, proproteína convertasa 9, PC9)],
anticuerpo monoclonal humanizado;
cadena pesada gamma4 (1-438) [VH (Homo sapiens
IGHV4-59*01 (79.2%) -(IGHD) - IGHJ1*01 (100%))
CDR-IMGT [8.7.5] (26-33.51-57.96-100) (1-111) -
Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (112-
209), bisagra 1-12 S10>P (219) (210-221), CH2 (222-
331), CH3 (332-436), CHS (437-438)) (112-438)],
(125-213')-disulfuro con la cadena ligera kappa (1'-
213') [V-KAPPA (Homo sapiens IGKV1-33*01 (85.1%)
-IGKJ1*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-
52.89-96) (1'-106') -Homo sapiens IGKC*01 (100%)
Km3 A45.1 (152), V101 (190) (107'-213')];
dímero (217-217'':220-220'')-bisdisulfuro, producida
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
747
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
ontorpaceptum #
ontorpacept human signal-regulatory protein alpha (SIRPα,
tyrosine-protein phosphatase non-receptor type
substrate 1, inhibitory receptor SHPS-1), (L14>S,
T20>S, T22>I, R24>H, A27>V, G45>A, D65>E, L66>S,
N70>E, R77>S, G79>S, D101>del, V102>T101)-variant, N-
terminal (1-118)-fragment [binding domain for CD47
(inhibitor of phagocytosis by macrophages)], fused to a
human immunoglobulin G1 C-terminal Fc fragment
(119-345), dimer (124-124':127-127')-bisdisulfide,
produced in Chinese hamster ovary (CHO) cells,
glycoform alfa
ontorpacept protéine régulatoire de signal alpha, humaine (SIRPα,
substrat 1 de type non-récepteur de la tyrosine-
protéine phosphatase, récepteur inhibitoire SHPS-1),
(L14>S, T20>S, T22>I, R24>H, A27>V, G45>A, D65>E,
L66>S, N70>E, R77>S, G79>S, D101>del, V102>T101)-
variant, fragment N-terminal (1-118) [domaine se liant
au CD47 (inhibiteur de la phagocytose par les
macrophages)], fusionnée au fragment Fc C-terminal
de l'immunoglobuline G1 (119-345), dimère (124-
124':127-127')-bisdisulfure, produit dans des cellules
ovariennes de hamster chinois (CHO), glycoforme alfa
ontorpacept proteína reguladora de señal alfa, humana (SIRPα,
sustrato 1 de tipo no-receptor de la tirosina-proteína
fosfatasa, receptor inhibidor SHPS-1), (L14>S, T20>S,
T22>I, R24>H, A27>V, G45>A, D65>E, L66>S, N70>E,
R77>S, G79>S, D101>del, V102>T101)-variante, fragmento
N-terminal (1-118) [dominio unido al CD47 (inhibidor
de la fagocitosis por los macrófagos)], fusionado con
el fragmento Fc C-terminal de la inmunoglobulina G1
(119-345), dímero (124-124':127-127')-bisdisulfuro,
producido en las células ováricas de hamster chino
(CHO), glicoforma alfa
748
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
Sequence / Séquence / Secuencia
EEELQVIQPD KSVSVAAGES AILHCTVTSL IPVGPIQWFR GAGPARELIY 50
NQKEGHFPRV TTVSESTKRE NMDFSISISN ITPADAGTYY CVKFRKGSPD 100
TEFKSGAGTE LSVRAKPSDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 150
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 200
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 250
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 300
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK 345
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
intra-chain 25-91 159-219 265-323
25'-91' 159'-219' 265'-323'
inter-chain: 124-124' 127-127'
Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N80, N195, N80', N195'
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires
complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados
C-terminal lysine clipping / Coupure de la lysine C-terminale / supresión de lisina C-terminal
H CHS K2: 345, 345'
opucolimabum #
opucolimab immunoglobulin G1-lambda, anti-[Homo sapiens
CD274 (programmed death ligand 1, PDL1, PD-L1, B7
homolog 1, B7H1)], monoclonal antibody;
gamma1 heavy chain (1-453) [VH (Homo sapiens
IGHV3-21*01 (94.9%) -(IGHD) -IGHJ3*01 (93.3%))
[8.8.16] (1-123) -Homo sapiens IGHG1*03v
G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124-
221), hinge 1-15 (222-236), CH2 N84.4>A (303) (237-
346), CH3 E12 (362), M14 (364) (347-451), CHS (452-
453)) (124-453)], (226-214')-disulfide with lambda light
chain humanized (1'-214') [V-LAMBDA (Homo sapiens
IGLV1-51*01 (82.3%) -IGLJ2*01 (100%)) [8.3.10] (1'-
109') -Homo sapiens IGLC3*03 (98.1%) K119>R
(207), P123>L (211) (110'-214')];
dimer (232-232":235-235")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells
opucolimab immunoglobuline G1-lambda, anti-[Homo sapiens
CD274 (ligand 1 de mort programmée, PDL1, PD-L1,
homologue 1 de B7, B7H1)], anticorps monoclonal;
chaîne lourde gamma1 (1-453) [VH (Homo sapiens
IGHV3-21*01 (94.9%) -(IGHD) -IGHJ3*01 (93.3%))
[8.8.16] (1-123) -Homo sapiens IGHG1*03v
G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124-
221), charnière 1-15 (222-236), CH2 N84.4>A (303)
(237-346), CH3 E12 (362), M14 (364) (347-451), CHS
(452-453)) (124-453)], (226-214')-disulfure avec la
chaîne légère (1'-214') [V-LAMBDA (Homo sapiens
IGLV1-51*01 (82.3%) -IGLJ2*01 (100%)) [8.3.10] (1'-
109') -Homo sapiens IGLC3*03 (98.1%) K119>R
(207), P123>L (211) (110'-214')];
dimère (232-232":235-235")-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO)
opucolimab inmunoglobulina G1-lambda, anti-[Homo sapiens
CD274 (ligando 1 de muerte programada, PDL1, PD-
L1, homólogo 1 de B7, B7H1)], anticuerpo monoclonal;
749
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
cadena pesada gamma1 (1-453) [VH (Homo sapiens
IGHV3-21*01 (94.9%) -(IGHD) -IGHJ3*01 (93.3%))
[8.8.16] (1-123) -Homo sapiens IGHG1*03v
G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124-
221), bisagra 1-15 (222-236), CH2 N84.4>A (303)
(237-346), CH3 E12 (362), M14 (364) (347-451), CHS
(452-453)) (124-453)], (226-214')-disulfuro con la
cadena ligera lambda (1'-214') [V-LAMBDA (Homo
sapiens IGLV1-51*01 (82.3%) -IGLJ2*01 (100%))
[8.3.10] (1'-109') -Homo sapiens IGLC3*03 (98.1%)
K119>R (207), P123>L (211) (110'-214')];
dímero (232-232":235-235")-bisdisulfuro, producido
por células ováricas de hamster chino (CHO)
Heavy chain / Chaîne lourde / Cadena pesada
EVQLVQSGGG LVKPGGSLRL SCAASGFTFS SYTMNWVRQA PGKGLEWVSS 50
ISSGSDYLYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARNE 100
LRWYPQAGAF DRWGQGTMVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYASTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK 453
Light chain / Chaîne légère / Cadena ligera
QSVVTQPPSM SAAPGQRVTI SCSGSSSYIE SSYVGWYQQL PGTAPRLLIY 50
DDDMRPSGIP DRFSGSKSGT SATLAITGLQ TGDEADYYCE IWRSGLGGVF 100
GGGTKLTVLS QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HKSYSCQVTH 200
EGSTVERTVA LTEC 214
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 150-206 267-327 373-431
22''-96'' 150''-206'' 267''-327'' 373''-431''
Intra-L (C23-C104) 22'-89' 137'-196'
22'''-89''' 137'''-196'''
Inter-H-L (h 5-CL 126) 226-214' 226''-214'''
Inter-H-H (h 11, h 14) 232-232'' 235-235''
No N-glycosylation sites / pas de sites de N-glycosylation / ningún posición de N-glicosilación:
H CH2 N84.4>A:
303, 303''
C-terminal lysine clipping:
H CHS K2:
453, 453''
orelabrutinibum
orelabrutinib 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-4-
yl]pyridine-3-carboxamide
orélabrutinib 2-(4-phénoxyphényl)-6-[1-(prop-2-énoyl)pipéridin-4-
yl]pyridine-3-carboxamide
orelabrutinib 2-(4-fenoxifenil)-6-[1-(prop-2-enoil)piperidin-4-
il]piridina-3-carboxamida
C26H25N3O3
750
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
orvacabtagenum autoleucelum #
orvacabtagene autoleucel autologous CD4+ and CD8+ T lymphocytes obtained
from peripheral blood mononuclear cells (PBMC),
transduced ex vivo with a replication-incompetent, self-
inactivating (SIN) lentiviral vector, encoding a chimeric
antigen receptor (CAR) consisting of the human B cell
maturation antigen (BCMA)-specific scFv, an lgG4-
CH2-CH3 hinge region, CD28 transmembrane domain,
CD137 (4-1BB) co-stimulatory domain and CD3 zeta
signalling domain, under the control of a hybrid
Elongation Factor 1 alpha (EF1α) / Human T cell
Leukemia Virus (HTLV) R element promoter. The
vector also encodes a truncated human epidermal
growth factor receptor (EGFRt) that is expressed
separately from the CAR on the cell surface.
orvacabtagène autoleucel lymphocytes T autologues CD4+ and CD8+ obtenus
de cellules mononuclées du sang périphérique
(PBMC), transduits ex vivo avec un vecteur lentiviral
non-répliquant, auto-inactivant (SIN) codant pour un
récepteur d'antigène chimérique (CAR) ciblant
l'antigène spécifique du scFv de maturation des
lymphocytes B (BCMA) humain, une région charnière
lgG4-CH2-CH3, un domaine transmembranaire du
CD28, un domaine co-stimulateur du CD137 (4-1BB),
et un domaine de signalisation CD3 zêta, sous le
contrôle d'un promoteur hybride du facteur
d'élongation 1-alpha humain (EF1α) / élément R du
virus du lymphome humain à cellules T (HTLV). Le
vecteur exprime un récepteur du facteur de croissance
des cellules épidermiques humain tronqué (EGFRt) qui
est exprimé séparément du CAR à la surface de la
cellule.
orvacabtagén autoleucel linfocitos T CD4+ y CD8+ autólogos obtenidos de
células mononucleares de sangre periférica,
transducidos con un vector lentiviral auto inactivante e
incompetente para replicación, que codifica un
receptor para antígenos quimérico (CAR) consistente
en un ssFv específico del antígeno de maduración de
linfocitos B humano (BCMA), una región bisagra IgG4-
CH2-CH3, un dominio transmembrana de CD28, un
domino coestimulador de CD137 (4-1BB) y un dominio
de señalización de CD3 zeta, bajo el control de un
promotor híbrido del Factor de Elongación 1 alfa
(EF1a) / elemento R del virus de la leucemia de
células T (HTLV) humana. El vector también codifica
para una forma truncada del receptor del factor de
crecimiento epidérmico (EGFRt) humano que se
expresa separado del CAR en la superficie celular.
osoresnontrinum
osoresnontrine 1-(oxan-4-yl)-6-[(pyridin-2-yl)methyl]-1,5-dihydro-4H-
pyrazolo[3,4-d]pyrimidin-4-one
osoresnontrine 1-(oxan-4-yl)-6-[(pyridin-2-yl)méthyl]-1,5-dihydro-4H-
pyrazolo[3,4-d]pyrimidin-4-one
osoresnontrina 1-(oxan-4-il)-6-[(piridin-2-il)metil]-1,5-dihidro-4H-
pirazolo[3,4-d]pirimidin-4-ona
751
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
C16H17N5O2
O
N
N
N N N
H
O
pelacarsenum
pelacarsen all-P-ambo-5'-O-(28-[(2-acetamido-2-deoxy-β-D-
galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acetamido-
2-deoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-
oxopropoxy]methyl}-1-hydroxy-1,10,14,21-tetraoxo-
2,18-dioxa-9,15,22-triaza-1λ5-phosphaoctacosan-1-yl)-
2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-
2'-O-(2-methoxyethyl)guanylyl-(3'→5')-2'-O-(2-
methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-O-(2-
methoxyethyl)-5-methyluridylyl-(3'→5')-2'-O-(2-
methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-deoxy-5-
methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-
(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-
(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-
thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-
P-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-P-
thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-(2-
methoxyethyl)-5-methyluridylyl-(3'→5')-2'-O-(2-
methoxyethyl)guanylyl-(3'→5')-2'-O-(2-methoxyethyl)-
5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-
5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-
5-methylcytidine
pélacarsen tout-P-ambo-5'-O-(28-[(2-acétamido-2-désoxy-β-D-
galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acétamido-
2-désoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-
oxopropoxy]méthyl}-1-hydroxy-1,10,14,21-tétraoxo-
2,18-dioxa-9,15,22-triaza-1λ5-phosphaoctacosan-1-yl)-
2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-
2'-O-(2-méthoxyéthyl)guanylyl-(3'→5')-2'-O-(2-
méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-O-(2-
méthoxyéthyl)-5-méthyluridylyl-(3'→5')-2'-O-(2-
méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-désoxy-5-
méthyl-P-thiocytidylyl-(3'→5')-2'-désoxy-P-
thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-
thiothymidylyl-(3'→5')-2'-désoxy-P-thioguanylyl-
(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-P-
thiothymidylyl-(3'→5')-2'-désoxy-P-thioguanylyl-
(3'→5')-2'-désoxy-5-méthyl-P-thiocytidylyl-(3'→5')-P-
thiothymidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-
méthyluridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)guanylyl-
(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-
(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-
(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthylcytidine
752
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
pelacarsén todo-P-ambo-5'-O-(28-[(2-acetamido-2-desoxi-β-D-
galactopiranosil)oxi]-16,16-bis{[3-({6-[(2-acetamido-2-
desoxi-β-D-galactopiranosil)oxi]hexil}amino)-3-
oxopropoxi]metil}-1-hidroxi-1,10,14,21-tetraoxo-2,18-
dioxa-9,15,22-triaza-1λ5-fosfaoctacosan-1-il)-2'-O-(2-
metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-
metoxietil)guanilil-(3'→5')-2'-O-(2-metoxietil)-5-
metilcitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridilil-
(3'→5')-2'-O-(2-metoxietil)-5-metilcitidilil-(3'→5')-2'-
desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-
tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-
(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-
tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-
tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-
P-tiotimidilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridilil-
(3'→5')-2'-O-(2-metoxietil)guanilil-(3'→5')-2'-O-(2-
metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-
metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-
metoxietil)-5-metilcitidina
C296H439N71O163P20S13
pelcitoclaxum
pelcitoclax (3-{[(10R)-14-chloro-35-fluoro-24-(methanesulfonyl)-25-
methyl-7,7-dioxo-10-[(phenylsulfanyl)methyl]-21-
(propan-2-yl)-83-(trifluoromethanesulfonyl)-21H-7λ6-
thia-6,9-diaza-4(1,4)-piperazina-13(1)-piperidina-
2(2,3)-pyrrola-1(1),3(1,3),5,8(1,4)-
tetrabenzenatridecaphane-134-
carbonyl]oxy}propyl)phosphonic acid
pelcitoclax acide (3-{[(10R)-14-chloro-35-fluoro-24-
(méthanesulfonyl)-25-méthyl-7,7-dioxo-10-
[(phénylsulfanyl)méthyl]-21-(propan-2-yl)-83-
(trifluorométhanesulfonyl)-21H-7λ6-thia-6,9-diaza-
4(1,4)-pipérazina-13(1)-pipéridina-2(2,3)-pyrrola-
1(1),3(1,3),5,8(1,4)-tétrabenzenatridécaphane-134-
carbonyl]oxy}propyl)phosphonique
pelcitoclax ácido (3-{[(10R)-14-cloro-10-[(fenilsulfanil)metil]-35-
fluoro-24-(metanosulfonil)-25-metil-7,7-dioxo-21-
(propan-2-il)-83-(trifluorometanosulfonil)-21H-7λ6-tia-
6,9-diaza-4(1,4)-piperazina-13(1)-piperidina-2(2,3)-
pirrola-1(1),3(1,3),5,8(1,4)-tetrabencenatridecafano-
134-carbonil]oxi}propil)fosfónico
753
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
C57H66ClF4N6O11PS4
H O
N
S O
N
F N CF3
S
NH O O
S
Cl O O
S
CH3 OH
N N O
H3C P OH
CH3
CH3
O O
pexopiprantum
pexopiprant ({8-chloro-3-[(4-chlorophenyl)methyl]-4-
(difluoromethoxy)-2-ethylquinolin-5-yl}oxy)acetic acid
pexopiprant acide ({8-chloro-3-[(4-chlorophényl)méthyl]-4-
(difluorométhoxy)-2-éthylquinolin-5-yl}oxy)acétique
pexopiprant ácido ({8-cloro-3-[(4-clorofenil)metil]-4-(difluorometoxi)-
2-etilquinolin-5-il}oxi)acético
C21H17Cl2F2NO4
F
F O O CO2H
Cl N
CH3 Cl
pimurutamabum #
pimurutamab immunoglobulin G1-kappa, anti-[Homo sapiens EGFR
(epidermal growth factor receptor, receptor tyrosine-
protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)],
humanized monoclonal antibody;
gamma1 heavy chain humanized (1-449) [VH (Homo
sapiens IGHV3-48*03 (78.6%) -(IGHD) -IGHJ3*01
(85.7%)) [8.7.13] (1-119) -Homo sapiens IGHG1*03
(100%) G1m3, nG1m1 (CH1 R120 (216) (120-217),
hinge 1-15 (218-232), CH2 (233-342), CH3 E12 (358),
M14 (360) (343-447), CHS (448-449)) (120-449)],
(222-214')-disulfide with kappa light chain humanized
(1'-214') [V-KAPPA (Homo sapiens IGKV3-11*01
(85.3%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') -Homo
sapiens IGKC*01 (100%) Km3 A45.1 (153), V101
(191) (108'-214')];
dimer (228-228":231-231")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
pimurutamab immunoglobuline G1-kappa, anti-[Homo sapiens
EGFR (récepteur du facteur de croissance
épidermique, récepteur tyrosine-protéine kinase erbB-
1, ERBB1, HER1, HER-1, ERBB)], anticorps
monoclonal humanisé;
754
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
chaîne lourde gamma1 humanisée (1-449) [VH (Homo
sapiens IGHV3-48*03 (78.6%) -(IGHD) -IGHJ3*01
(85.7%)) [8.7.13] (1-119) -Homo sapiens IGHG1*03
(100%) G1m3, nG1m1 (CH1 R120 (216) (120-217),
charnière 1-15 (218-232), CH2 (233-342), CH3 E12
(358), M14 (360) (343-447), CHS (448-449)) (120-
449)], (222-214')-disulfure avec la chaîne légère kappa
humanisée (1'-214') [V-KAPPA (Homo sapiens IGKV3-
11*01 (85.3%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') -
Homo sapiens IGKC*01 (100%) Km3 A45.1 (153),
V101 (191) (108'-214')];
dimère (228-228":231-231")-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
pimurutamab inmunoglobulina G1-kappa, anti-[Homo sapiens EGFR
(receptor del factor de crecimiento epidérmico,
receptor tirosina-proteína kinasa erbB-1, ERBB1,
HER1, HER-1, ERBB)], anticuerpo monoclonal
humanizado;
cadena pesada gamma1 humanizada (1-449) [VH
(Homo sapiens IGHV3-48*03 (78.6%) -(IGHD) -
IGHJ3*01 (85.7%)) [8.7.13] (1-119) -Homo sapiens
IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (216)
(120-217), bisagra 1-15 (218-232), CH2 (233-342),
CH3 E12 (358), M14 (360) (343-447), CHS (448-449))
(120-449)], (222-214')-disulfuro con la cadena ligera
kappa humanizada (1'-214') [V-KAPPA (Homo sapiens
IGKV3-11*01 (85.3%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-
107') -Homo sapiens IGKC*01 (100%) Km3 A45.1
(153), V101 (191) (108'-214')];
dímero (228-228":231-231")-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
755
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
posenacaftorum
posenacaftor 8-methyl-2-(3-methyl-1-benzofuran-2-yl)-5-[(1R)-1-(oxan-4-
yl)ethoxy]quinoline-4-carboxylic acid
posénacaftor acide 8-méthyl-2-(3-méthyl-1-benzofuran-2-yl)-5-[(1R)-1-
(oxan-4-yl)éthoxy]quinoléine-4-carboxylique
posenacaftor ácido 8-metil-2-(3-metil-1-benzofuran-2-il)-5-[(1R)-1-(oxan-4-
il)etoxi]quinolina-4-carboxílico
C27H27NO5
pudexacianinii chloridum
pudexacianinium chloride 3-(3-{[3-(cyclomaltoheptaos-2I-O-yl)propyl]amino}-3-
oxopropyl)-2-{(1E)-2-[(3E)-3-{(2E)-2-[3-(3-{[3-
(cyclomaltoheptaos-2I-O-yl)propyl]amino}-3-oxopropyl)-1,1-
dimethyl-1,3-dihydro-2H-benzo[e]indol-2-ylidene]ethylidene}-
2-methoxycyclohex-1-en-1-yl]ethen-1-yl}-1,1-dimethyl-1H-
benzo[e]indol-3-ium chloride
chlorure de pudexacianinium chlorure de 3-(3-{[3-(cyclomaltoheptaos-2I-O-
yl)propyl]amino}-3-oxopropyl)-2-{(1E)-2-[(3E)-3-{(2E)-2-[3-(3-
{[3-(cyclomaltoheptaos-2I-O-yl)propyl]amino}-3-oxopropyl)-
1,1-diméthyl-1,3-dihydro-2H-benzo[e]indol-2-
ylidène]éthylidène}-2-méthoxycyclohex-1-en-1-yl]éthèn-1-yl}-
1,1-diméthyl-1H-benzo[e]indol-3-ium
cloruro de pudexacianinio cloruro de 3-(3-{[3-(ciclomaltoheptaos-2I-O-il)propil]amino}-3-
oxopropil)-2-{(1E)-2-[(3E)-3-{(2E)-2-[3-(3-{[3-
(ciclomaltoheptaos-2I-O-il)propil]amino}-3-oxopropil)-1,1-
dimetil-1,3-dihidro-2H-benzo[e]indol-2-ilideno]etilideno}-2-
metoxiciclohex-1-en-1-il]eten-1-il}-1,1-dimetil-1H-
benzo[e]indol-3-ium
C135H197ClN4O73
CH3 H3C
CH3 OCH3 H3C
N N
R R
HO HO
. Cl
O O
O O
HO OH 6 HO O
R = CH2 HN
O
756
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
quavonlimabum #
quavonlimab immunoglobulin G1-kappa, anti-[Homo sapiens CTLA4
(cytotoxic T-lymphocyte-associated protein 4, CD152)],
humanized monoclonal antibody;
gamma1 heavy chain humanized (1-445) [VH (Homo
sapiens IGHV3-72*01 (84.7%) -(IGHD) -IGHJ4*01
(92.9%)) CDR-IMGT [8.10.6] (26-33.51-60.99-104) (1-
115) -Homo sapiens IGHG1*01 (100%) G1m17,1
(CH1 K120 (212) (116-213), hinge 1-15 (214-228),
CH2 (229-338), CH3 D12 (354), L14 (356) (339-443),
CHS (444-445)) (116-445)], (224-214')-disulfide with
kappa light chain humanized (1'-214') [V-KAPPA
(Homo sapiens IGKV1-6*01 (81.6%) -IGKJ2*02
(90.9%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-
107') -Homo sapiens IGKC*01 (100%) Km3 A45.1
(153), V101 (191) (108'-214')];
dimer (224-224":227-227")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
quavonlimab immunoglobuline G1-kappa, anti-[Homo sapiens
CTLA4 (protéine 4 associée aux lymphocytes T
cytotoxiques, CD152)], anticorps monoclonal
humanisé;
chaîne lourde gamma1 humanisée (1-445) [VH (Homo
sapiens IGHV3-72*01 (84.7%) -(IGHD) -IGHJ4*01
(92.9%)) CDR-IMGT [8.10.6] (26-33.51-60.99-104) (1-
115) -Homo sapiens IGHG1*01 (100%) G1m17,1
(CH1 K120 (212) (116-213), charnière 1-15 (214-228),
CH2 (229-338), CH3 D12 (354), L14 (356) (339-443),
CHS (444-445)) (116-445)], (224-214')-disulfure avec
la chaîne légère kappa humanisée (1'-214') [V-KAPPA
(Homo sapiens IGKV1-6*01 (81.6%) -IGKJ2*02
(90.9%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-
107') -Homo sapiens IGKC*01 (100%) Km3 A45.1
(153), V101 (191) (108'-214')];
dimère (224-224":227-227")-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
quavonlimab inmunoglobulina G1-kappa, anti-[Homo sapiens
CTLA4 (proteína 4 asociada a los linfocitos T
citotóxicos, CD152)], anticuerpo monoclonal
humanizado;
cadena pesada gamma1 humanizada (1-445) [VH
(Homo sapiens IGHV3-72*01 (84.7%) -(IGHD) -
IGHJ4*01 (92.9%)) CDR-IMGT [8.10.6] (26-33.51-
60.99-104) (1-115) -Homo sapiens IGHG1*01 (100%)
G1m17,1 (CH1 K120 (212) (116-213), bisagra 1-15
(214-228), CH2 (229-338), CH3 D12 (354), L14 (356)
(339-443), CHS (444-445)) (116-445)], (224-214')-
disulfuro con la cadena ligera kappa humanizada (1'-
214') [V-KAPPA (Homo sapiens IGKV1-6*01 (81.6%) -
IGKJ2*02 (90.9%)) CDR-IMGT [6.3.9] (27-32.50-
52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%)
Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (224-224":227-227")-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
757
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
ragifilimabum #
ragifilimab immunoglobulin G1-kappa, anti-[Homo sapiens TNFRSF18 (tumor
necrosis factor receptor (TNFR) superfamily member 18,
activation-inducible TNFR family receptor, AITR, glucocorticoid-
induced TNFR-related, GITR, CD375)], humanized monoclonal
antibody;
gamma1 heavy chain humanized (1-447) [VH (Homo sapiens
IGHV1-2*02 (80.6%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT
[8.8.11] (26-33.51-58.97-107) (1-118) -Homo sapiens IGHG1*03
(100%) G1m3, nG1m1 (CH1 R120 (215) (119-216), hinge 1-15
(217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446),
CHS K>del (447)) (119-447)], (221-220')-disulfide with kappa light
chain humanized (1'-220') [V-KAPPA (Homo sapiens IGKV4-1*01
(91.1%) -IGKJ2*01 (100%)) CDR-IMGT [12.3.9] (27-38.56-58.95-
103) (1'-113') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (159),
V101 (197) (114'-220')];
dimer (227-227":230-230")-bisdisulfide, produced in Chinese
hamster ovary (CHO) cells, glycoform alfa
ragifilimab immunoglobuline G1-kappa, anti-[Homo sapiens TNFRSF18
(membre 18 de la superfamille des récepteurs du TNF, récepteur
de la famille TNFR induit par activation, AITR, récepteur
apparenté au TNFR et induit par les glucocorticoïdes, GITR,
CD375), anticorps monoclonal humanisé;
chaîne lourde gamma1 humanisée (1-447) [VH (Homo sapiens
IGHV1-2*02 (80.6%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT
[8.8.11] (26-33.51-58.97-107) (1-118) -Homo sapiens IGHG1*03
(100%) G1m3, nG1m1 (CH1 R120 (215) (119-216), charnière 1-
15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-
446), CHS K>del (447)) (119-447)], (221-220')-disulfure avec la
chaîne légère kappa humanisée (1'-220') [V-KAPPA (Homo
sapiens IGKV4-1*01 (91.1%) -IGKJ2*01 (100%)) CDR-IMGT
[12.3.9] (27-38.56-58.95-103) (1'-113') -Homo sapiens IGKC*01
(100%) Km3 A45.1 (159), V101 (197) (114'-220')];
dimère (227-227":230-230")-bisdisulfure, produit dans des cellules
ovariennes de hamster chinois (CHO), glycoforme alfa
758
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
ragifilimab inmunoglobulina G1-kappa, anti-[Homo sapiens
TNFRSF18 (miembro 18 de la superfamilia de los
receptores del TNF, receptor de la familia TNFR
inducido por activación, AITR, receptor relacionado
con el TNFR e inducido por los glucocorticoides,
GITR, CD375), anticuerpo monoclonal humanizado;
cadena pesada gamma1 humanizada (1-447) [VH
(Homo sapiens IGHV1-2*02 (80.6%) -(IGHD) -
IGHJ4*01 (92.9%)) CDR-IMGT [8.8.11] (26-33.51-
58.97-107) (1-118) -Homo sapiens IGHG1*03 (100%)
G1m3, nG1m1 (CH1 R120 (215) (119-216), bisagra 1-
15 (217-231), CH2 (232-341), CH3 E12 (357), M14
(359) (342-446), CHS K>del (447)) (119-447)], (221-
220')-disulfuro con la cadena ligera kappa humanizada
(1'-220') [V-KAPPA (Homo sapiens IGKV4-1*01
(91.1%) -IGKJ2*01 (100%)) CDR-IMGT [12.3.9] (27-
38.56-58.95-103) (1'-113') -Homo sapiens IGKC*01
(100%) Km3 A45.1 (159), V101 (197) (114'-220')];
dímero (227-227":230-230")-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
Heavy chain / Chaîne lourde / Cadena pesada
QVQLVQSGAE VKKPGASVKV SCKGSGYTFT DYAMYWVRQA PGQGLEWIGV 50
IRTYSGDVTY NQKFKDRATM TVDKSISTAY MELSRLRSDD TAVYYCAKSG 100
TVRGFAYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG 447
Light chain / Chaîne légère / Cadena ligera
DIVMTQSPDS LAVSLGERAT INCKSSQSLL NSGNQKNYLT WYQQKPGQPP 50
KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYHCQNDYSY 100
PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC 220
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22''-96'' 145''-201'' 262''-322'' 368''-426''
Intra-L (C23-C104) 23'-94' 140'-200'
23'''-94''' 140'''-200'''
Inter-H-L (h 5-CL 126) 221-220' 221''-220'''
Inter-H-H (h 11, h 14) 227-227'' 230-230''
N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1:
1, 1''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
reciferceptum #
recifercept human fibroblast growth factor receptor 3 (FGFR-3,
CD333) (1-336)-(401-413) fragment (1-349) [soluble
isoform (337-400>del, 414-784>del)-sFGFR3],
produced in Chinese hamster ovary (CHO) cells,
glycoform alfa
récifercept fragment (1-336)-(401-413) du récepteur 3 du facteur
de croissance des fibroblastes humain (FGFR-3,
CD333) (1-349) [isoforme soluble (337-400>del, 414-
784>del)-sFGFR3], produit dans des cellules
ovariennes de hamster chinois (CHO), glycoforme alfa
759
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
recifercept fragmento (1-336)-(401-413) del receptor 3 del factor
de crecimiento de los fibroblastos humanos (FGFR-3,
CD333) (1-349) [isoforma soluble (337-400>del, 414-
784>del)-sFGFR3], producido en las células ováricas
de hamster chino (CHO), glicoforma alfa
Sequence / Séquence / Secuencia
ESLGTEQRVV GRAAEVPGPE PGQQEQLVFG SGDAVELSCP PPGGGPMGPT 50
VWVKDGTGLV PSERVLVGPQ RLQVLNASHE DSGAYSCRQR LTQRVLCHFS 100
VRVTDAPSSG DDEDGEDEAE DTGVDTGAPY WTRPERMDKK LLAVPAANTV 150
RFRCPAAGNP TPSISWLKNG REFRGEHRIG GIKLRHQQWS LVMESVVPSD 200
RGNYTCVVEN KFGSIRQTYT LDVLERSPHR PILQAGLPAN QTAVLGSDVE 250
FHCKVYSDAQ PHIQWLKHVE VNGSKVGPDG TPYVTVLKTA GANTTDKELE 300
VLSLHNVTFE DAGEYTCLAG NSIGFSHHSA WLVVLPVSLE SNASMSSNT 349
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
intra-chain 39-97 154-206 253-317
(Cys-SH: 87)
Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N76, N203, N240, N272, N293, N306, N342
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires
complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados
relzomostatum
relzomostat (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-
methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-
6-yl 6-(2,2-difluoroethyl)-2,6-diazaspiro[3.3]heptane-2-
carboxylate
relzomostat 6-(2,2-difluoroéthyl)-2,6-diazaspiro[3.3]heptane-2-
carboxylate de (3R,4S,5S,6R)-5-méthoxy-4-[(2R,3R)-
2-méthyl-3-(3-méthylbut-2-én-1-yl)oxiran-2-yl]-1-
oxaspiro[2.5]octan-6-yle
relzomostat 6-(2,2-difluoroetil)-2,6-diazaspiro[3.3]heptano-2-
carboxilato de (3R,4S,5S,6R)-5-metoxi-4-[(2R,3R)-2-
metil-3-(3-metilbut-2-en-1-il)oxiran-2-il]-1-
oxaspiro[2.5]octan-6-ilo
C24H36F2N2O5
resiquimodum pegolum
resiquimod pegol 2,2',2'',2'''-{methanetetrayltetrakis[methylenepoly
(oxyethylene)oxy]}tetrakis[N-(2-{[2-(ethoxymethyl)-1-
(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinolin-
4-yl]amino}-2-oxoethyl)acetamide]
résiquimod pégol 2,2',2'',2'''-{méthanetétrayltétrakis[méthylènepoly
(oxyéthylène)oxy]}tétrakis[N-(2-{[2-(éthoxyméthyl)-1-
(2-hydroxy-2-méthylpropyl)-1H-imidazo[4,5-
c]quinoléin-4-yl]amino}-2-oxoéthyl)acétamide]
resiquimod pegol 2,2',2'',2'''-{metanotetrailtetrakis[metilenepoli
(oxietileno)oxi]}tetrakis[N-(2-{[2-(etoximetil)-1-(2-
hidroxi-2-metilpropil)-1H-imidazo[4,5-c]quinolin-4-
il]amino}-2-oxoetil)acetamida]
760
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
C89H112N20O20 . (C2H4O)4n
H3C
O R O O R
n n
H3C CH3
OH N
N R O n
O n
R
O
H
N
N N O = R
H
O
revdofilimabum #
revdofilimab immunoglobulin G1-kappa, anti-[Homo sapiens
TNFRSF4 (tumor necrosis factor receptor (TNFR)
superfamily member 4, ACT35, OX40, CD134)],
monoclonal antibody;
gamma1 heavy chain (1-450) [VH (Mus musculus
IGHV5-6-3*01 (88.8%) -IGHJ4*01 (93.8%)/Homo
sapiens IGHV3-7*01 (88.8%) -(IGHD) -IGHJ4*01
(92.3%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-
120) -Homo sapiens IGHG1*03v, G1m3>G1m17,
nG1m1 (CH1 R120>K (217) (121-218), hinge 1-15
(219-233), CH2 (234-343), CH3 E12 (359), M14 (361)
(344-448), CHS (449-450)) (121-450)], (223-218')-
disulfide with kappa light chain (1'-218') [V-KAPPA
(Mus musculus IGKV3-4*01 (83.8%) -IGKJ1*01
(90.9%)/Homo sapiens IGKV4-1*01 (83.2%) -
IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-
56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%)
Km3 A45.1 (157), V101 (195) (112'-218')];
dimer (229-229":232-232")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
revdofilimab immunoglobuline G1-kappa, anti-[Homo sapiens
TNFRSF4 (membre 4 de la superfamille des
récepteurs du facteur de nécrose tumorale, ACT35,
OX40, CD134)], anticorps monoclonal;
chaîne lourde gamma1 (1-450) [VH (Mus musculus
IGHV5-6-3*01 (88.8%) -IGHJ4*01 (93.8%)/Homo
sapiens IGHV3-7*01 (88.8%) -(IGHD) -IGHJ4*01
(92.3%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-
120) -Homo sapiens IGHG1*03v, G1m3>G1m17,
nG1m1 (CH1 R120>K (217) (121-218), charnière 1-15
(219-233), CH2 (234-343), CH3 E12 (359), M14 (361)
(344-448), CHS (449-450)) (121-450)], (223-218')-
disulfure avec la chaîne légère kappa (1'-218') [V-
KAPPA (Mus musculus IGKV3-4*01 (83.8%) -
IGKJ1*01 (90.9%)/Homo sapiens IGKV4-1*01 (83.2%)
-IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-
56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%)
Km3 A45.1 (157), V101 (195) (112'-218')];
dimère (229-229":232-232")-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
revdofilimab inmunoglobulina G1-kappa, anti-[Homo sapiens
TNFRSF4 (miembro 4 de la superfamilia de los
receptores del factor de necrosis tumoral, ACT35,
OX40, CD134)], anticuerpo monoclonal;
761
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
cadena pesada gamma1 (1-450) [VH (Mus musculus IGHV5-6-3*01
(88.8%) -IGHJ4*01 (93.8%)/Homo sapiens IGHV3-7*01 (88.8%) -
(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.13] (26-33.51-58.97-
109) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1
(CH1 R120>K (217) (121-218), bisagra 1-15 (219-233), CH2 (234-
343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-
450)], (223-218')-disulfuro con la cadena ligera kappa (1'-218') [V-
KAPPA (Mus musculus IGKV3-4*01 (83.8%) -IGKJ1*01
(90.9%)/Homo sapiens IGKV4-1*01 (83.2%) -IGKJ4*01 (100%))
CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -Homo sapiens
IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')];
dímero (229-229":232-232")-bisdisulfuro, producido por células
ováricas de hamster chino (CHO), forma glicosilada alfa
rezivertinibum
rezivertinib N-(2-[2-(dimethylamino)ethoxy]-4-methoxy-5-{[4-(1-methyl-1H-
indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
rézivertinib N-(2-[2-(diméthylamino)éthoxy]-4-méthoxy-5-{[4-(1-méthyl-1H-
indol-3-yl)pyrimidin-2-yl]amino}phényl)prop-2-énamide
rezivertinib N-(2-[2-(dimetilamino)etoxi]-5-{[4-(1-metil-1H-indol-3-il)pirimidin-2-
il]amino}fenil)-4-metoxiprop-2-enamida
C27H30N6O3
762
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
rilematovirum
rilematovir 3-({5-chloro-1-[3-(methanesulfonyl)propyl]-1H-indol-2-
yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-
imidazo[4,5-c]pyridin-2-one
rilématovir 3-({5-chloro-1-[3-(méthanesulfonyl)propyl]-1H-indol-2-
yl}méthyl)-1-(2,2,2-trifluoroéthyl)-1,3-dihydro-2H-
imidazo[4,5-c]pyridin-2-one
rilematovir 3-({5-cloro-1-[3-(metanosulfonil)propil]-1H-indol-2-
il}metil)-1-(2,2,2-trifluoroetil)-1,3-dihidro-2H-
imidazo[4,5-c]piridin-2-ona
C21H20ClF3N4O3S
ripafollitropinum alfa (bovinum) #
ripafollitropin alfa (bovine) bovine follicle-stimulating hormone (synthetic analog):
[follitropin (Bos taurus) subunit β (1-109)]-[human
chorionic gonadotropin (hCG) C-terminal 28-peptide
linker (110-137)]-[glycoprotein hormones α chain
(follitropin subunit α) (Bos taurus) (138-233)] fusion
protein, produced in Chinese hamster ovary (CHO)
cells, glycoform alfa
ripafollitropine alfa (bovine) hormone folliculostimulante bovine (analogue
synthétique):
protéine de fusion [follitropine (Bos taurus) sous-unité
β (1-109)]-[peptide liant: 28-peptide C-terminal de la
gonadotrophine chorionique humaine (hCG) (110-
137)]-[chaîne α des hormones glycoprotéiques
(follitropine sous-unité α) (Bos taurus) (138-233)],
produit par des cellules ovariennes de hamster chinois
(CHO), forme glycosylée alfa
ripafolitropina alfa (bovina) hormona estimulante del folículo bovina (análogo
sintético):
proteína de fusión [folitropina (Bos taurus) subunidad β
(1-109)]-[conector: 28-péptido C-terminal de la
gonadotropina coriónica humana (hCG) (110-137)]-
[cadena α de las hormonas glicoproteicas (folitropina
subunidad α) (Bos taurus) (138-233)], producida por
células ováricas de hamster chino (CHO), forma
glicosilada alfa
763
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
ripertamabum #
ripertamab immunoglobulin G1-kappa, anti-[Homo sapiens
MS4A1 (membrane-spanning 4-domains subfamily A
member 1, CD20)], chimeric monoclonal antibody;
gamma1 heavy chain chimeric (1-451) [VH (Mus
musculus IGHV1-12*01 (91.8%) -(IGHD) -IGHJ1*01
(87.5%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-
121) -Homo sapiens IGHG1*01 (100%) G1m17,1
(CH1 K120 (218) (122-219), hinge 1-15 (220-234),
CH2 (235-344), CH3 D12 (360), L14 (362) (345-449),
CHS (450-451)) (122-451)], (224-213')-disulfide with
kappa light chain chimeric (1'-213') [V-KAPPA (Mus
musculus IGKV4-72*01 (95.8%) -IGKJ1*01 (100%))
CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'-106') -
Homo sapiens IGKC*01 (100%), Km3 A45.1 (152),
V101 (190) (107'-213')];
dimer (230-230'':233-233'')-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
ripertamab immunoglobuline G1-kappa, anti-[Homo sapiens
MS4A1 (membre 1 de la sous-famille A à 4 domaines
transmembranaires, CD20)], anticorps monoclonal
chimérique;
chaîne lourde gamma1 chimérique (1-451) [VH (Mus
musculus IGHV1-12*01 (91.8%) -(IGHD) -IGHJ1*01
(87.5%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-
121) -Homo sapiens IGHG1*01 (100%) G1m17,1
(CH1 K120 (218) (122-219), charnière 1-15 (220-234),
CH2 (235-344), CH3 D12 (360), L14 (362) (345-449),
CHS (450-451)) (122-451)], (224-213')-disulfure avec
la chaîne légère kappa chimérique (1'-213') [V-KAPPA
(Mus musculus IGKV4-72*01 (95.8%) -IGKJ1*01
(100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'-
106') -Homo sapiens IGKC*01 (100%), Km3 A45.1
(152), V101 (190) (107'-213')];
dimère (230-230'':233-233'')-bisdisulfure, produite
dans des cellules ovariennes de hamster chinois
(CHO), glycoforme alfa
ripertamab inmunoglobulina G1-kappa, anti-[Homo sapiens
MS4A1 (miembro 1 de la subfamilia A con 4 dominios
transmembranarios, CD20)], anticuerpo monoclonal
quimérico;
764
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
cadena pesada gamma1 quimérica (1-451) [VH (Mus musculus
IGHV1-12*01 (91.8%) -(IGHD) -IGHJ1*01 (87.5%)) CDR-IMGT
[8.8.14] (26-33.51-58.97-110) (1-121) -Homo sapiens IGHG1*01
(100%) G1m17,1 (CH1 K120 (218) (122-219), bisagra 1-15 (220-
234), CH2 (235-344), CH3 D12 (360), L14 (362) (345-449), CHS
(450-451)) (122-451)], (224-213')-disulfuro con la cadena ligera
kappa quimérica (1'-213') [V-KAPPA (Mus musculus IGKV4-
72*01 (95.8%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-
51.88-96) (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1
(152), V101 (190) (107'-213')];
dímero (230-230'':233-233'')-bisdisulfuro, producida por células
ováricas de hamster chino (CHO), forma glicosilada alfa
Heavy chain / Chaîne lourde / Cadena pesada
QVQLQQPGAE LVKPGASVKM SCKASGYTFT SYNMHWVKQT PGRGLEWIGA 50
IYPGNGDTSY NQKFKGKATL TADKSSSTAY MQLSSLTSED SAVYYCARST 100
YYGGDWYFNV WGAGTTVTVS AASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K 451
Light chain / Chaîne légère / Cadena ligera
QIVLSQSPAI LSASPGEKVT MTCRASSSVS YIHWFQQKPG SSPKPWIYAT 50
SNLASGVPVR FSGSGSGTSY SLTISRVEAE DAATYYCQQW TSNPPTFGGG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC 213
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 148-204 265-325 371-429
22''-96'' 148''-204'' 265''-325'' 371''-429''
Intra-L (C23-C104) 23'-87' 133'-193'
23'''-87''' 133'''-193'''
Inter-H-L (h 5-CL 126) 224-213' 224''-213'''
Inter-H-H (h 11, h14) 230-230'' 233-233''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
rocakinogenum sifuplasmidum #
rocakinogene sifuplasmid A DNA plasmid encoding both subunits of human interleukin-12
(IL12), subunit alpha (IL12A, IL-12 subunit p35) and subunit
beta (IL12B; IL-12 subunit p40), under the control of a human
cytomegalovirus (CMV) immediate-early 1 (IE1) promoter and a
simian cytomegalovirus (sCMV) promoter, respectively.
rocakinogène sifuplasmide plasmide dont l'ADN code pour les deux sous-unités de
l'interleukine 12 humaine (IL-12), sous-unité alpha (IL12A,
sous-unité p35 de l'IL-12) et sous-unité bêta (IL12B; sous-unité
p40 de l'IL-12), sous le contrôle d'un activateur/promoteur
immédiat-précoce 1 (IE1) du cytomégalovirus (CMV) et d'un
promoteur du cytomégalovirus simiesque (sCMV),
respectivement
rocakinogén sifuplasmida Un plásmido de DNA que codifica para ambas subunidades de
la interleucina 12 (IL12) humana, la subunidad alfa (IL12A, IL-
12 subunidad p35) y la subunidad beta (IL12B; IL-12 subunidad
p40), bajo el control de un promotor inmediato-temprano 1 (IE1)
del citomegalovirus (CMV) humano y un promotor del
citomegalovirus de simio (sCMV), respectivamente.
765
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
rosopatamabum #
rosopatamab immunoglobulin G1-kappa, anti-[Homo sapiens FOLH1
(folate hydrolase, prostate specific membrane antigen,
PSMA)], monoclonal antibody;
gamma1 heavy chain (1-445) [VH (Mus musculus
IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01
(92.9%)/Homo sapiens IGHV1-69-2*01 (76.3%) -(IGHD)
-IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo sapiens
IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-
213), hinge 1-15 (214-228), CH2 (229-338), CH3 D12
(354), L14 (356) (339-443), CHS (444-445)) (116-445)],
(218-214')-disulfide with kappa light chain (1'-214') [V-
KAPPA (Mus musculus IGKV6-23*01 (80.9%) -
IGKJ2*03 (72.7%)Homo sapiens IGKV1-13*02 (78.7%)
-IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -Homo sapiens
IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-
214')];
dimer (224-224":227-227")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
rosopatamab immunoglobuline G1-kappa, anti-[Homo sapiens FOLH1
(folate hydrolase, antigène membranaire spécifique de
la prostate, PSMA)], anticorps monoclonal;
chaîne lourde gamma1 (1-445) [VH (Mus musculus
IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01
(92.9%)/Homo sapiens IGHV1-69-2*01 (76.3%) -(IGHD)
-IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo sapiens
IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-
213), charnière 1-15 (214-228), CH2 (229-338), CH3
D12 (354), L14 (356) (339-443), CHS (444-445)) (116-
445)], (218-214')-disulfure avec la chaîne légère kappa
(1'-214') [V-KAPPA Mus musculus IGKV6-23*01
(80.9%) -IGKJ2*03 (72.7%)/(Homo sapiens IGKV1-
13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -
Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101
(191) (108'-214')];
dimère (224-224":227-227")-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
rosopatamab inmunoglobulina G1-kappa, anti-[Homo sapiens FOLH1
(folato hidrolasa, antígeno membranario específico de
la próstata, PSMA)], anticuerpo monoclonal;
cadena pesada gamma1 (1-445) [VH (Mus musculus
IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01
(92.9%)/Homo sapiens IGHV1-69-2*01 (76.3%) -(IGHD)
-IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo sapiens
IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-
213), bisagra 1-15 (214-228), CH2 (229-338), CH3 D12
(354), L14 (356) (339-443), CHS (444-445)) (116-445)],
(218-214')-disulfuro con la cadena ligera kappa (1'-214')
[V-KAPPA Mus musculus IGKV6-23*01 (80.9%) -
IGKJ2*03 (72.7%)/(Homo sapiens IGKV1-13*02
(78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -Homo
sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191)
(108'-214')];
dímero (224-224":227-227")-bisdisulfuro, producido por
células ováricas de hamster chino (CHO), forma
glicosilada alfa
766
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
rosopatamabum tetraxetanum #
rosopatamab tetraxetan immunoglobulin G1-kappa, anti-[Homo sapiens FOLH1
(folate hydrolase, prostate specific membrane antigen,
PSMA)], monoclonal antibody, tetraxetan conjugate;
gamma1 heavy chain (1-445) [VH (Mus musculus
IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/Homo
sapiens IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01
(92.9%)) [8.8.8] (1-115) -Homo sapiens IGHG1*01
(100%) G1m17,1 (CH1 K120 (212) (116-213), hinge 1-15
(214-228), CH2 (229-338), CH3 D12 (354), L14 (356)
(339-443), CHS (444-445)) (116-445)], (218-214')-
disulfide with kappa light chain (1'-214') [V-KAPPA (Mus
musculus IGKV6-23*01 (80.9%) -IGKJ2*03 (72.7%)Homo
sapiens IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9]
(1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1
(153), V101 (191) (108'-214')];
dimer (224-224":227-227")-bisdisulfide; produced in
Chinese hamster ovary (CHO) cells, glycoform alfa,
tetraxetan (DOTA) conjugate (on an average of 3 to 5
lysyl, linked to the chelator by their N6)
rosopatamab tétraxétan immunoglobuline G1-kappa, anti-[Homo sapiens FOLH1
(folate hydrolase, antigène membranaire spécifique de la
prostate, PSMA)], anticorps monoclonal, conjugué au
tétraxétan;
chaîne lourde gamma1 (1-445) [VH (Mus musculus
IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/Homo
sapiens IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01
(92.9%)) [8.8.8] (1-115) -Homo sapiens IGHG1*01
(100%) G1m17,1 (CH1 K120 (212) (116-213), charnière
1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14
(356) (339-443), CHS (444-445)) (116-445)], (218-214')-
disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA
Mus musculus IGKV6-23*01 (80.9%) -IGKJ2*03
(72.7%)/(Homo sapiens IGKV1-13*02 (78.7%) -IGKJ3*01
(91.7%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (100%)
Km3 A45.1 (153), V101 (191) (108'-214')];
767
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
dimère (224-224":227-227")-bisdisulfure; produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa, conjugué au tétraxétan (DOTA) (avec
une moyenne de 3 à 5 lysyl liés au chélateur par leur
N6)
rosopatamab tetraxetán inmunoglobulina G1-kappa, anti-[Homo sapiens
FOLH1 (folato hidrolasa, antígeno membranario
específico de la próstata, PSMA)], anticuerpo
monoclonal, conjugado con tetraxetán ;
cadena pesada gamma1 (1-445) [VH (Mus musculus
IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01
(92.9%)/Homo sapiens IGHV1-69-2*01 (76.3%) -
(IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -Homo
sapiens IGHG1*01 (100%) G1m17,1 (CH1 K120 (212)
(116-213), bisagra 1-15 (214-228), CH2 (229-338),
CH3 D12 (354), L14 (356) (339-443), CHS (444-445))
(116-445)], (218-214')-disulfuro con la cadena ligera
kappa (1'-214') [V-KAPPA Mus musculus IGKV6-23*01
(80.9%) -IGKJ2*03 (72.7%)/(Homo sapiens IGKV1-
13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -
Homo sapiens IGKC*01 (100%) Km3 A45.1 (153),
V101 (191) (108'-214')];
dímero (224-224":227-227")-bisdisulfuro; producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa, conjugado con tetraxetán (DOTA) (con
una media de 3 a 5 restos lisil unidos al quelante por
sus respectivos N6)
Heavy chain / Chaîne lourde / Cadena pesada
EVQLVQSGPE VKKPGATVKI SCKTSGYTFT EYTIHWVKQA PGKGLEWIGN 50
INPNNGGTTY NQKFEDKATL TVDKSTDTAY MELSSLRSED TAVYYCAAGW 100
NFDYWGQGTL LTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK 445
Light chain / Chaîne légère / Cadena ligera
DIQMTQSPSS LSTSVGDRVT LTCKASQDVG TAVDWYQQKP GPSPKLLIYW 50
ASTRHTGIPS RFSGSGSGTD FTLTISSLQP EDFADYYCQQ YNSYPLTFGP 100
GTKVDIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 142-198 259-319 365-423
22''-96'' 142''-198'' 259''-319'' 365''-423''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (h 5-CL 126) 218-214' 218''-214'''
Inter-H-H (h 11, h 14) 224-224'' 227-227''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
Potential modified residues / résidus modifiés potentiels / restos modificados potenciales
3 to 5 lysyl (K) NH
3 à 5 lysyl (K) CO2H
3 a 5 lisil (K) O N N
H
N6-(tetraxetan)-L-lysyl N C
H N N
O HO2C CO2H
768
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
sabatolimabum #
sabatolimab immunoglobulin G4-kappa, anti-[Homo sapiens
HAVCR2 (hepatitis A virus cellular receptor 2, T-cell
immunoglobulin mucin family member 3, Tim-3, TIM3,
TIMD3, CD366)], humanized monoclonal antibody;
gamma4 heavy chain humanized (1-444) [VH (Homo
sapiens IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01
(92.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-
118)-Homo sapiens IGHG4*01, G4v5 h P10 (CH1
(119-216), hinge 1-12 S10>P (226) (217-228), CH2
(229-338), CH3 (339-443), CHS K>del (444)) (119-
444)], (132-218')-disulfide with kappa light chain
humanized (1'-218') [V-KAPPA (Homo sapiens IGKV1-
39*01 (81.6%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9]
(27-36.54-56.93-101) (1'-111') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-
218')];
dimer (224-224":227-227")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
sabatolimab immunoglobuline G4-kappa, anti-[Homo sapiens
HAVCR2 (récepteur cellulaire 2 du virus de l'hépatite
A, CD366, membre 3 de la famille mucine
immunoglobuline des cellules T, Tim-3, TIM3, TIMD3,
CD366)], anticorps monoclonal humanisé;
chaîne lourde gamma4 humanisée (1-444) [VH (Homo
sapiens IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01
(92.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-
118) -Homo sapiens IGHG4*01, G4v5 h P10 (CH1
(119-216), charnière 1-12 S10>P (226) (217-228),
CH2 (229-338), CH3 (339-443), CHS K>del (444))
(119-444)], (132-218')-disulfure avec la chaîne légère
kappa humanisée (1'-218') [V-KAPPA (Homo sapiens
IGKV1-39*01 (81.6%) -IGKJ4*01 (100%)) CDR-IMGT
[10.3.9] (27-36.54-56.93-101) (1'-111') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-
218')];
dimère (224-224":227-227")-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
sabatolimab inmunoglobulina G4-kappa, anti-[Homo sapiens
HAVCR2 (receptor celular 2 del virus de la hepatitis A,
CD366, miembro 3 de la familia mucina
inmunoglobulina de las células T, Tim-3, TIM3, TIMD3,
CD366)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 humanizada (1-444) [VH
(Homo sapiens IGHV1-46*01 (87.8%) -(IGHD) -
IGHJ4*01 (92.3%)) CDR-IMGT [8.8.11] (26-33.51-
58.97-107) (1-118) -Homo sapiens IGHG4*01, G4v5 h
P10 (CH1 (119-216), bisagra 1-12 S10>P (226) (217-
228), CH2 (229-338), CH3 (339-443), CHS K>del
(444)) (119-444)], (132-218')-disulfuro con la cadena
ligera kappa humanizada (1'-218') [V-KAPPA (Homo
sapiens IGKV1-39*01 (81.6%) -IGKJ4*01 (100%))
CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -
Homo sapiens IGKC*01 (100%), Km3 A45.1 (157),
V101 (195) (112'-218')];
dímero (224-224":227-227")-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
769
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
samelisantum
samelisant N-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-2-
(morpholin-4-yl)acetamide
samélisant N-{4-[(1-cyclobutylpipéridin-4-yl)oxy]phényl}-2-
(morpholin-4-yl)acetamide
samelisant N-{4-[(1-ciclobutilpiperidin-4-il)oxi]fenil}-2-(morfolin-4-
il)acetamida
C21H31N3O3
samuraciclibum
samuraciclib (3R,4R)-4-({[7-(benzylamino)-3-(propan-2-
yl)pyrazolo[1,5-a]pyrimidin-5-yl]amino}methyl)piperidin-
3-ol
samuraciclib (3R,4R)-4-({[7-(benzylamino)-3-(propan-2-
yl)pyrazolo[1,5-a]pyrimidin-5-yl]amino}méthyl)pipéridin-
3-ol
samuraciclib (3R,4R)-4-({[7-(benzilamino)-3-(propan-2-
il)pirazolo[1,5-a]pirimidin-5-il]amino}metil)piperidin-3-ol
770
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
C22H30N6O
OH
HN
H H
N N
N N
N
H3C
CH3
seralutinibum
seralutinib N-{3-[(1S)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2-
yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide
séralutinib N-{3-[(1S)-1-{[6-(3,4-diméthoxyphényl)pyrazin-2-
yl]amino}éthyl]phényl}-5-méthylpyridine-3-carboxamide
seralutinib N-{3-[(1S)-1-{[6-(3,4-dimetoxifenil)pirazin-2-
il]amino}etil]fenil}-5-metilpiridina-3-carboxamida
C27H27N5O3
simoladagenum autotemcelum #
simoladagene autotemcel autologous CD34+ hematopoietic stem cells (HSC),
obtained by leukapheresis or from bone marrow,
transduced ex vivo with a non-replicating, self-
inactivating (SIN) lentiviral vector encoding codon
optimised human adenosine deaminase (ADA) under
the internal control of elongation factor 1α short
promoter (EFS)
simoladagène autotemcel cellules souches hématopoïétiques CD34+ autologues
obtenues par leucophérèse ou de la moëlle osseuse,
transduites ex vivo avec un vecteur lentiviral non-
répliquant, auto-inactivant (SIN) codant pour
l'adénosine déaminase (ADA) humaine codon optimisé
sous le contrôle interne d'un promoteur court du
facteur d'élongation 1α (EFS)
simoladagén autotemcel células madre hematopoyéticas CD34+ autólogas
obtenidas por leucoaféresis o de médula ósea,
transducidas ex vivo con un vector lentiviral no
replicativo y auto inactivante (SIN), que codifica para
la adenosina deaminasa (ADA) humana con codones
optimizados bajo el control interno del promotor corto
del factor de elongación 1α (EFS)
sisunatovirum
sisunatovir 1'-{[5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-
benzimidazol-2-yl]methyl}-6'-fluorospiro[cyclopropane-
1,3'-indol]-2'(1'H)-one
771
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
sisunatovir 1'-{[5-(aminométhyl)-1-(4,4,4-trifluorobutyl)-1H-
benzimidazol-2-yl]méthyl}-6'-fluoro-spiro[cyclopropane-
1,3'-[3H]indol]-2'(1'H)-one
sisunatovir 1'-{[5-(aminometil)-1-(4,4,4-trifluorobutil)-1H-
benzimidazol-2-il]metil}-6'-fluoro-spiro[ciclopropano-
1,3'-[3H]indol]-2'(1'H)-ona
C23H22F4N4O
sovesudilum
sovesudil propyl 2'-(aminomethyl)-5'-[(3-fluoropyridin-4-
yl)carbamoyl][1,1'-biphenyl]-3-carboxylate
sovésudil 2'-(aminométhyl)-5'-[(3-fluoropyridin-4-
yl)carbamoyl][1,1'-biphényl]-3-carboxylate de propyle
sovesudil 2'-(aminometil)-5'-[(3-fluoropiridin-4-il)carbamoil][1,1'-
bifenil]-3-carboxilato de propilo
C23H22FN3O3
O O
CH3
F
N O
N
H
NH2
sugemalimabum #
sugemalimab immunoglobulin G4-lambda, anti-[Homo sapiens
CD274 (programmed death ligand 1, PDL1, PD-L1, B7
homolog 1, B7H1)], Homo sapiens monoclonal
antibody;
gamma4 heavy chain Homo sapiens (1-448) [VH
(Homo sapiens IGHV3-23*01 (98.0%) -(IGHD) -
IGHJ4*01 (100%)) [8.8.14] (1-121) -Homo sapiens
IGHG4*01, G4v5 h P10 (CH1 (122-219), hinge 1-12
S10>P (229) (220-231), CH2 (232-341), CH3 (342-
446), CHS (447-448)) (122-448)], (135-213')-disulfide
with lambda light chain Homo sapiens (1'-214') [V-
LAMBDA (Homo sapiens IGLV3-21*02 (100%) -
IGLJ2*01 (100%)) [6.3.11] (1'-108') -Homo sapiens
IGLC2*01 (100%) (109'-214')];
dimer (227-227'':230-230'')-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
sugémalimab immunoglobuline G4-lambda, anti-[Homo sapiens
CD274 (ligand 1 de mort programmée, PDL1, PD-L1,
homologue 1 de B7, B7H1)], anticorps monoclonal
Homo sapiens;
772
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
chaîne lourde gamma4 Homo sapiens (1-448) [VH
(Homo sapiens IGHV3-23*01 (98.0%) -(IGHD) -
IGHJ4*01 (100%)) [8.8.14] (1-121) -Homo sapiens
IGHG4*01, G4v5 h P10 (CH1 (122-219), charnière 1-
12 S10>P (229) (220-231), CH2 (232-341), CH3 (342-
446), CHS (447-448)) (122-448)], (135-213')-disulfure
avec la chaîne légère lambda Homo sapiens (1'-214')
[V-LAMBDA (Homo sapiens IGLV3-21*02 (100%) -
IGLJ2*01 (100%)) [6.3.11] (1'-108') -Homo sapiens
IGLC2*01 (100%) (109'-214')];
dimère (227-227'':230-230'')-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
sugemalimab inmunoglobulina G4-lambda, anti-[Homo sapiens
CD274 (ligando 1 de muerte programada, PDL1, PD-
L1, homólogo 1 de B7, B7H1)], anticuerpo monoclonal
Homo sapiens;
cadena pesada gamma4 Homo sapiens (1-448) [VH
(Homo sapiens IGHV3-23*01 (98.0%) -(IGHD) -
IGHJ4*01 (100%)) [8.8.14] (1-121) -Homo sapiens
IGHG4*01, G4v5 h P10 (CH1 (122-219), bisagra 1-12
S10>P (229) (220-231), CH2 (232-341), CH3 (342-
446), CHS (447-448)) (122-448)], (135-213')-disulfuro
con la cadena ligera lambda Homo sapiens (1'-214')
[V-LAMBDA (Homo sapiens IGLV3-21*02 (100%) -
IGLJ2*01 (100%)) [6.3.11] (1'-108') -Homo sapiens
IGLC2*01 (100%) (109'-214')];
dímero (227-227'':230-230'')-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
Heavy chain / Chaîne lourde / Cadena pesada
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSG 50
ISGSGGFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPP 100
RGYNYGPFDY WGQGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK 200
TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350
TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK 448
Light chain / Chaîne légère / Cadena ligera
SYVLTQPPSV SVAPGQTARI TCGGNNIGSK SVHWYQQKPG QAPVLVVYDD 50
SDRPSGIPER FSGSNSGNTA TLTISRVEAG DEADYYCQVW DSSSDHVVFG 100
GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
GSTVEKTVAP TECS 214
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 148-204 262-322 368-426
22''-96'' 148''-204'' 262''-322'' 368''-426''
Intra-L (C23-C104) 22'-87' 136'-195'
22'''-87''' 136'''-195'''
Inter-H-L (CH1 10-CL 126) 135-213' 135''-213'''
Inter-H-H (h 8, h 11) 227-227'' 230-230''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
Deamidation sites / Sites de déamidation / Posiciones de desamidación
H CH3 N44: 385, 385''
H CH3 N114: 435, 435''
Oxidation sites / Sites de oxydation / Posiciones de oxidación
H CH2 M15.1: 253, 253''
H CH3 M107: 429, 429''
773
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
suvecaltamidum
suvecaltamide 2-[4-(propan-2-yl)phenyl]-N-{(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-
yl]ethyl}acetamide
suvécaltamide 2-[4-(propan-2-yl)phényl]-N-{(1R)-1-[5-(2,2,2-trifluoroéthoxy)pyridin-2-
yl]éthyl}acetamide
suvecaltamida 2-[4-(propan-2-il)fenil]-N-{(1R)-1-[5-(2,2,2-trifluoroetoxi)piridin-2-
il]etil}acetamida
C20H23F3N2O2
tebotelimabum #
tebotelimab immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1 (programmed cell
death 1, PD-1, PD1, CD279)] and anti-[Homo sapiens LAG3 (lymphocyte
activating 3, lymphocyte-activation 3, CD223)], humanized monoclonal
antibody, bispecific tetravalent;
gamma4 heavy chain scFv-h-CH2-CH3 humanized (1-496) [V-KAPPA anti-
LAG3 (Homo sapiens IGKV1-39*01 (88.4%) -IGKJ4*01 (90.9%)) [6.3.9] (1-
107) -8-mer linker (108-115)-VH anti-PDCD1 (Homo sapiens IGHV1-
46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (116-234) -6-mer
diglycyl-cysteinyl-triglycyl linker (235-240)-E-coil motif (241-268) -Homo
sapiens IGHG4*01, G4v5 h P10, G4v21 CH2 Y15.1, T16, E18 (hinge 1-12
S10>P (278) (269-280), CH2 M15.1>Y (302), S16>T (304), T18>E (306)
(281-390), CH3 (391-495), CHS K>del (496) (269-496))], (237-240':245-
248')-bisdisulfide with kappa light chain humanized (1'-271')[V-KAPPA anti-
PDCD1 (Homo sapiens IGKV3D-11*02 (77.7%) -IGKJ4*01 (100%))
[10.3.9] (1'-111') -8-mer linker (112'-119')-VH anti LAG3 (Homo sapiens
IGHV1-18*01 (86.7%) -(IGHD) -IGHJ4*01 (82.7%)) [8.8.11] (120'-237') -6-
mer diglycyl-cysteinyl-triglycyl linker (238'-243') -K-coil motif (244'-271')];
dimer (276-276":279-279")-bisdisulfide, produced in Chinese hamster
ovary (CHO) cells, glycoform alfa
tébotélimab immunoglobuline G4-kappa, anti-[Homo sapiens PDCD1 (protéine 1 de
mort cellulaire programmée, PD-1, PD1, CD279)] et anti-[Homo sapiens
LAG3 (activateur 3 des lymphocytes, lymphocyte-activation 3, CD223)],
anticorps monoclonal humanisé, bispécifique tétravalent;
chaîne lourde gamma4 scFv-h-CH2-CH3 humanisée (1-496) [V-KAPPA
anti-LAG3 (Homo sapiens IGKV1-39*01 (88.4%) -IGKJ4*01 (90.9%))
[6.3.9] (1-107) -8-mer linker (108-115) -VH anti-PDCD1 (Homo sapiens
IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (116-234) -6-
mer diglycyl-cystéinyl-triglycyl linker (235-240)-E-coil motif (241-268) -
Homo sapiens IGHG4*01, G4v5 h P10, G4v21 CH2 Y15.1, T16, E18
(charnière 1-12 S10>P (278) (269-280), CH2 M15.1>Y (302), S16>T (304),
T18>E (306) (281-390), CH3 (391-495), CHS K>del (496) (269-496))],(237-
240':245-248')-bisdisulfure avec la chaîne légère kappa humanisée (1'-
271') [V-KAPPA anti-PDCD1 (Homo sapiens IGKV3D-11*02 (77.7%) -
IGKJ4*01 (100%)) [10.3.9] (1'-111') -8-mer linker (112'-119')-VH anti-
LAG3(Homo sapiens IGHV1-18*01 (86.7%) -(IGHD) -IGHJ4*01 (82.7%))
[8.8.11] (120'-237') -6-mer diglycyl-cystéinyl-triglycyl linker (238'-243') -K-
coil motif (244'-271')];
dimère (276-276":279-279")-bisdisulfure, produit dans des cellules
ovariennes de hamster chinois (CHO), glycoforme alfa
774
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
tebotelimab inmunoglobulina G4-kappa, anti-[Homo sapiens PDCD1 (proteína 1 de
muerte celular programada, PD-1, PD1, CD279)] y anti-[Homo sapiens
LAG3 (activador 3 de los linfocitos, linfocito-activación 3, CD223)],
anticuerpo monoclonal humanizado, biespecífico tetravalente;
cadena pesada gamma4 scFv-h-CH2-CH3 humanizada (1-496) [V-
KAPPA anti-LAG3 (Homo sapiens IGKV1-39*01 (88.4%) -IGKJ4*01
(90.9%)) [6.3.9] (1-107) -conector octámero (108-115) -VH anti-PDCD1
(Homo sapiens IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%))
[8.8.12] (116-234) -conector sexámero diglicil-cisteinil-triglicil (235-240) -
E-coil motif (241-268) -Homo sapiens IGHG4*01, G4v5 h P10, G4v21
CH2 Y15.1, T16, E18 (bisagra 1-12 S10>P (278) (269-280), CH2
M15.1>Y (302), S16>T (304), T18>E (306) (281-390), CH3 (391-495),
CHS K>del (496) (269-496))],(237-240':245-248')-bisdisulfuro con la
cadena ligera kappa humanizada (1'-271') [V-KAPPA anti-PDCD1 (Homo
sapiens IGKV3D-11*02 (77.7%) -IGKJ4*01 (100%)) [10.3.9] (1'-111') -
conector octámero (112'-119')-VH anti-LAG3(Homo sapiens IGHV1-18*01
(86.7%) -(IGHD) -IGHJ4*01 (82.7%)) [8.8.11] (120'-237') -conector
sexámero diglicil-cisteinil-triglicil (238'-243') -K-coil motif (244'-271')];
dímero (276-276":279-279")-bisdisulfuro, producido por células ováricas
de hamster chino (CHO), forma glicosilada alfa
Heavy chain / Chaîne lourde / Cadena pesada
DIQMTQSPSS LSASVGDRVT ITCRASQDVS SVVAWYQQKP GKAPKLLIYS 50
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSTPWTFGG 100
GTKLEIKGGG SGGGGQVQLV QSGAEVKKPG ASVKVSCKAS GYSFTSYWMN 150
WVRQAPGQGL EWIGVIHPSD SETWLDQKFK DRVTITVDKS TSTAYMELSS 200
LRSEDTAVYY CAREHYGTSP FAYWGQGTLV TVSSGGCGGG EVAACEKEVA 250
ALEKEVAALE KEVAALEKES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 300
LYITREPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 350
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 400
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 450
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLG 496
Light chain / Chaîne légère / Cadena ligera
EIVLTQSPAT LSLSPGERAT LSCRASESVD NYGMSFMNWF QQKPGQPPKL 50
LIHAASNQGS GVPSRFSGSG SGTDFTLTIS SLEPEDFAVY FCQQSKEVPY 100
TFGGGTKVEI KGGGSGGGGQ VQLVQSGAEV KKPGASVKVS CKASGYTFTD 150
YNMDWVRQAP GQGLEWMGDI NPDNGVTIYN QKFEGRVTMT TDTSTSTAYM 200
ELRSLRSDDT AVYYCAREAD YFYFDYWGQG TTLTVSSGGC GGGKVAACKE 250
KVAALKEKVA ALKEKVAALK E 271
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 23-88 137-211 311-371 417-475
23''-88'' 137''-211'' 311''-371'' 417''-475''
Intra-L (C23-C104) 23'-92' 141'-215'
23'''-92''' 141'''-215'''
Inter-H-L 237-240' 245-248'
237''-240''' 245''-248'''
Inter-H-H (h 8, h 11) 276-276'' 279-279''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
347, 347''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
telazorlimabum #
telazorlimab immunoglobulin G1-kappa, anti-[Homo sapiens TNFRSF4 (tumor
necrosis factor receptor (TNFR) superfamily member 4, ACT35, OX40,
CD134)], humanized monoclonal antibody;
gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV2-
70*10 (93.0%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [10.7.10] (26-
35.53-59.98-107) (1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1
(CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3
D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-213')-
disulfide with kappa light chain humanized (1'-213') [V-KAPPA (Homo
sapiens IGKV3-11*01 (87.4%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9]
(27-31.49-51.38-46) (1'-106') -Homo sapiens IGKC*01 (100%) Km3
A45.1 (152), V101 (190) (107'-213')];
dimer (227-227":230-230")-bisdisulfide, produced in Chinese hamster
ovary (CHO) cells, glycoform alfa
775
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
télazorlimab immunoglobuline G1-kappa, anti-[Homo sapiens TNFRSF4
(membre 4 de la superfamille des récepteurs du facteur de
nécrose tumorale, ACT35, OX40, CD134)], anticorps monoclonal
humanisé;
chaîne lourde gamma1 humanisée (1-448) [VH (Homo sapiens
IGHV2-70*10 (93.0%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT
[10.7.10] (26-35.53-59.98-107) (1-118) -Homo sapiens IGHG1*01
(100%), G1m17,1 (CH1 K120 (215) (119-216), charnière 1-15
(217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446),
CHS (447-448)) (119-448)], (221-213')-disulfure avec la chaîne
légère kappa humanisée (1'-213') [V-KAPPA (Homo sapiens
IGKV3-11*01 (87.4%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-
31.49-51.38-46) (1'-106') -Homo sapiens IGKC*01 (100%) Km3
A45.1 (152), V101 (190) (107'-213')];
dimère (227-227":230-230")-bisdisulfure, produit dans des cellules
ovariennes de hamster chinois (CHO), glycoforme alfa
telazorlimab inmunoglobulina G1-kappa, anti-[Homo sapiens TNFRSF4
(miembro 4 de la superfamilia de los receptores del factor de
necrosis tumoral, ACT35, OX40, CD134)], anticuerpo monoclonal
humanizado;
cadena pesada gamma1 humanizada (1-448) [VH (Homo sapiens
IGHV2-70*10 (93.0%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT
[10.7.10] (26-35.53-59.98-107) (1-118) -Homo sapiens IGHG1*01
(100%), G1m17,1 (CH1 K120 (215) (119-216), bisagra 1-15 (217-
231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS
(447-448)) (119-448)], (221-213')-disulfuro con la cadena ligera
kappa humanizada (1'-213') [V-KAPPA (Homo sapiens IGKV3-
11*01 (87.4%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-
51.38-46) (1'-106') -Homo sapiens IGKC*01 (100%) Km3 A45.1
(152), V101 (190) (107'-213')];
dímero (227-227":230-230")-bisdisulfuro, producido por células
ováricas de hamster chino (CHO), forma glicosilada alfa
Heavy chain / Chaîne lourde / Cadena pesada
QVTLKESGPA LVKPTQTLTL TCSFSGFSLS TSGMGVGWIR QPPGKALEWI 50
AHIWWDDDKY YNTALKTRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI 100
DWDGFAYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448
Light chain / Chaîne légère / Cadena ligera
EIVLTQSPAT LSLSPGERAT LSCRASSSVS YMHWYQQKPG QAPRPWIYAT 50
SNRATGIPAR FSGSGSGTDY TLTISSLEPE DFAVYYCQQW SSNPWTFGQG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC 213
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-97 145-201 262-322 368-426
22''-97'' 145''-201'' 262''-322'' 368''-426''
Intra-L (C23-C104) 23'-87' 133'-193'
23'''-87''' 133'''-193'''
Inter-H-L (h 5-CL 126) 221-213' 221''-213'''
Inter-H-H (h 11, h 14) 227-227'' 230-230''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
C-terminal lysine clipping:
H CHS K2:
448, 448''
776
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
tesnatilimabum
tesnatilimab immunoglobulin G4-kappa, anti-[Homo sapiens KLRK1
(killer cell lectin like receptor K1, NKG2D, KLR, NKG2-
D, CD314)], Homo sapiens monoclonal antibody;
gamma4 heavy chain Homo sapiens (1-442) [VH
(Homo sapiens IGHV4-59*01 (93.8%) -(IGHD) -
IGHJ3*02 (93.8%)) CDR-IMGT [8.7.9] (26-33.51-
57.96-104) (1-115) -Homo sapiens IGHG4*01, G4v5 h
P10 (CH1 (116-213), hinge S10>P (223) (214-225),
CH2 (226-335), CH3 (336-440), CHS (441-442)) (116-
442)], (129-215')-disulfide with kappa light chain Homo
sapiens (1'-215') [V-KAPPA (Homo sapiens IGKV3-
20*01 (100%) -IGKJ1*01 (100%)) CDR-IMGT [7.3.9]
(27-33.51-53.90-98) (1'-108') -Homo sapiens IGKC*01
(100%), Km3 A45.1 (154), V101 (192) (109'-215')];
dimer (221-221'':224-224'')-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
tesnatilimab immunoglobuline G4-kappa, anti-[Homo sapiens
KLRK1 (récepteur lectine like K1 de cellule tueuse,
NKG2D, KLR, NKG2-D, CD314)], anticorps
monoclonal Homo sapiens;
chaîne lourde gamma1 Homo sapiens (1-442) [VH
(Homo sapiens IGHV4-59*01 (93.8%) -(IGHD) -
IGHJ3*02 (93.8%)) CDR-IMGT [8.7.9] (26-33.51-
57.96-104) (1-115) -Homo sapiens IGHG4*01, G4v5 h
P10 (CH1 (116-213), charnière S10>P (223) (214-
225), CH2 (226-335), CH3 (336-440), CHS (441-442))
(116-442)], (129-215')-disulfure avec la chaîne légère
kappa Homo sapiens (1'-215') [V-KAPPA (Homo
sapiens IGKV3-20*01 (100%) -IGKJ1*01 (100%))
CDR-IMGT [7.3.9] (21-33.51-53.90-98) (1'-108') -
Homo sapiens IGKC*01 (100%), Km3 A45.1 (154),
V101 (192) (109'-215')];
dimère (221-221'':224-224'')-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
tesnatilimab inmunoglobulina G4-kappa, anti-[Homo sapiens
KLRK1 (receptor lectina like K1 de célula asesina,
NKG2D, KLR, NKG2-D, CD314)], anticuerpo
monoclonal Homo sapiens;
cadena pesada gamma1 Homo sapiens (1-442) [VH
(Homo sapiens IGHV4-59*01 (93.8%) -(IGHD) -
IGHJ3*02 (93.8%)) CDR-IMGT [8.7.9] (26-33.51-
57.96-104) (1-115) -Homo sapiens IGHG4*01, G4v5 h
P10 (CH1 (116-213), bisagra S10>P (223) (214-225),
CH2 (226-335), CH3 (336-440), CHS (441-442)) (116-
442)], (129-215')-disulfuro con la cadena ligera kappa
Homo sapiens (1'-215') [V-KAPPA (Homo sapiens
IGKV3-20*01 (100%) -IGKJ1*01 (100%)) CDR-IMGT
[7.3.9] (21-33.51-53.90-98) (1'-108') -Homo sapiens
IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-
215')];
dímero (221-221'':224-224'')-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
777
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
tezatabepum matraxetanum #
tezatabep matraxetan three-alpha-helix binding protein, derived from an
immunoglobulin G (IgG)-binding domain of a
staphylococcal protein A (SpA), designed to bind
receptor tyrosine-protein kinase erbB-2 (ERBB2, Neu,
HER2), produced by peptide synthesis, conjugated at
the C-terminal Cys61 to one (3RS)-2,5-dioxo-1-(2-{2-
[4,7,10-tris(carboxymethyl)-1,4,7,10-
tetraazacyclododecan-1-yl]acetamido}ethyl)pyrrolidin-
3-yl (matraxetan) group
tézatabep matraxétan protéine à trois hélices alpha, dérivée du domaine de
l'immunoglobuline G (IgG) se liant à la protéine
staphylococcique A (SpA), mise au point pour se lier
au récepteur tyrosine-protéine kinase erbB-2 (ERBB2,
Neu, HER2), produite par synthèse peptidique,
conjuguée sur la Cys61 en sa partie C-terminale à un
groupe (3RS)-2,5-dioxo-1-(2-{2-[4,7,10-
tris(carboxyméthyl)-1,4,7,10-tétraazacyclododécan-1-
yl]acétamido}éthyl)pyrrolidin-3-yle (matraxétan)
tezatabep matraxetán proteína de tres hélices alfa, derivada del dominio de
la inmunoglobulina G (IgG) que se une a la proteína
estafilocócica A (SpA), diseñada para unirse al
receptor tirosina-proteína kinasa erbB-2 (ERBB2, Neu,
HER2), producida por síntesis peptídica, conjugada
con la Cys61 en su parte C-terminal a un grupo (3RS)-
2,5-dioxo-1-(2-{2-[4,7,10-tris(carboximetil)-1,4,7,10-
tetraazaciclododecan-1-il]acetamido}etil)pirrolidin-3-ilo
(matraxetán)
778
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
tifalibepum #
tifalibep fusion protein composed of 3 binding domains, each
consisting of a three-alpha-helix motif derived from the
immunoglobulin (Ig)-binding Z-domain of
staphylococcal protein A (SpA), engineered for binding
to the human neonatal Fc receptor (FcRn) with the two
identical N- and C-terminal domains (1-58, 116-173),
and for binding to the domain II of human serum
albumin (HSA) with the central domain (59-110),
connected via a G4S peptide linker (111-115);
[FcRn-binding engineered SpA peptide (1-58)]-[HSA-
binding engineered SpA peptide (59-110)]-[G4S linker
(111-115)]-[FcRn-binding engineered SpA peptide
(116-173] fusion protein;
produced in Escherichia coli
tifalibep protéine de fusion composée de 3 domaines liants,
chacun consistant en un motif à 3 hélices alfa dérivé
du domaine Z de la protéine staphylococcique A (SpA)
se liant à l'immunoglobuline (Ig), mis au point pour se
lier au récepteur Fc néonatal humain (FcRn) avec les
deux domaines N- et C-terminaux identiques (1-58,
116-173), et au domaine II de l'albumine sérique
humaine (ASH, HSA) avec le domaine central (59-
110), connecté via un peptide liant G4S (111-115) ;
protéine de fusion [peptide SpA mis au point pour se
lier au FcRn (1-58)]-[peptide SpA mis au point pour se
lier au HSA (59-110)]-[peptide liant G4S (111-115)]-
[peptide SpA mis au point pour se lier au FcRn (116-
173)];
produite par Escherichia coli
tifalibep proteína de fusión compuesta de 3 dominios de unión,
cada uno consistente en un motivo con 3 hélices alfa
derivado del dominio Z de la proteína estafilocócica A
(SpA) que se une a la inmunoglobulina (Ig), diseñada
para unirse al receptor Fc neonatal humano (FcRn)
con los dos dominios N- y C-terminal idénticos (1-58,
116-173), y con el dominio II de la albúmina sérica
humana (ASH, HSA) con el dominio central (59-110),
conectado a través de un péptido linker G4S (111-
115) ;
proteína de fusión [péptido SpA diseñado para unirse
al FcRn (1-58)]-[péptido SpA diseñado para unirse al
HSA (59-110)]-[G4S linker (111-115)]-[péptido SpA
diseñado para unirse al FcRn (116-173)];
producida por Escherichia coli
779
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
tilogotamabum #
tilogotamab immunoglobulin G1-kappa, anti-[Homo sapiens
TNFRSF10B (tumor necrosis factor receptor (TNFR)
superfamily member 10B, death receptor 5, DR5, TNF-
related apoptosis-inducing ligand receptor 2, TRAILR2,
TRAIL-R2, TR-2, CD262)], humanized monoclonal
antibody;
gamma1 heavy chain humanized (1-447) [VH (Homo
sapiens IGHV1-3*01 (84.7%) -(IGHD) -IGHJ4*01
(93.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-
118) -Homo sapiens IGHG1*03, G1m3, nG1m1,
G1v34 CH3 G109 (CH1 R120 (215) (119-216), hinge
1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14
(359), E109>G (431) (342-446), CHS K>del (447))
(119-447)], (221-213')-disulfide with kappa light chain
humanized (1'-213') [V-KAPPA (Homo sapiens IGKV1-
16*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [5.3.9]
(27-31.49-51.88-96) (1'-106') -Homo sapiens IGKC*01
(100%) Km3 A45.1 (152), V101 (190) (107'-213')];
dimer (227-227":230-230")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
tilogotamab immunoglobuline G1-kappa, anti-[Homo sapiens
TNFRSF10B (membre 10B de la superfamille des
récepteurs du facteur de nécrose tumorale (TNFR),
récepteur de mort 5, DR5, TRAILR2, TRAIL-R2, TR-2,
CD262)], anticorps monoclonal humanisé;
chaîne lourde gamma1 humanisée (1-447) [VH (Homo
sapiens IGHV1-3*01 (84.7%) -(IGHD) -IGHJ4*01
(93.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-
118) -Homo sapiens IGHG1*03, G1m3, nG1m1,
G1v34 CH3 G109 (CH1 R120 (215) (119-216),
charnière 1-15 (217-231), CH2 (232-341), CH3 E12
(357), M14 (359), E109>G (431) (342-446), CHS
K>del (447)) (119-447)], (221-213')-disulfure avec la
chaîne légère kappa humanisée (1'-213') [V-KAPPA
(Homo sapiens IGKV1-16*01 (83.2%) -IGKJ4*01
(100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'-
106') -Homo sapiens IGKC*01 (100%) Km3 A45.1
(152), V101 (190) (107'-213')];
dimère (227-227":230-230")-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
tilogotamab inmunoglobulina G1-kappa, anti-[Homo sapiens
TNFRSF10B (miembro 10B de la superfamilia de los
receptores del factor de necrosis tumoral (TNFR),
receptor de muerte 5, DR5, TRAILR2, TRAIL-R2, TR-
2, CD262)], anticuerpo monoclonal humanizado;
780
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
cadena pesada gamma1 humanizada (1-447) [VH
(Homo sapiens IGHV1-3*01 (84.7%) -(IGHD) -
IGHJ4*01 (93.3%)) CDR-IMGT [8.8.11] (26-33.51-
58.97-107) (1-118) -Homo sapiens IGHG1*03, G1m3,
nG1m1, G1v34 CH3 G109 (CH1 R120 (215) (119-
216), bisagra 1-15 (217-231), CH2 (232-341), CH3
E12 (357), M14 (359), E109>G (431) (342-446), CHS
K>del (447)) (119-447)], (221-213')-disulfuro con la
cadena ligera kappa humanizada (1'-213') [V-KAPPA
(Homo sapiens IGKV1-16*01 (83.2%) -IGKJ4*01
(100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'-
106') -Homo sapiens IGKC*01 (100%) Km3 A45.1
(152), V101 (190) (107'-213')];
dímero (227-227":230-230")-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
tolebrutinibum
tolebrutinib 4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-(prop-2-
enoyl)piperidin-3-yl]-1,3-dihydro-2H-imidazo[4,5-
c]pyridin-2-one
tolébrutinib 4-amino-3-(4-phénoxyphényl)-1-[(3R)-1-(prop-2-
énoyl)pipéridin-3-yl]-1,3-dihydro-2H-imidazo[4,5-
c]pyridin-2-one
tolebrutinib 4-amino-3-(4-fenoxifenil)-1-[(3R)-1-(prop-2-
enoil)piperidin-3-il]-1,3-dihidro-2H-imidazo[4,5-
c]piridin-2-ona
C26H25N5O3
781
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
tovinontrinum
tovinontrine 6-{(3S,4S)-4-methyl-1-[(pyrimidin-2-yl)methyl]pyrrolidin-3-
yl}-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8(7H)-one
tovinontrine 6-{(3S,4S)-4-méthyl-1-[(pyrimidin-2-yl)méthyl]pyrrolidin-3-
yl}-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8(7H)-one
tovinontrina 6-{(3S,4S)-4-metil-1-[(pirimidin-2-il)metil]pirrolidin-3-il}-3-
(oxan-4-il)imidazo[1,5-a]pirazin-8(7H)-ona
C21H26N6O2
O
HN
N
N
N
N CH3
N
O
udonitrectagum
udonitrectag (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-
azabicyclo[3.2.1]octane-7-carboxylic acid
udonitrectag acide (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-
azabicyclo[3.2.1]octane-7-carboxylique
udonitrectag ácido (1S,4R,5R,7S)-3,4-dibencil-2-oxo-6,8-dioxa-3-
azabiciclo[3.2.1]octano-7-carboxílico
C20H19NO5
H CO2H
H
O
O
O
N
H
H
upifitamabum #
upifitamab immunoglobulin G1-kappa, anti-[Homo sapiens SLC34A2
(solute carrier family 34 (sodium phosphate) member 2,
sodium/phosphate cotransporter 2B, NaPi2b, NaPi3b)],
monoclonal antibody;
gamma1 heavy chain (1-449) [VH (Homo sapiens IGHV1-
46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (1-
119) -glycyl (120) -Homo sapiens IGHG1*03, G1m3,
nG1m1 (CH1 R120 (217) (121-218), hinge 1-15 (219-233),
CH2 (234-343), CH3 E12 (359), M14 (361) (344-448),
CHS K>del (449)) (121-449)], (223-215')-disulfide with
kappa light chain (1'-215') [V-KAPPA (Mus musculus
IGKV10-94*01 (84.2%) -IGKJ5*01 (91.7%)/Homo sapiens
IGKV1-16*01 (83.2%) -IGKJ2*01 (90.9%)) [6.3.9] (1'-107')
-arginyl (108') -Homo sapiens IGKC*01 (100%) Km3 A45.1
(154), V101 (192) (109'-215')];
dimer (229-229":232-232")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
782
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
upifitamab immunoglobuline G1-kappa, anti-[Homo sapiens SLC34A2
(membre 2 de la famille 34 (phosphate de sodium) de
transporteurs de solutés, cotransporteur 2B de
sodium/phosphate, NaPi2b, NaPi3b)], anticorps monoclonal;
chaîne lourde gamma1 (1-449) [VH (Homo sapiens IGHV1-
46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (1-119) -
glycyl (120) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1
R120 (217) (121-218), charnière 1-15 (219-233), CH2 (234-
343), CH3 E12 (359), M14 (361) (344-448), CHS K>del (449))
(121-449)], (223-215')-disulfure avec la chaîne légère kappa
(1'-215') [V-KAPPA (Mus musculus IGKV10-94*01 (84.2%) -
IGKJ5*01 (91.7%)/Homo sapiens IGKV1-16*01 (83.2%) -
IGKJ2*01 (90.9%)) [6.3.9] (1'-107') -arginyl (108') -Homo
sapiens IGKC*01 (100%) Km3 A45.1 (154), V101 (192) (109'-
215')];
dimère (229-229":232-232")-bisdisulfure, produit dans des
cellules ovariennes de hamster chinois (CHO), glycoforme alfa
upifitamab inmunoglobulina G1-kappa, anti-[Homo sapiens SLC34A2
(miembro 2 de la familia 34 (fosfato de sodio) de
transportadores de solutos, cotransportador 2B de
sodio/fosfato, NaPi2b, NaPi3b)], anticuerpo monoclonal;
cadena pesada gamma1 (1-449) [VH (Homo sapiens IGHV1-
46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (1-119) -
glicil (120) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1
R120 (217) (121-218), bisagra 1-15 (219-233), CH2 (234-
343), CH3 E12 (359), M14 (361) (344-448), CHS K>del (449))
(121-449)], (223-215')-disulfuro con la cadena ligera kappa (1'-
215') [V-KAPPA (Mus musculus IGKV10-94*01 (84.2%) -
IGKJ5*01 (91.7%)/Homo sapiens IGKV1-16*01 (83.2%) -
IGKJ2*01 (90.9%)) [6.3.9] (1'-107') -arginil (108') -Homo
sapiens IGKC*01 (100%) Km3 A45.1 (154), V101 (192) (109'-
215')];
dímero (229-229":232-232")-bisdisulfuro, producido por
células ováricas de hamster chino (CHO), forma glicosilada
alfa
783
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
urabrelimabum #
urabrelimab immunoglobulin G4-kappa, anti-[Homo sapiens CD47
(integrin associated protein, IAP, MER6, OA3)], Homo
sapiens monoclonal antibody;
gamma4 heavy chain Homo sapiens (1-452) [VH
(Homo sapiens IGHV4-4*02 (94.9%) -(IGHD) -
IGHJ6*01 (94.7%)) CDR-IMGT [9.7.18] (26-34.52-
58.97-114) (1-125)-Homo sapiens IGHG4*01 (CH1
(126-223), hinge 1-12 (224-235), CH2 (236-345), CH3
(346-450), CHS (451-452)) (126-452)], (139-212')-
disulfide with kappa light chain Homo sapiens (1'-212')
[V-KAPPA (Homo sapiens IGKV3-11*01 (94.7%) -
IGKJ4*01 (91.7%)) CDR-IMGT [6.3.8] (27-32.50-
52.89-96) (1'-106') -Homo sapiens IGKC*01 (100%),
Km3 A45.1 (151), V101 (189) (107'-212')];
dimer (231-231":234-234")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
urabrélimab immunoglobuline G4-kappa, anti-[Homo sapiens CD47
(protéine associée à l'intégrine, IAP, MER6, OA3)],
anticorps monoclonal Homo sapiens;
chaîne lourde gamma4 Homo sapiens (1-452) [VH
(Homo sapiens IGHV4-4*02 (94.9%) -(IGHD) -
IGHJ6*01 (94.7%)) CDR-IMGT [9.7.18] (26-34.52-
58.97-114) (1-125)-Homo sapiens IGHG4*01 (CH1
(126-223), charnière 1-12 (224-235), CH2 (236-345),
CH3 (346-450), CHS (451-452)) (126-452)], (139-
212')-disulfure avec la chaîne légère kappa Homo
sapiens (1'-212') [V-KAPPA (Homo sapiens IGKV3-
11*01 (94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.8]
(27-32.50-52.89-96) (1'-106') -Homo sapiens IGKC*01
(100%), Km3 A45.1 (151), V101 (189) (107'-212')];
dimère (231-231":234-234")-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
urabrelimab inmunoglobulina G4-kappa, anti-[Homo sapiens CD47
(proteína asociada a la integrina, IAP, MER6, OA3)],
anticuerpo monoclonal Homo sapiens;
cadena pesada gamma4 Homo sapiens (1-452) [VH
(Homo sapiens IGHV4-4*02 (94.9%) -(IGHD) -
IGHJ6*01 (94.7%)) CDR-IMGT [9.7.18] (26-34.52-
58.97-114) (1-125)-Homo sapiens IGHG4*01 (CH1
(126-223), bisagra 1-12 (224-235), CH2 (236-345),
CH3 (346-450), CHS (451-452)) (126-452)], (139-
212')-disulfuro con la cadena ligera kappa Homo
sapiens (1'-212') [V-KAPPA (Homo sapiens IGKV3-
11*01 (94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.8]
(27-32.50-52.89-96) (1'-106') -Homo sapiens IGKC*01
(100%), Km3 A45.1 (151), V101 (189) (107'-212')];
dímero (231-231":234-234")-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
784
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
uzansertibum
uzansertib N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-
methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-
cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-
fluoropyridine-2-carboxamide
uzansertib N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-
méthylpipéridin-1-yl]-7-hydroxy-6,7-dihydro-5H-
cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophényl)-5-
fluoropyridine-2-carboxamide
uzansertib N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hidroxi-5-
metilpiperidin-1-il]-7-hidroxi-6,7-dihidro-5H-
ciclopenta[b]piridin-3-il}-6-(2,6-difluorofenil)-5-
fluoropiridina-2-carboxamida
C26H26F3N5O3
F
O NH2
N OH
NH
F N
F CH3
N
HO
vebicorvirum
vebicorvir 5,5,11-trioxo-N-{[2-(trifluoromethyl)-1,3-thiazol-5-
yl]methyl}-10,11-dihydro-5H-5λ6-
dibenzo[b,f][1,4]thiazepine-8-carboxamide
vébicorvir 5,5,11-trioxo-N-{[2-(trifluorométhyl)-1,3-thiazol-5-
yl]méthyl}-10,11-dihydro-5H-5λ6-
dibenzo[b,f][1,4]thiazépine-8-carboxamide
785
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
vebicorvir 5,5,11-trioxo-N-{[2-(trifluorometil)-1,3-tiazol-5-il]metil}-
10,11-dihidro-5H-5λ6-dibenzo[b,f][1,4]tiazepina-8-
carboxamida
C19H12F3N3O4S2
velmupressinum
velmupressin 1,5-anhydro{4-chloro-L-phenylalanyl-3-(thiophen-2-yl)-
L-alanyl-L-valyl-L-asparaginyl-S-(3-carboxypropyl)-L-
cysteinyl-N-[4-(carbamimidoylamino)butyl]-L-
prolinamide}
velmupressine 1,5-anhydro{4-chloro-L-phénylalanyl-3-(thiophén-2-yl)-
L-alanyl-L-valyl-L-asparaginyl-S-(3-carboxypropyl)-L-
cystéinyl-N-[4-(carbamimidoylamino)butyl]-L-
prolinamide}
velmupresina 1,5-anhidro{4-cloro-L-fenilalanil-3-(tiofen-2-il)-L-alanil-L-
valil-L-asparaginil-S-(3-carboxipropil)-L-cisteinil-N-[4-
(carbamimidoilamino)butil]-L-prolinamida}
C42H60ClN11O8S2
velufenacinum
velufenacin [(3R)-1-methylpyrrolidin-3-yl]methyl (3'-chloro-4'-
fluoro[1,1'-biphenyl]-2-yl)carbamate
vélufénacine (3'-chloro-4'-fluoro[1,1'-biphényl]-2-yl)carbamate de
[(3R)-1-méthylpyrrolidin-3-yl]méthyle
velufenacina (3'-cloro-4'-fluoro[1,1'-bifenil]-2-il)carbamato de [(3R)-
1-metilpirrolidin-3-il]metilo
C19H20ClFN2O2
786
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
verbrinacogenum setparvovecum #
verbrinacogene setparvovec A recombinant non-replicating adeno-associated virus
of a modified liver-tropic serotype (S3) (rAAVS3)
vector, encoding a gain-of-function variant (R338L;
Padua) of codon-optimised human coagulation factor
IX (hFIX) under the control of a liver-specific promoter
(FRE1) comprising a truncated version of the human
apolipoprotein E locus control region (i.e. enhancer)
with a truncated version of the human alpha-1-
antitrypsin promoter.
verbrinacogène setparvovec vecteur viral adéno-associé recombinant, non-
répliquant, d'un sérotype hépatotropique modifié (S3)
(rAAVS3), codant pour le variant Padua (R338L) du
facteur de coagulation IX humain (F9, Facteur IX, FIX)
dont les codons sont optimisés, sous le contrôle du
promoteur spécifique du foie (FRE1) comprenant une
version tronquée de la région de contrôle du locus de
l'apoprotéine E humaine (c.-à-d. amplificateur) avec
une version tronquée du promoteur de l'antitrypsine
alpha-1 humaine.
verbrinacogén setparvovec Un vector de virus adeno-asociado recombinante, no
replicativo, de un serotipo hepatotrópico modificado
(S3) (rAAVS3), que codifica una variante de ganancia
de función (R338L; Padua) del factor de coagulación
IX humano (hFIX) con codones optimizados, bajo el
control de un promotor específico de hígado (FRE1)
que consta de una versión truncada de la región de
control del locus de la apolipoproteína E humana (es
decir, potenciador) con una versión truncada del
promotor de la alfa-1-antitripsina humana.
vilobelimabum #
vilobelimab immunoglobulin G4-kappa, anti-[Homo sapiens C5
(complement 5) anaphylatoxin (C5a, C5 Pr678-751)],
chimeric monoclonal antibody;
gamma4 heavy chain chimeric (1-446) [VH (Mus
musculus IGHV1-61*01 (81.6%) -(IGHD) -IGHJ3*01
(92.9%)/Homo sapiens IGHV1-46*01 (62.2%) -(IGHD)
-IGHJ4*01 (92.9%)) [8.8.13] (1-119) -Homo sapiens
IGHG4*01 (CH1 (120-217), hinge 1-12 (218-229), CH2
(230-339), CH3 (340-444), CHS (445-446)) (120-446)],
(133-218')-disulfide with kappa light chain chimeric (1'-
218') [V-KAPPA (Mus musculus IGKV3-4*01 (98.0%) -
IGKJ2*01 (100%)/Homo sapiensIGKV3D-11*02
(69.1%) -IGKJ2*01 (91.7%)) [10.3.9] (1'-111') -Homo
sapiens IGKC*01 (100%), Km3 A45.1 (157), V101
(195) (112'-218')];
dimer (225-225":228-228")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
vilobélimab immunoglobuline G4-kappa, anti-[Homo sapiens C5
(complément 5) anaphylatoxine (C5a, C5 Pr678-751)],
anticorps monoclonal chimérique;
787
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
chaîne lourde gamma4 chimérique (1-446) [VH (Mus
musculus IGHV1-61*01 (81.6%) -(IGHD) -IGHJ3*01
(92.9%)/Homo sapiens IGHV1-46*01 (62.2%) -(IGHD)
-IGHJ4*01 (92.9%)) [8.8.13] (1-119) -Homo sapiens
IGHG4*01 (CH1 (120-217), charnière 1-12 (218-229),
CH2 (230-339), CH3 (340-444), CHS (445-446)) (120-
446)], (133-218')-disulfure avec la chaîne légère kappa
chimérique (1'-218') [V-KAPPA (Mus musculus IGKV3-
4*01 (98.0%) -IGKJ2*01 (100%)/Homo
sapiensIGKV3D-11*02 (69.1%) -IGKJ2*01 (91.7%))
[10.3.9] (1'-111') -Homo sapiens IGKC*01 (100%),
Km3 A45.1 (157), V101 (195) (112'-218')];
dimère (225-225":228-228")-bisdisulfure, produit dans
des cellules ovariennes de hamster chinois (CHO),
glycoforme alfa
vilobelimab inmunoglobulina G4-kappa, anti-[Homo sapiens C5
(complemento 5) anafilatoxina (C5a, C5 Pr678-751)],
anticuerpo monoclonal quimérico;
cadena pesada gamma4 quimérica (1-446) [VH (Mus
musculus IGHV1-61*01 (81.6%) -(IGHD) -IGHJ3*01
(92.9%)/Homo sapiens IGHV1-46*01 (62.2%) -(IGHD)
-IGHJ4*01 (92.9%)) [8.8.13] (1-119) -Homo sapiens
IGHG4*01 (CH1 (120-217), bisagra 1-12 (218-229),
CH2 (230-339), CH3 (340-444), CHS (445-446)) (120-
446)], (133-218')-disulfuro con la cadena ligera kappa
quimérica (1'-218') [V-KAPPA (Mus musculus IGKV3-
4*01 (98.0%) -IGKJ2*01 (100%)/Homo
sapiensIGKV3D-11*02 (69.1%) -IGKJ2*01 (91.7%))
[10.3.9] (1'-111') -Homo sapiens IGKC*01 (100%),
Km3 A45.1 (157), V101 (195) (112'-218')];
dímero (225-225":228-228")-bisdisulfuro, producido
por células ováricas de hamster chino (CHO), forma
glicosilada alfa
788
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
vonafexorum
vonafexor 4-chloro-5-[4-(2,6-dichlorobenzene-1-
sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid
vonafexor acide 4-chloro-5-[4-(2,6-dichlorobenzène-1-
sulfonyl)pipérazin-1-yl]-1-benzofuran-2-carboxylique
vonafexor ácido 4-cloro-5-[4-(2,6-diclorobenceno-1-
sulfonil)piperazin-1-il]-1-benzofuran-2-carboxílico
C19H15Cl3N2O5S
vosilasarmum
vosilasarm 2-chloro-4-({(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-
oxadiazol-2-yl]-2-hydroxypropyl}amino)-3-
methylbenzonitrile
vosilasarm 2-chloro-4-({(1R,2S)-1-[5-(4-cyanophényl)-1,3,4-
oxadiazol-2-yl]-2-hydroxypropyl}amino)-3-
méthylbenzonitrile
vosilasarm 4-({(1R,2S)-1-[5-(4-cianofenil)-1,3,4-oxadiazol-2-il]-2-
hidroxipropil}amino)-2-cloro-3-metilbenzonitrilo
C20H16ClN5O2
vulinacimabum #
vulinacimab immunoglobulin G1-kappa, anti-[Homo sapiens
VEGFR2 (vascular endothelial growth factor receptor
2, KDR, kinase insert domain receptor, FLK1,
CD309)], Homo sapiens monoclonal antibody;
gamma1 heavy chain Homo sapiens (1-447) [VH
(Homo sapiens IGHV3-23*04 (90.8%) -(IGHD) -
IGHJ1*01 (100%)) [8.8.10] (1-117) -Homo sapiens
IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K
(214) (118-215), hinge 1-15 (216-230), CH2 (231-340),
CH3 E12 (356), M14 (358) (341-445), CHS (446-457))
(118-447)], (220-219')-disulfide with kappa light chain
Homo sapiens (1'-219') [V-KAPPA (Homo sapiens
IGKV2-30*01 (83.0%) -IGKJ2*01 (100%)) [11.3.9] (1'-
112') -Homo sapiens IGKC*01 (100%) Km3 A45.1
(158), V101 (196) (113'-219')];
dimer (226-226":229-229")-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
789
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
vulinacimab immunoglobuline G1-kappa, anti-[Homo sapiens VEGFR2
(récepteur 2 du facteur de croissance endothélial vasculaire,
KDR, récepteur à domaine insert kinase, FLK1, CD309)], Homo
sapiens anticorps monoclonal;
chaîne lourde gamma1 Homo sapiens (1-447) [VH (Homo
sapiens IGHV3-23*04 (90.8%) -(IGHD) -IGHJ1*01 (100%))
[8.8.10] (1-117) -Homo sapiens IGHG1*03v, G1m3>G1m17,
nG1m1 (CH1 R120>K (214) (118-215), charnière 1-15 (216-
230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445),
CHS (446-457)) (118-447)], (220-219')-disulfure avec la chaîne
légère kappa Homo sapiens (1'-219') [V-KAPPA (Homo sapiens
IGKV2-30*01 (83.0%) -IGKJ2*01 (100%)) [11.3.9] (1'-112') -
Homo sapiens IGKC*01 (100%) Km3 A45.1 (158), V101 (196)
(113'-219')];
dimère (226-226":229-229")-bisdisulfure, produit dans des
cellules ovariennes de hamster chinois (CHO), glycoforme alfa
vulinacimab inmunoglobulina G1-kappa, anti-[Homo sapiens VEGFR2
(receptor 2 del factor de crecimiento endotelial vascular, KDR,
receptor con dominio inserto kinasa, FLK1, CD309)], Homo
sapiens anticuerpo monoclonal;
cadena pesada gamma1 Homo sapiens (1-447) [VH (Homo
sapiens IGHV3-23*04 (90.8%) -(IGHD) -IGHJ1*01 (100%))
[8.8.10] (1-117) -Homo sapiens IGHG1*03v, G1m3>G1m17,
nG1m1 (CH1 R120>K (214) (118-215), bisagra 1-15 (216-230),
CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS
(446-457)) (118-447)], (220-219')-disulfuro con la cadena ligera
kappa Homo sapiens (1'-219') [V-KAPPA (Homo sapiens
IGKV2-30*01 (83.0%) -IGKJ2*01 (100%)) [11.3.9] (1'-112') -
Homo sapiens IGKC*01 (100%) Km3 A45.1 (158), V101 (196)
(113'-219')];
dímero (226-226":229-229")-bisdisulfuro, producido por células
ováricas de hamster chino (CHO), forma glicosilada alfa
Heavy chain / Chaîne lourde / Cadena pesada
QVQLVQSGGG LVQPGGSLRL SCAASGFSFS TYAMSWVRQA PGKGLEWVSG 50
ISGSGGTTHY ADSVKGRFTI SRDNSKNTVN LQMNSLRAED TAVYYCAKGL 100
WFGEGLWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447
Light chain / Chaîne légère / Cadena ligera
DVVMTQSPLS LPVTLGQPAS ISCRSSQSLY YRSGYTFLDW YVQKPGQSPQ 50
LLIYQSSKRD SGVPDRISGS GSGTDFTLRI SRVEAEDVGV YYCFQGTHWP 100
YTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC 219
Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 144-200 261-321 367-425
22''-96'' 144''-200'' 261''-321'' 367''-425''
Intra-L (C23-C104) 23'-93' 139'-199'
23'''-93''' 139'''-199'''
Inter-H-L (h 5-CL 126) 220-219' 220''-219'''
Inter-H-H (h 11, h 14) 226-226'' 229-229''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
C-terminal lysine clipping:
H CHS K2:
447, 447''
790
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
xevinapantum
xevinapant (5S,8S,10aR)-N-(diphenylmethyl)-5-[(2S)-2-
(methylamino)propanamido]-3-(3-methylbutanoyl)-6-
oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-
carboxamide
xévinapant (5S,8S,10aR)-N-(diphénylméthyl)-5-[(2S)-2-
(méthylamino)propanamido]-3-(3-méthylbutanoyl)-6-
oxodécahydropyrrolo[1,2-a][1,5]diazocine-8-
carboxamide
xevinapant (5S,8S,10aR)-N-(difenilmetil)-5-[(2S)-2-
(metilamino)propanamido]-3-(3-metilbutanoil)-6-
oxodecahidropirrolo[1,2-a][1,5]diazocina-8-
carboxamida
C32H43N5O4
H3C
NH
H H O O
N H
H3C
N
N H
O
H3C N
H
CH3 O
zandelisibum
zandelisib 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-N-{2-
methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-
yl}-6-(morpholin-4-yl)-1,3,5-triazin-2-amine
zandélisib 4-[2-(difluorométhyl)-1H-benzimidazol-1-yl]-N-{2-
méthyl-1-[2-(1-méthylpipéridin-4-yl)phényl]propan-2-
yl}-6-(morpholin-4-yl)-1,3,5-triazin-2-amine
zandelisib 4-[2-(difluorometil)-1H-benzimidazol-1-il]-N-{2-metil-1-
[2-(1-metilpiperidin-4-il)fenil]propan-2-il}-6-(morfolin-4-
il)-1,3,5-triazin-2-amina
C31H38F2N8O
CH3
N
O
H
N N N
N N H3C CH3
F
N
F
N
zoligratinibum
zoligratinib [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-
pyrazol-4-yl](1H-indol-2-yl)methanone
zoligratinib [5-amino-1-(2-méthyl-1H-benzimidazol-5-yl)-1H-
pyrazol-4-yl](1H-indol-2-yl)méthanone
791
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
zoligratinib [5-amino-1-(2-metil-1H-benzimidazol-5-il)-1H-pirazol-4-
il](1H-indol-2-il)metanona
C20H16N6O
zotiraciclibum
zotiraciclib (8E)-6-methyl-12-oxa-3,6-diaza-2(4,2)-pyrimidina-
1,4(1,3)-dibenzenacyclododecaphan-8-ene
zotiraciclib (8E)-6-méthyl-12-oxa-3,6-diaza-2(4,2)-pyrimidina-
1,4(1,3)-dibenzénacyclododécaphan-8-ène
zotiraciclib (8E)-6-metil-12-oxa-3,6-diaza-2(4,2)-pirimidina-
1,4(1,3)-dibencenaciclododecafan-8-eno
C23H24N4O
zuberitamabum #
zuberitamab immunoglobulin G1-kappa, anti-[Homo sapiens
MS4A1 (membrane spanning 4-domains subfamily A
member 1, CD20)], chimeric monoclonal antibody;
gamma1 heavy chain chimeric (1-452) [VH (Mus
musculus IGHV1-12*01 (96.9%) -(IGHD) -IGHJ1*03
(100%)/Homo sapiens IGHV1-46*01 (70.4%) -(IGHD) -
IGHJ1*03 (85.7%)) [8.8.15] (1-122) -Homo sapiens
IGHG1*01 (100%) G1m17,1 (CH1 K120 (219) (123-
220), hinge 1-15 (221-235), CH2 (236-345), CH3 D12
(361), L14 (363) (346-450), CHS (451-452)) (123-
452)], (225-213')-disulfide with kappa light chain
chimeric (1'-213') [V-KAPPA (Mus musculus IGKV4-
72*01 (96.8%) -IGKJ1*01 (90.9 %)/Homo sapiens
IGKV3-11*01 (64.9%) -IGKJ2*01 (90.9%)) [5.3.9] (1'-
106') -Homo sapiens IGKC*01 (100%), Km3 A45.1
(152), V101 (190) (107'-213')];
dimer (231-231'':234-234'')-bisdisulfide, produced in
Chinese hamster ovary (CHO) cells, glycoform alfa
zubéritamab immunoglobuline G1-kappa, anti-[Homo sapiens
MS4A1 (membre 1 de la sous-famille A à 4 domaines
transmembranaires, CD20)], anticorps monoclonal
chimérique;
792
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
chaîne lourde gamma1 chimérique (1-452) [VH (Mus
musculus IGHV1-12*01 (96.9%) -(IGHD) -IGHJ1*03
(100%)/Homo sapiens IGHV1-46*01 (70.4%) -(IGHD) -
IGHJ1*03 (85.7%)) [8.8.15] (1-122) -Homo sapiens
IGHG1*01 (100%) G1m17,1 (CH1 K120 (219) (123-220),
charnière 1-15 (221-235), CH2 (236-345), CH3 D12 (361),
L14 (363) (346-450), CHS (451-452)) (123-452)], (225-213')-
disulfure avec la chaîne légère kappa chimérique (1'-213') [V-
KAPPA (Mus musculus IGKV4-72*01 (96.8%) -IGKJ1*01
(90.9 %)/Homo sapiens IGKV3-11*01 (64.9%) -IGKJ2*01
(90.9%)) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (100%),
Km3 A45.1 (152), V101 (190) (107'-213')];
dimère (231-231'':234-234'')-bisdisulfure, produit dans des
cellules ovariennes de hamster chinois (CHO), glycoforme
alfa
zuberitamab inmunoglobulina G1-kappa, anti-[Homo sapiens MS4A1
(miembro 1 de la subfamilia A con 4 dominios
transmembranarios, CD20)], anticuerpo monoclonal
quimérico;
cadena pesada gamma1 quimérica (1-452) [VH (Mus
musculus IGHV1-12*01 (96.9%) -(IGHD) -IGHJ1*03
(100%)/Homo sapiens IGHV1-46*01 (70.4%) -(IGHD) -
IGHJ1*03 (85.7%)) [8.8.15] (1-122) -Homo sapiens
IGHG1*01 (100%) G1m17,1 (CH1 K120 (219) (123-220),
bisagra 1-15 (221-235), CH2 (236-345), CH3 D12 (361), L14
(363) (346-450), CHS (451-452)) (123-452)], (225-213')-
disulfuro con la cadena ligera kappa quimérica (1'-213') [V-
KAPPA (Mus musculus IGKV4-72*01 (96.8%) -IGKJ1*01
(90.9 %)/Homo sapiens IGKV3-11*01 (64.9%) -IGKJ2*01
(90.9%)) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (100%),
Km3 A45.1 (152), V101 (190) (107'-213')];
dímero (231-231'':234-234'')-bisdisulfuro, producido por
células ováricas de hamster chino (CHO), forma glicosilada
alfa
793
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES
Recommended International Nonproprietary Names (Rec. INN): List 63
Dénominations communes internationales recommandées (DCI Rec.): Liste 63
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)
p.45 bardoxolonum
bardoxolone replace the molecular formula by the following one
bardoxolone remplacer la formule moléculaire brute par la suivante
bardoxolona sustitúyase la fórmula molecular por la siguiente
C31H41NO4
Recommended International Nonproprietary Names (Rec. INN): List 79
Dénominations communes internationales recommandées (DCI Rec.): Liste 79
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 79
(WHO Drug Information, Vol. 32, No. 1, 2018)
p.112 davamotecanum pegadexamerum
davamotecan pegadexamer replace the structure by the following one
davamotécan pégadexamère remplacer la structure par la suivante
davamotecán pegadexámero sustitúyase la estructura por la siguiente
p.123 ianalumabum #
-124 ianalumab replace the description and the structure by the following ones
ianalumab remplacer la description et la structure par les suivantes
ianalumab sustitúyase la descripción y la estructura por las siguientes
immunoglobulin G1-kappa, anti-[Homo sapiens TNFRSF13C (tumor
necrosis factor receptor (TNFR) superfamily member 13C, BAFFR,
BAFF-R, BR3, B cell activating factor receptor, CD268)], Homo
sapiens monoclonal antibody;
gamma1 heavy chain (1-454) [Homo sapiens VH (IGHV6-1*01
(96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -Homo sapiens
IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge (223-
237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-
454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215')
[Homo sapiens V-KAPPA (IGKV3D-11*01 (89.00%) -IGKJ1*01) [7.3.9]
(1'-108') -Homo sapiens IGKC*01, Km3 A45.1 (154), V101 (192) (109'-
215')]; dimer (233-233'':236-236'')-bisdisulfide;
produced in Chinese hamster ovary (CHO) cells, glycoform alfa
794
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
immunoglobuline G1-kappa, anti-[Homo sapiens TNFRSF13C
(membre 13C de la super famille du récepteur du facteur de nécrose
tumorale (TNFR), BAFFR, BAFF-R, BR3, récepteur du facteur
d'activation des lymphocytes B, CD268], Homo sapiens anticorps
monoclonal;
chaîne lourde gamma1 (1-454) [Homo sapiens VH (IGHV6-1*01
(96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -Homo sapiens
IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière
(223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS
(453-454)) (125-454)], (227-215')-disulfure avec la chaîne légère (1'-
215') [Homo sapiens V-KAPPA (IGKV3D-11*01 (89.00%) -IGKJ1*01)
[7.3.9] (1'-108') -Homo sapiens IGKC*01, Km3 A45.1 (154), V101
(192) (109'-215')]; dimère (233-233'':236-236'')-bisdisulfure,
produit dans des cellules de hamster chinois (CHO), glycoforme alfa
inmunoglobulina G1-kappa, anti-[Homo sapiens TNFRSF13C
(miembro 13C de la super familia del receptor del factor de necrosis
tumoral (TNFR), BAFFR, BAFF-R, BR3, receptor del factor de
activación de los linfocitos B, CD268], Homo sapiens anticuerpo
monoclonal;
cadena pesada gamma1 (1-454) [Homo sapiens VH (IGHV6-1*01
(96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -Homo sapiens
IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra (223-
237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-
454)) (125-454)], (227-215')-disulfuro con la cadena ligera (1'-215')
[Homo sapiens V-KAPPA (IGKV3D-11*01 (89.00%) -IGKJ1*01) [7.3.9]
(1'-108') -Homo sapiens IGKC*01, Km3 A45.1 (154), V101 (192) (109'-
215')]; dímero (233-233'':236-236'')-bisdisulfuro,
producido en las células ováricas de hamster chino (CHO), glicoforma
alfa
795
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
Recommended International Nonproprietary Names (Rec. INN): List 81
Dénominations communes internationales recommandées (DCI Rec.): Liste 81
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 81
(WHO Drug Information, Vol. 33, No. 1, 2019)
p.128 vutrisiranum
vutrisiran replace the structure by the following one
vutrisiran remplacer la structure par la suivante
vutrisirán sustitúyase la estructura por la siguiente
Recommended International Nonproprietary Names (Rec. INN): List 82
Dénominations communes internationales recommandées (DCI Rec.): Liste 82
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 82
(WHO Drug Information, Vol. 33, No. 3, 2019)
p.606 adlinacogenum civaparvovecum #
-607 adlinacogene civaparvovec replace the description by the following one
adlinacogène civaparvovec remplacer la description par la suivante
adlinacogén civaparvovec sustitúyase la descripción por la siguiente
a recombinant non-replicating adeno-associated virus type 2/6 (rAAV6)
vector, which contains a promoter-less human coagulation factor IX (hF9,
Factor IX or FIX) transgene cassette, encoding exons 2-8 and splice
acceptor site sequence (SA) from hF9 exon 2, flanked by a sequence
homologous to the zinc-finger nuclease (ZFN) cleavage site of the human
albumin (hALB) intron 1
vecteur viral adéno-associé de type 2/6 recombinant (rAAV6), non-
répliquant, contenant la cassette avec le transgène du facteur de
coagulation IX humain (hF9, Facteur IX, FIX) sans promoteur, codant pour
les exons 2-8 et la séquence du site accepteur (SA) d'épissage de l'exon 2
de hF9, flanqué par une séquence homologue au site de clivage de la
nucléase à doigts de zinc (ZFN) de l'intron 1 l'albumine humaine (hALB).
un vector de virus adeno asociado tipo 2/6 recombinante (rAAV6), no
replicativo, que contiene un casete con el transgen del factor de
coagulación IX (hF9, Factor IX o FIX) humano sin promotor, que codifica
para los exones 2-8 y la secuencia del sitio aceptor (SA) del splicing del
exon 2 de hf9, flanqueado por una secuencia homóloga al sitio de rotura
por la nuclease con dedos de zinc (ZFN) del intron 1 de la albúmina
humana (hALB)
796
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
p.625 devafidugenum civaparvovecum #
-626 devafidugene civaparvovec replace the description by the following one
devafidugène civaparvovec remplacer la description par la suivante
devafidugén civaparvovec sustitúyase la descripción por la siguiente
a recombinant non-replicating adeno-associated virus type 2/6 (rAAV6)
vector, which contains a promoter-less human alpha-L-iduronidase
(hIDUA) transgene cassette, encoding partial exon 1 and full exons 2-14
with the first 28 amino acids removed, and splice acceptor site sequence
(SA) from hIDUA exon 2, flanked by a sequence homologous to the zinc-
finger nuclease (ZFN) cleavage site of the human albumin (hALB) intron
1
vecteur viral adéno-associé de type 2/6 recombinant (rAAV6), non-
répliquant, contenant la cassette du transgène de l'alpha-L-iduronidase
humaine (hIDUA) sans promoteur, codant partiellement l'exon 1 et
entièrement les exons 2-14 dont la partie correspondant aux 28 premiers
acides aminés a été retirée, et la séquence du site accepteur (SA)
d'épissage de l'exon 2 de l'hIDUA, flanqué d'une séquence homologue
au site de clivage de la nucléase à doigts de zinc (ZFN) de l'intron 1 de
l'albumine humaine (hALB)
un vector de virus adeno asociado tipo 2/6 recombinante (rAAV6), no
replicativo, que contiene un casete con el transgen de la alfa-L-
iduronidasa humana (hIDUA) sin promotor, que codifica para el exón 1
parcial y los exones 2-14 completos con los primeros 28 amino ácidos
eliminados, y la secuencia del sitio aceptor (SA) del splicing del exón 2
de hIDUA, flanqueado por una secuencia homóloga al sitio de rotura por
la nuclease con dedos de zinc (ZFN) del intron 1 de la albúmina humana
(hALB)
p.645 inlezifigenum civaparvovecum #
inlezifigene civaparvovec replace the description by the following one
inlezifigène civaparvovec remplacer la description par la suivante
inlezifigén civaparvovec sustitúyase la descripción por la siguiente
a recombinant non-replicating adeno-associated virus type 2/6 (rAAV6)
vector, expressing a cDNA that targets 447-461 bp of the albumin locus
(relative to the transcription initiation site), fused to the obligate
heterodimeric FokI nuclease domain ELD, under the control of an
apolipoprotein E hepatic control region and human alpha-1-antitrypsin
promoter (ApoE/hAAT)
vecteur viral adéno-associé de type 2/6 recombinant (rAAV6), non-
répliquant, exprimant un ADNc ciblant les paires de bases 447-461 du
locus de l'albumine (en relation avec le site initial de transcription),
fusionné au domaine hétérodimérique ELD de la nucléase Fokl, sous le
contrôle d'une région de contrôle de l'apolipoprotéine E (ApoE) spécifique
du foie et du promoteur de l'alpha1-antitrypsine humaine (ApoE/hAAT)
un vector de virus adeno asociado tipo 2/6 recombinante (rAAV6), no
replicativo, que expresa un cDNA dirigido a unirse a los pares de bases
447-461 (en relación al sitio de iniciación de la transcripción) del locus de
la albúmina, fusionado al dominio heterodimérico ELD de la nuclease
FokI, bajo el control de una región de control hepático de la
apolipoproteína E y el promotor de la alfa 1 antitripsina humana
(ApoE/hAAT)
797
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
p.669 ranuzifigenum civaparvovecum #
-670 ranuzifigene civaparvovec replace the description by the following one
ranuzifigène civaparvovec remplacer la description par la suivante
ranuzifigén civaparvovec sustitúyase la descripción por la siguiente
a recombinant non-replicating adeno-associated virus type 2/6 (rAAV6)
vector, expressing a cDNA that targets 468-485 bp of the albumin locus
(relative to the transcription initiation site), fused to the obligate
heterodimeric FokI nuclease domain ELD, under the control of an
apolipoprotein E hepatic control region and human alpha-1-antitrypsin
promoter (ApoE/hAAT)
vecteur viral adéno-associé de type 2/6 recombinant (rAAV6), non-
répliquant, exprimant un ADNc ciblant les paires de bases 468-485 du
locus de l'albumine (en relation avec le site initial de transcription),
fusionné au domaine hétérodimérique ELD de la nucléase Fokl, sous le
contrôle d'une région de contrôle de l'apolipoprotéine E (ApoE)
spécifique du foie et du promoteur de l'alpha1-antitrypsine humaine
(ApoE/hAAT)
un vector de virus adeno asociado tipo 2/6 recombinante (rAAV6), no
replicativo, que expresa un cDNA dirigido a unirse a los pares de bases
468-485 (en relación al sitio de iniciación de la transcripción) del locus
de la albúmina, fusionado al dominio heterodimérico ELD de la
nuclease FokI, bajo el control de una región de control hepático de la
apolipoproteína E y el promotor de la alfa 1 antitripsina humana
(ApoE/hAAT)
p.676 selitrectinibum
selitrectinib replace the chemical name by the following one
sélitrectinib remplacer le nom chimique par le suivant
selitrectinib sustitúyase el nombre químico por el siguiente
(22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-
3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one
(22R,6R)-35-fluoro-6-méthyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-
3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one
(22R,6R)-35-fluoro-6-metil-7-aza-1(5,3)-pirazolo[1,5-a]pirimidina-3(3,2)-
piridina-2(1,2)-pirrolidinaciclooctafan-8-ona
p.688 tefidsogenum civaparvovecum #
-689 tefidsogene civaparvovec replace the description by the following one
téfidsogène civaparvovec remplacer la description par la suivante
tefidsogén civaparvovec sustitúyase la descripción por la siguiente
a recombinant non-replicating adeno-associated virus type 2/6
(rAAV6) vector, which contains a promoter-less human iduronate 2-
sulfatase (hIDS) transgene cassette, encoding parts of exon 1 plus
exons 2-9 from hIDS and a splice acceptor site (SA) derived from
human coagulation factor IX (hF9, factor IX or FIX) exon 2, flanked by
a sequence homologous to the zinc-finger nuclease (ZFN) cleavage
site of the human albumin (hALB) intron 1
798
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
vecteur viral adéno-associé de type 2/6 recombinant (rAAV6), non-
répliquant, contenant la cassette du transgène de l’iduronate 2-
sulfatase humaine (hIDS) sans promoteur, codant partiellement
l’exon 1 et les exons 2-9 de hIDS, et la séquence du site accepteur
(SA) d’épissage dérivé de l’exon 2 du facteur de coagulation IX
humain (hF9, facteur IX, FIX), flanqué d’une séquence homologue
au site de clivage de la nucléase à doigts de zinc (ZFN) de l’intron 1
de l’albumine humaine (hALB)
un vector de virus adeno asociado tipo 2/6 recombinante (rAAV6),
no replicativo, que contiene un casete con el transgen de la
iduronato 2-sulfatasa humana (hIDS) sin promotor, que codifica
para partes del exón 1 más los exones 2-9 de hIDS y un sitio
aceptor del splicing derivado del exón 2 del factor de coagulación IX
humano (hF9, factor IX o FIX), flanqueado por una secuencia
homóloga al sitio de rotura por la nuclease con dedos de zinc (ZFN)
del intron 1 de la albúmina humana (hALB)
Recommended International Nonproprietary Names (Rec. INN): List 83
Dénominations communes internationales recommandées (DCI Rec.): Liste 83
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 83
(WHO Drug Information, Vol. 34, No. 1, 2020)
p.25 avalotcagenum ontaparvovecum #
-26 avalotcagene ontaparvovec replace the description by the following one
avalotcagène ontaparvovec remplacer la description par la suivante
avalotcagén ontaparvovec sustitúyase la descripción por la siguiente
A recombinant non-replicating adeno-associated virus type 2/8
(rAAV8) vector, encoding codon-optimized, wild-type human
ornithine transcarbamylase (OTC) under the control of a hybrid
human thyroxine-binding globulin (TBG) / human alpha 1-
microglobulin/bikunin precursor (AMBP) promoter/enhancer. The
vector genome is a head-to-head dimer, with the vector genome
cassette located 5' of the mutated internal inverted terminal repeat
(ITR) in a reverse orientation and the vector genome cassette
located 3' of the mutated internal ITR in a forward orientation.
vecteur viral adéno-associé de type 2/8 recombinant non-répliquant
(rAAV8), codant pour l'ornithine transcarbamylase humaine
sauvage (OTC) avec des codons optimisés, sous le contrôle de
l'activateur/promoteur hybride de la globuline liant la thyroxine (TBP)
humaine /précurseur de microglobuline alpha 1 / bikunine (AMBP).
Le génome du vecteur est un dimère en tête à tête avec la cassette
contenant le génome du vecteur en position 5´ de la séquence
inverse terminale répétée (ITR) interne et mutée dont l'orientation
est inverse et la cassette contenant le vecteur du génome en
position 3´ de l'ITR interne et mutée dont l'orientation est vers l'avant
Un vector de virus adenoasociado recombinante no replicativo del
serotipo 2/8 (rAAV8), que codifica para la ornitina transcarbamilasa
silvestre humana (OTC) con codones optimizados, bajo el control
de un promotor/potenciador híbrido de la globulina fijadora de
tiroxina humana (TBG) / precursor de microglobulina alfa 1
humana/bicunina (AMBP). El genoma del vector es un dímero de
cabeza con cabeza, con el casete del genoma del vector en
posición 5' a la repetición terminal invertida (ITR) interna y mutada
localizado en orientación inversa. y el casete del genoma del vector
en posición 3' a la ITR localizado en orientación hacia adelante.
799
Recommended INN: List 84 WHO Drug Information, Vol. 34, No. 3, 2020
p.49 epcoritamabum #
epcoritamab replace the structure by the following one
épcoritamab remplacer la structure par la suivante
epcoritamab sustitúyase la estructura por la siguiente
p.55 giroctocogenum fitelparvovecum #
giroctocogene fitelparvovec replace the description by the following one
giroctocogène fitelparvovec remplacer la description par la suivante
giroctocogén fitelparvovec sustitúyase la descripción por la siguiente
A recombinant non-replicating adeno-associated virus type 2/6
(rAAV6) vector, encoding human B-domain-deleted blood coagulation
factor VIII (hF8, FVIII) under the control of a synthetic liver-specific
promoter.
Vecteur viral adéno-associé de type 2/6 recombinant non-répliquant
(rAAV6), codant pour le facteur de coagulation sanguine VIII humain
(hF8, FVIII), dont le domaine B a été supprimé, sous le contrôle d'un
promoteur synthétique spécifique du foie.
800
WHO Drug Information, Vol. 34, No. 3, 2020 Recommended INN: List 84
Un vector de virus adenoasociado recombinante no replicativo del tipo
2/6 (rAAV6), que codifica para el factor de coagulación sanguíneo VIII
humano (hF8, FVIII) con el dominio B delecionado, bajo el control de
un promotor sintético específico del hígado.
p.63 supprimer insérer
lététresgéne autoleucel lététresgène autoleucel
p.132 zildistrogenum varoparvovecum #
zildistrogene varoparvovec replace the description by the following one
zildistrogène varoparvovec remplacer la description par la suivante
zildistrogén varoparvovec sustitúyase la descripción por la siguiente
A recombinant non-replicating adeno-associated virus type 2/9
(rAAV9) vector, encoding human microdystrophin 5 (h-μD5) under
control of CK8 muscle creatine kinase promoter and enhancer
elements
vecteur viral adéno-associé de type 2/9 recombinant non-répliquant
(rAAV9) codant pour la microdystrophine 5 humaine (h-mD5) sous le
contrôle de l'activateur/promoteur de la créatine kinase musculaire
CK8
Un vector de virus adenoasociado recombinante no replicativo del
tipo 2/9 (rAAV9), que codifica para la microdistrofina 5 humana
(h-mD5) bajo el control del promotor y elementos potenciadores
(enhancer) de la creatina quinasa CK8 de músculo.
# Electronic structure available on Mednet: http://mednet.who.int/
# Structure électronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/
* http://www.who.int/medicines/services/inn/publication/en/
Procedure and Guiding Principles / Procédure et Directives / Procedimientos y
principios generales
The text of the Procedures for the Selection of Recommended International
Nonproprietary Names for Pharmaceutical Substances and General Principles for
Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes
internationales recommandées pour les substances pharmaceutiques et des
Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes
des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes
internacionales recomendadas para las sustancias farmacéuticas y de los Principios
generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.
801